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Abstract 
P2X4 is a purinergic receptor distributed all over the body with various roles. Among 
them, it was reportedly overexpressed in several neuronal and immune cell types 
following peripheral nerve injury and its activation leads to neuropathic pain. Several 
compounds were found to block P2X4 but none has gone into a clinical stage, probably 
due to insufficient information about the compound itself and P2X4 in general. One of 
such compounds, 5-(3-Bromophenyl)-1,3-dihydro-2H-Benzofuro[3,2-e]-1,4-
diazepin-2-one (5-BDBD) is known to be widely used in P2X4-related studies despite 
its limited information. Therefore, this study aimed to (i) find a novel compound that 
can block the activation of P2X4 through high throughput screening and characterise 
it, and (ii) study structural-activity relationship between 5-BDBD and P2X4. Human 
P2X4 receptor was stably expressed in human 1321N1 astrocytoma cells and 1710 
compounds from National Cancer Institute were screened for their activity at P2X4. 
Extensive tests led to identifying a natural product (thaspine) as the most potent 
inhibitor at reducing P2X4 activation. Further characterisation experiments revealed 
that thaspine had an IC50 value of 3.8 ± 0.2 µM and showed an allosteric mode, time-
dependent and irreversible inhibition. Thaspine was similarly potent at mouse P2X4, 
but not effective at human P2X2, P2X2/3 and P2X7. It was also inactive at human P2Y2 
and P2Y6 at concentrations below 10 µM and 30 µM respectively. In primary 
microglial cell model (BV2), it inhibited ivermectin-potentiated responses but not 
normal ATP-evoked responses. Meanwhile, 5-BDBD was found to be inhibiting P2X4 
receptor competitively and diazepinone was a pivotal group of the structure to cause 
inhibition. The binding pocket of 5-BDBD at P2X4 was also predicted using molecular 
docking. In this study, a novel compound thaspine, has been shown to be effective at 
inhibiting human P2X4 and thus may have potential therapeutic applications while 
novel information about 5-BDBD was also acquired. 
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CHAPTER 1  
INTRODUCTION 
1.1 Purinergic signalling 
Purine nucleotides and nucleosides, adenosine triphosphate (ATP), and adenosine 
were first proposed as extracellular signalling molecules in a seminal paper by Drury 
and Szent-Györgyi (1929). The scientists observed the potent action of these molecules 
on the heart and blood vessels. Emmelin and Feldberg (1948) provided more evidence 
on the involvement of ATP in producing systemic effect on cat, particularly on the 
circulatory and respiratory systems. There were several other studies suggested the 
involvement of ATP and other purines nucleotides as neurotransmitters, as reviewed 
by Burnstock (1998). These allowed the proposal of purinergic term by Burnstock 
(1971) to refer ATP and other related purine nucleotides, in an effort to simplify the 
nomenclature of the mentioned compounds. 
 
In 1972, the term purinergic signalling was proposed by Geoffrey Burnstock. He 
defined the term purinergic receptors in 1976 as the receptors that bind to purine 
molecules (Burnstock, 2006). In 1978, the term was formally used and purinergic 
receptors were divided into two families, P1 and P2, by Burnstock based on the natural 
ligands they bind to. P1 purinoreceptors bind to adenosine while P2 purinoceptors bind 
to ATP and ADP (Ralevic & Burnstock, 1998). The P2 family was further subdivided 
based on their pharmacological characteristics which were ligand-gated ion channel 
P2X and G protein-coupled P2Y receptors (GPCR) (Burnstock & Kennedy, 1985). 
The early development of purinergic signalling has received a significant amount of 
challenge because of the global reluctance to accept that a nucleotide, like ATP, can 
act as a neurotransmitter. The reluctance could be due to the fact that ATP is 
ubiquitously present and as the main currency of energy in human body, it was hard to 
digest the notion of ATP being a messenger (Burnstock, 2006). 
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1.1.1 P1 receptors 
P1 receptors can be categorised into four subtypes and their natural ligand is adenosine. 
These receptors share one common feature with P2Y in which they are coupled to a G 
protein. The activation of A2A and A2B receptors leads to the production of cyclic AMP 
(cAMP) while activation of A1 and A3 receptors results in the inhibition of cAMP 
production (Abbracchio et al., 2009). These receptors have been reported to play 
various roles related to the central nervous system, cerebral blood flow, pain 
regulation, respiration, functions of basal ganglia, and sleep (Jaakola et al., 2008). 
1.1.2 P2Y receptors (P2YR) 
The first member of the P2Y family, i.e., P2Y1 (formerly known as P2Y) was 
introduced by Webb et al. (1993). Since then, several other P2Y receptors have been 
identified and named in a consecutive order based on the time of their discovery. To 
date, there are eight established subtypes of P2Y namely P2Y1, P2Y2, P2Y4, P2Y6, and 
P2Y11-14 (Abbracchio et al., 2003, 2006; Communi et al., 2001; Hollopeter et al., 2001; 
Zhang et al., 2002). The current accepted classification of the P2Y family was 
established after the discovery and reclassification of the last three receptors (P2Y12-
14) between the year of 2000 and 2003 (Burnstock, 2007).  
 
P2Y receptors are G protein-coupled receptors (GPCR) which are composed of seven 
hydrophobic transmembrane domains with an intracellular C-terminus and 
extracellular N-terminus. The transmembrane domains are connected by three 
extracellular and intracellular loops. The seven subunit transmembrane motifs form a 
pocket for ligand binding (Burnstock, 2004; Ralevic & Burnstock, 1998). The P2Y 
receptors have been reported to respond towards both endogenous and exogenous 
purine and pyrimidine nucleotides (ATP, ADP, UTP, UDP, and UDP-glucose). 
Dissimilar to P2X, the calcium influx caused by these receptors is not caused by the 
direct opening of the receptors, rather the cascade involves secondary signalling 
pathway.  
 
P2Y receptors are divided into two groups based on their structural and functional 
features. The first group consists of P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 which signals 
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through Gαq/11 to activate phospholipase C (PLC) and the second group consists of 
P2Y12, P2Y13, and P2Y14 which signals through Gαi/0 to inhibit adenylyl cyclase (AC) 
(von Kügelgen & Hoffmann, 2016). The activation of the first group of P2Y receptors 
by nucleotides causes the dissociation of heterotrimeric G protein, i.e., separation of 
Gβγ dimer from Gα subunit. This leads to the activation of PLC by Gαq/11 subunit and 
PLC subsequently hydrolyses the phosphatidylinositol-4,5-bisphosphate (PIP2) to 
inositol-1,4,5-trisphosphate (IP3). The IP3 then acts on its receptor (IP3R) at the 
endoplasmic reticulum (ER) which then leads to the release of calcium ion from ER 
into cytosol. Meanwhile, the activation of the second group of P2Y receptors causes 
the inhibition of AC that results in the alteration of cyclic adenosine monophosphate 
(cAMP) level. P2Y11 has also been reported to couple to Gαs proteins that results in 
the stimulation of AC (Abbracchio et al., 2006; Bridges & Lindsley, 2008; von 
Kügelgen & Hoffmann, 2016).  
 
The functions of P2Y have been demonstrated in various literatures and one of them 
was explained by Hechler et al. (1998). The study revealed that P2Y1, which was found 
on platelets, in co-operation with P2Y12 (Hollopeter et al., 2001) were crucial for ADP-
induced platelet aggregation. Both receptors were found to be important in the 
aggregation of platelets in response to damaged vessels. Meanwhile, the function of 
P2Y2 has been investigated by several studies that proved the involvement of P2Y2 in 
the amplification of signals to recruit more neutrophils for phagocytic activity (Chen 
et al., 2006) and during the development of intimal hyperplasia in response to vascular 
injury (Seye et al., 2002). A more recent study highlighted the role of P2Y2 in graft-
versus-host disease (GvHD) after allogeneic hematopoietic cell transplantation (allo-
HCT). The researchers found that P2Y2-deficient recipient mice could survive longer 
than wild-type mice after receiving the allogeneic wild-type bone marrow and T cells. 
However, the GvHD was independent of the donor because both P2Y2 wild-type and 
deficient donors produced the same GvHD-related mortality rate (Klämbt et al., 2015). 
The detailed characteristics of P2Y receptors are shown in Table 1.1. 
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 Table 1.1 P2Y receptor characteristics 
Adapted from Burnstock (2007).
P2YR 
subtype 
Primary distribution Agonist Antagonist Downstream signalling 
pathways 
P2Y1 Epithelial and endothelial cells, 
platelets, immune cells, osteoclasts 
2-MeSADP=ADPβS>2-
MeSATP=ADP>ATP, 
MRS2365 
MRS2179, MRS2500, 
MRS2279, PIT 
Gαq/11; PLC-β activation 
P2Y2 Immune cells, osteoblasts, epithelial 
and endothelial cells, kidney tubules  
UTP=ATP, UTPγS, INS 
37217, INS365 
suramin>RB2, ARC126313 Gαq/11 and 
Gαi/0; PLC-β activation 
P2Y4 Endothelial cells UTP≥ATP, UTPγS, INS 
37217 
RB2>suramin Gαq/11; PLC-β activation 
P2Y6 Some epithelial cells, placenta, T 
cells, thymus 
UDP>UTP>>ATP, UDPβS, 
IDP 
MRS2578 Gαq/11; PLC-β 
activation 
P2Y11 Spleen, intestine, granulocytes ARC67085MX> 
BzATP≥ATPγS>ATP 
suramin>RB2, NF157, 5’-
AMPS 
Gαq/11and Gαs; PLC-β 
activation, AC activation 
P2Y12 Platelets, glial cells 2-MeSADP≥ADP>>ATP CT50547, AR-C69931MX, 
INS49266, AZD6140, PSB0413, 
ARL66096, 2-MeSAMP 
Gαi/o; AC inhibition 
P2Y13 Spleen, brain, lymph nodes, bone 
marrow 
ADP=2-MeSADP>> ATP=2-
MeSATP 
MRS2211, 2-MeSAMP Gαq/11and Gαi; PLC-β 
activation, AC inhibition 
P2Y14 Placenta, adipose tissue, stomach 
intestine, discrete brain regions 
UDP glucose=UDP-galactose - Gαi/o; AC inhibition  
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1.1.3 P2X receptors (P2XR) 
P2X receptors are ionotropic receptors which involved in fast excitatory 
neurotransmission (Burnstock & WIlliams, 2000). The length of the receptors ranges 
from 384 to 595 amino acids across the subtypes (North, 2002). They are known to be 
distributed throughout the human body (Surprenant & North, 2009). There are seven 
subtypes of P2X receptors identified, namely P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, 
and P2X7. The receptor family members shared few common characteristics. The first 
one is their N- and C- termini are located intracellularly and connected by a large 
extracellular loop comprised of 10 conserved cysteine residues across the family. 
Secondly, all P2X receptor subunits have two transmembrane regions (TM1 and TM2) 
and ATP-binding site (Burnstock, 2004), and are activated by ATP (Figure 1.1) 
(Hernandez-Olmos et al., 2012). Lastly, they share a common topology in which they 
consist of three subunits either as homotrimers or heterotrimers (Burnstock & 
WIlliams, 2000). The first evidence indicating the organisation of P2X heterotrimers 
was demonstrated by Lewis et al. (1995) where the co-expression of P2X2 and P2X3 
formed a new phenotype. A subsequent immunoprecipitation study predicted eleven 
form of heteromers involving all P2X receptors except P2X7 (Torres et al., 1999), 
however only six have been functionally established which are P2X1/2, P2X1/4, P2X1/5, 
P2X2/3, P2X2/6, and P2X4/6 (Burnstock, 2007). The detailed characteristics of P2X 
receptors are shown in Table 1.2. 
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Figure 1.1 General structure of P2X receptors. 
All P2X receptor subunits have two transmembrane domains of TM1 and TM2, which 
are connected by a large extracellular loop consisting of 10 cysteine residues that keep 
the extracellular structure stable via disulphide bridges. Both N- and C- termini are 
located intracellularly. 
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Table 1.2 P2X receptor characteristics 
Adapted from Burnstock (2007) 
P2XR 
subtype 
Primary distribution Agonist Antagonist Downstream signalling 
pathways 
P2X1 Smooth muscle, platelets, 
cerebellum, dorsal horn spinal 
neurons 
α,β-meATP=ATP=2-
MeSATP, L-β,γ-meATP 
(rapid desensitisation) 
MRS2220, MRS2159, NF449, 
NF279, Ro-0437626, Suramin, 
PPADS, TNP-ATP 
Increase in cytosolic 
calcium level 
P2X2 Smooth muscle, CNS, retina, 
chromaffin cells, autonomic and 
sensory ganglia 
ATP≥ATPγS≥2-
MeSATP>>α,β-meATP (pH 
+ zinc-sensitive) 
Suramin, PPADS, RB2, NF770, 
NF279, NF776, NF778, PSB-12011, 
PSB-10211 
Increase in cytosolic 
calcium level 
P2X3 sensory neurones, nucleus 
tractus solitarius, some 
sympathetic neurons 
2-MeSATP≥ATP≥α,β-
meATP 
≥Ap4A (rapid desensitisation) 
NF023, NF279, NF449, RO-4, RO-
3, MRS2159, MRS2257, Suramin, 
PPADS, A317491, NF110, Ip5I, 
Increase in cytosolic 
calcium level 
P2X4 CNS, testis, colon ATP>> α,β-meATP, CTP 5-BDBD, PSB12062, BX430, NP-
1815-PX, Suramin, PPADS, 
Paroxetine, TNP-ATP 
Increase in cytosolic 
calcium level 
P2X5 Skin, gut, bladder, thymus, 
spinal cord 
ATP>> α,β-meATP, ATPγS Suramin, PPADS, BBG, TNP-ATP Increase in cytosolic 
calcium level 
P2X6 CNS, motor neurons in spinal 
cord 
ATP > 2-meSATP 
(does not function as 
homomer) 
TNP-ATP, PPADS Increase in cytosolic 
calcium level 
P2X7 Immune cells, pancreas, skin BzATP>ATP≥2-MeSATP>> 
α,β-meATP 
KN62, KN04, A-438079, A-
740003.0, A-804598, AZ11645373, 
Brilliant blue G 
Increase in cytosolic 
calcium level 
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1.2 P2X4 receptor 
P2X4 receptors were originally cloned from the brain of rat by Bo et al. (1995) and 
Soto et al. (1996). Both reported that rat P2X4 was insensitive to known P2X 
antagonists, suramin and pyridoxal-phosphate-6-azophenyl-2`,4`-disulfonic acid 
(PPADS). Subsequently, P2X4 was cloned from the brain of human (Garcia-Guzman 
et al., 1997) and mouse (Simon et al., 1999). Heterologous expression of both P2X4 
orthologues yielded ATP-evoked responses which were blocked by suramin (weak 
blockade at mouse P2X4) and PPADS, in contrast to the rat P2X4. The human P2X4 
was found to exhibit broad tissue expression. The order of agonist potency reported 
for the human P2X4 receptor was ATP >> 2-methylthio-ATP (2meSATP) ≥ CTP > 
αβ-meATP > dATP (Garcia-Guzman et al., 1997). The P2X4 receptors were also 
demonstrated to form functional heterotrimers with other P2X substypes, i.e., P2X1/4 
(Nicke et al., 2005) and P2X4/6 (Le et al., 1998), where both showed increased 
sensitivity to suramin. 
1.2.1 Molecular structure of P2X4 
The P2X4 receptor consists of three subunits that cluster together and become a 
trimeric receptor. It is an ion channel primarily modulated by ATP as the physiological 
agonist, of which activation results in the fluxes of Ca2+, Na+, and K+. The reported 
EC50 of ATP at the human P2X4 receptor was 1.4 µM (Jones et al., 2000). The first 
ever solved crystal structure of P2X4 was from zebrafish (zfP2X4) in its closed, resting 
state and this has significantly improved the insight of the structure of P2X receptor 
family (Kawate et al., 2009). The shape of homotrimeric zfP2X4 can be analogised to 
a goblet. A relatively big portion of extracellular loop (~70 Å) protruding from the 
lipid bilayer of the plasma membrane resembles the cup portion of a goblet while the 
stand looks like the relatively small portion of transmembrane motifs embedded in the 
membrane (~28 Å) (Figure 1.2). The structure of each subunit resembles a dolphin 
shape. The flukes are similar to the two transmembrane helices and the upper body 
resembles the extracellular portion of the subunit (Figure 1.3). Kawate et al. (2009) 
also proposed two ways that extracellular cations can enter cells through the receptor. 
The first way was through the openings known as lateral fenestrations which are 
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slightly above the transmembrane motifs. In the closed state, the diameter of the 
fenestrations is ~8 Å, which is sufficient for Ca2+, Na+, and K+ ion fluxes. This route 
was also suggested by Samways et al. (2011) through cysteine-scanning mutagenesis 
study. The second proposal was through the upper vestibule of the receptor, 
surrounded by the three subunits. Though the opening was too small (~2.3 Å) for 
hydrated ions to go through in the closed state, it was hypothesised that the opening 
may enlarge after activation by agonist (Figure 1.4) (Kawate et al., 2009). 
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Figure 1.2 Stereo view of zfP2X4 from the side (A) and the top (B). 
 (Kawate et al., 2009) 
P2X4 receptor consists of three subunits, coded with different colours (red, blue, and 
yellow). Panel A shows side view (parallel to the plasma membrane) of P2X4 receptor. 
The grey bars indicate the outer and inner membranes. Panel B shows top view (from 
the extracellular space) of the receptor.  
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Figure 1.3 Crystal structure of a subunit of P2X4 resembling dolphin. 
(Kawate et al., 2009) 
The figure shows the resemblance of one P2X4 subunit to a dolphin. Each part of 
dolphin is colour-coded according to the parts of P2X4 subunit. 
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Figure 1.4 Conformation of closed state P2X4. 
(Kawate et al., 2009) 
The left panel shows sagittal plane of P2X4 and reveals four vestibules (as shown 
schematically on the right panel) in the middle of receptor, surrounded by three 
subunits. The first proposed ion channel is marked with the orange arrow which is 
connected to extracellular vestibule and the second proposal is through the green 
opening on top of upper vestibule (right panel). 
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In 2012, the same group solved the crystal structure of zfP2X4 in an open state with 
bound ATP at the ligand binding site at a resolution of 2.8 Å, together with another 
closed, resting state at higher resolution of 2.9 Å (Hattori & Gouaux, 2012). This study 
benefitted researchers with a vast amount of information about the ATP binding site 
of P2X4 that is very important in drug screening. With the crystal structures, they could 
identify the exact location of ATP binding and vital residues that make up the binding. 
Also, they could confirm the hypothesised routes of ion transfer. 
 
Through this unearthing, the binding sites were identified to be pockets in the middle 
of two subunits. Between the two subunits, there was one binding site. Thus, there are 
three binding sites in a P2X4 receptor. This observation was in agreement with a theory 
hypothesised by Bean (1990) based on his experiments, where the stoichiometry of 
ATP binding to P2X4 was at least 3:1. These findings were also in line with previous 
studies at other P2Xs. Wilkinson et al. (2006) proved that the ATP binding site of 
P2X2/3 was made up of two subunits and Marquez-Klaka et al. (2007) also reported the 
same finding for P2X1. 
 
Based on the ATP-bound P2X4 crystal structure, the zfP2X4 residues that interacted 
with ATP were Asn296, Arg298 and Lys316 of the first subunit and Lys70, Lys72, 
and Thr189 of the adjacent subunit. The residues established direct polar interaction 
with ATP molecules while Lys193 of the adjacent subunit interacted indirectly with 
ATP through interaction with glycerol molecule. There were a few other residues that 
have hydrophobic interactions with ATP which were Ala291 and Ala292 of the first 
subunit, and Arg143, Ile232, Leu217, and Leu191 of the adjacent subunit. 
 
The crystal structure also revealed that the first proposal regarding ion transfer channel 
was revealed true. When ATP binds to the binding site, the size of upper, extracellular, 
and intracellular vestibules is enlarged while the top middle opening remains relatively 
unchanged and thus, not allowing ions to pass through (Figure 1.5). The acidic 
environment of the extracellular vestibule also helps to repel anions and attract cations 
to transport them into the cytosol (Hattori & Gouaux, 2012). At P2X3, the extracellular 
and intracellular boundaries are gated by Ile323 and Thr330 respectively, as well as 
Val326 that also contributes to the occlusion of the vestibules. However, the 
desensitised state is not the reverse of open state, rather the movement of 
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transmembrane motifs towards the extracellular surface by 4.4 Å and an inward 
rotation of Val334 cause the pore to close (Mansoor et al., 2016). 
 
Nevertheless, there was a concern regarding the gating mechanism proposed by Hattori 
and Gouaux (2012) because both terminal domains were truncated in their crystal 
constructs (Mansoor et al., 2016). Based on the study on the rat P2X2, Habermacher et 
al. (2015) found that there was a discrepancy in the fenestration observed in the crystal 
structure of ATP-bound zfP2X4, where such fenestration was absent in the rat P2X2 
receptor. Molecular dynamics simulations also showed that such opening was smaller 
than that observed in the ATP-bound crystal structure of zfP2X4 (Heymann et al. 
2013). Mansoor et al. (2016) gave a new insight into the gating mechanism by solving 
crystal structures of human P2X3 in its apo/resting, agonist-bound/open-pore, agonist-
bound/closed-pore/desensitized, and antagonist-bound/closed states. They described 
the changes during the transition from the resting to open and from open to desensitised 
states, and also revealed the existence of a cytoplasmic cap anchor which was absent 
in the crystals of zfP2X4 because of the truncated termini. It was hypothesised that this 
cytoplasmic cap affects the rate of desensitisation of P2X receptors. In short, the pore 
opening observed in the zfP2X4 crystal was not accurate because of the truncation of 
the termini, however the path of ion fluxes was true. Later studies provided new 
information on important residues that were involved in the gating mechanism and 
most importantly, the cytoplasmic cap that influenced the desensitisation state of P2X 
receptors (Habermacher et al., 2016; Heymann et al., 2013; Mansoor et al., 2016).
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Figure 1.5 Differences between open and closed conformation of P2X4. 
(Hattori & Gouaux, 2012) 
Panel A shows sagittal plane of zfP2X4 in open state, revealing even larger vestibules 
compared to apo state as schematically represented in panel B and C. The crystal 
structure confirms that ion transfer occurs through the fenestration marked with orange 
arrow. Ions then enter the enlarged extracellular and intracellular vestibules before 
going into the cytosol. 
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1.2.2 Polymorphisms in P2X4 
The P2RX4 gene contains a few single nucleotide polymorphisms but not many studies 
were done to identify its functional impact on the P2X4 receptor. Stokes et al. (2011) 
were the first to demonstrate the impact of P2RX4 gene polymorphisms. They 
investigated four nonsynonymous coding single nucleotide polymorphisms (SNP) 
which were identified from the National Centre for Biotechnology Information Single 
Nucleotide Polymorphism database (build 126). It was found that one SNP (mutation 
at Tyr315>Cys (rs28360472)) appeared to have a profound effect on current amplitude 
compared to wild-type (WT) P2X4. Subsequent epidemiological study on 2,874 
subjects from the Victorian Family Heart Study revealed that 1.4 % from that 
population carried the minor allele mutation. Further analysis showed a positive 
correlation between the mutation and increased pulse pressure which may reflect 
reduced large arterial compliance because of vasodilation failure by large arterial 
vascular endothelial cells. 
 
Further study by Gu et al. (2013) also found a correlation between the same mutation 
at P2RX4 gene and Gly150>Arg mutation in the P2RX7 gene, with age-related macular 
degeneration (AMD) patients. This medical condition is the main factor for blindness 
in western countries which is characterised by the deposition of yellow substance 
called drusen, beneath retina. These deposits are physiologically scavenged by 
phagocytosis which is controlled by P2X7. Based on a population of 744 AMD patients 
and 557 control patients, they discovered that those mutations form a unique haplotype 
that is associated with increased susceptibility to AMD (odds ratio = 4.05). 
 
In another study, the researchers examined the effect of three non-synonymous SNPs 
at P2RX4 gene on bone mineral density (BMD) in an association with the risk of 
osteoporosis (Wesselius et al., 2013). The risk of osteoporosis was assessed by 
measuring BMD at different locations. The study was done on 921 patients with bone 
fractures which were divided into two groups; osteoporotic and non-osteoporotic. 
They found that patients with this polymorphism (Tyr315>Cys) in the P2RX4 gene 
have a 2.68-fold higher risk of osteoporosis compared to wild-type subject, with a 
significant decrease in BMD at the lower lumbar spine. They also found an anomaly 
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with another polymorphism (Ser242>Gly) where the affected patients gave contrary 
measurements of BMD at lumbar spine compared to the wild-type subject. 
1.2.3 Roles of P2X4 
P2X4 is widely distributed throughout many tissues of human body. The evidence of 
their tissue-specific roles have been highlighted by several studies, which will be 
discussed in greater detail below. 
1.2.3.1 Roles in the cardiovascular system 
Studies utilising the transgenic mouse model overexpressing P2X4 by Hu et al. (2001) 
illustrated that these mice have a higher basal level of cardiac output when compared 
to wild-type mice. This highlights the role of P2X4 in stimulating cardiac contractility 
in the human heart muscles. In addition to this, Yang et al. (2014) established a more 
sophisticated role of P2X4 in myocytes. Their finding was that P2X4 serves as 
protection against heart failure. This was based on their observation on cardiac-specific 
P2X4 knock-out and overexpressed mouse models which showed a clear difference on 
the impact of contractile performance and pressure overload between those models 
after infarction. The knock-out mice exhibited reduced contraction and pressure 
overload while the overexpressed mice showed the opposite. 
 
In addition to this, Northern blot analysis by Yamamoto et al. (2000) demonstrated 
that P2X4 was abundantly present in human vascular endothelial cells (ECs), e.g., 
aorta, pulmonary artery, and umbilical cord vein. Functionally, it was found to be 
responsible for the sustained phase of calcium influx in ECs (Yamamoto et al., 2000). 
Later, the same group showed a more detailed study on the functions of P2X4 in the 
ECs. P2X4 receptors were shown to play an important role in adapting the ECs 
structure and function in response to physical development and exercise. It was 
reported that the presence of P2X4 in ECs holds the key for blood vessel adaptation to 
blood flow and that there was no calcium influx that in turn leads to the production of 
nitric oxide (NO, a vasodilator) in P2X4 knock-out mice as well as a marked increase 
in blood pressure (Yamamoto et al., 2006). 
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In addition to that, Harhun et al. (2014) contributed the evidence of heteromeric P2X1/4 
presence in vascular smooth muscle cells. It has been understood that ATP is 
implicated in cerebral vasospasm via activation of rapidly-desensitising P2X1. 
However, it was unclear how the pathological condition sustains as P2X1 was rapidly 
desensitised. Therefore, the researchers discovered that P2X1/4 was involved with the 
process in which P2X4 contributed to the sustained phase of vasospasm. 
1.2.3.2 Roles in the respiratory system 
P2X4 receptors have also been found in various parts of the respiratory system, 
including in lamellar bodies (LBs) of alveolar type II epithelial cells (APII). Lamellar 
bodies are the large organelles that store insoluble surfactant which function to ease 
the surface tension. The surfactant is not easily released into the alveolar space. 
Miklavc et al. (2013) found that the P2X4 receptor facilitated the process. When LBs 
fuse with the APII membrane, the extracellular ATP from the alveolar space comes 
into the LBs and activates P2X4 which in turn promotes the release of Ca
2+ and Na+ 
into APII cells surrounding the fused vesicle. This further enlarges the pore of 
exocytosis and helps the release of surfactant. 
 
Recently, P2X4 has also been implicated in the development of allergic asthma (Zech 
et al., 2016). The study discovered that P2X4 played a role in causing airway 
inflammation that leads to asthma. P2X4 knock-out and 5-BDBD-treated wild-type 
mice were exposed to albumin in order to develop the allergen-induced airway 
inflammation (AAI) (that resembles allergic asthma). All mice were reported to exhibit 
increased expression of P2X4 and P2X7, as well as increased production of IL-1β 
following ATP stimulation. However, both P2X4 knock-out and wild-type mice treated 
with P2X4 antagonist (5-BDBD) showed reduced expression of P2X7 and IL-1β 
production along with reduced inflammation. The findings suggested that P2X4 played 
a role in the progression of allergic asthma and mediated the P2X7 expression in 
response to allergen. These findings were also in agreement with a previous study 
(Nagaoka et al., 2009) that proposed a link between P2X4 and bronchial asthma. 
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1.2.3.3 Roles in the nervous system 
In the nervous system, P2X4 receptors are abundantly present in glial cells and 
throughout the central nervous system. For example, microglia are the immune 
effector cells that naturally present in a ramified condition under physiological 
condition. In response to stimuli, microglia undergo morphological changes into a 
motile amoeboid form which then migrate to lesion sites, and subsequently release 
certain substances. Ohsawa et al. (2007) reported low P2X4 expression in normal brain 
and spinal cord, however the expression was enhanced in activated microglia 
following nerve injury. This finding was later verified by Li and co-researchers (2011) 
which suggests that the chemotactic microglial cells in postnatal rat brain were also 
mediated by P2X4. 
 
P2X4 has also been reported to be expressed at various regions of the central nervous 
system. This includes the CA1 region of hippocampus, in which P2X4 receptors are 
concentrated at the perisynaptic region of pre- and post-synaptic membranes (Rubio 
& Soto, 2001). This localisation of P2X4 receptors was shown to be involved in long-
term potentiation (LTP) (Sim et al., 2006). The stimulation of Schaffer collaterals in 
P2X4R knock-out mice produced significantly lower LTP magnitude compared to 
wild-type mice. This was further confirmed when ivermectin (IVM, a P2X4 allosteric 
positive modulator) further increased the LTP magnitude in wild-type mice. Unaltered 
LTP magnitude in knock-out mice, on other hand, ruled out the possibility of IVM 
potentiation on other receptors such as GABAA (GABAAR) and α7 nicotinic receptors. 
Thus, it was deduced that calcium influx through P2X4 receptor could enhance the 
long-term synaptic plasticity of hippocampal CA1 neurons. It was also postulated that 
P2X4 may be responsible for incorporating more AMPA receptors to subsynaptic 
membrane that result in LTP (Baxter et al., 2011). 
 
P2X4 receptor has also been directly associated with the neurotransmission process by 
interacting with GABAAR that might affect synaptic plasticity (Jo et al., 2011). 
Moreover, an interaction between P2X4 and dopamine transmission has recently been 
established (Khoja et al., 2016), where P2X4-deficient mice showed altered level of 
pre-synaptic markers such as dopamine transporter and post-synaptic markers such as 
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dopamine receptors. This remarkable finding provides a ground for new insights to 
treat the dopamine-related diseases such as psychiatry disorders. 
 
Apart from P2X4 receptor involvement in neurotransmission and synaptic plasticity, 
growing evidence indicates that P2X4 was also involved in alcohol-related issues 
(Yardley et al., 2012). It was initially shown that ethanol inhibited purinergic receptors, 
particularly P2X receptors (Li et al., 1993, 1998). Later, ethanol was shown to inhibit 
P2X4 expressed in Xenopus oocytes (Xiong et al., 2005, 2000) and HEK293 cells 
(Ostrovskaya et al., 2011). Converging lines of evidence suggested alcohol-related 
problems could be due to the P2X4 inhibition by ethanol. P2X4 knock-out mice 
displayed increased alcohol intake in relative to wild-type (Franklin et al., 2015), in 
agreement with a finding that reported the low expression of P2X4 receptors in alcohol-
preferring mice (Kimpel et al., 2007). The localisation of P2X4 receptors within 
mesolimbic pathway including the ventral tegmental area (VTA) of the midbrain, 
amygdala, and hippocampus supported the hypothetical link between P2X4 receptors 
and reward- and aversion-related neurotransmission (as reviewed by Franklin et al. 
(2014)). 
1.2.3.4 Roles in the immune system 
The expression of P2X4 receptor has been shown to be upregulated during 
inflammatory conditions. One of the discoveries of P2X4 in pathological conditions 
was described by Solini et al. (2007) who suggested the involvement of P2X4 in the 
apoptosis of human mesangial cells (HMC). Extracellular ATP activates the highly 
expressed P2X4 receptor in HMC that in turn triggers the cell death in case of chronic 
renal disease. 
 
P2X4 receptor was also found to be highly expressed in peripheral myeloid cells (Wang 
et al., 2004). It was thought that P2X4 was involved during inflammatory processes, 
which contributed the release of prostaglandin E2 (PGE2), a regulator for 
inflammatory responses. The synthesis of inflammation-linked PGE2 is a result of 
cytosolic phospholipase A2 α (cPLA2) that releases arachidonic acid (AA). The 
enzymatic reaction of cPLA2 is highly dependent on intracellular calcium and ATP is 
one of several extracellular signalling molecules that can trigger calcium rise and 
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therefore, an activator for cPLA2 (Balboa et al., 1999). Ulmann et al. (2010) 
investigated the possibility of P2X4 activation in cultured macrophages to cause AA 
production and consequently PGE2 production and their finding was in accordance 
with the theory that P2X4 activation lead to PGE2 release through cPLA2 activity 
which in turn, caused the inflammation. 
 
P2X4 was also reported to be related with immune response stimulation involving T 
cell activation and proliferation. It is known that T cell activation requires an 
immunological synapse with antigen-presenting cells (APC) which subsequently 
activates a signalling cascade that includes ATP release as one of intermediates. The 
release of ATP is facilitated by pannexin-1, a gap junction hemichannel, once the T 
cell receptor (TCR) communicates with APC. The P2X4 receptor has also been shown 
to take part in T cell activation (Schenk et al., 2008). Therefore, Woehrle et al. (2010) 
investigated the relationship between pannexin-1, P2X1, and P2X4 in relation to T cell 
stimulation. It was found that the pannexin-1 and P2X4 were involved during the 
amplification of T cell activation and proliferation, despite the limited number of TCR 
at immune synapse that may restrict T cell activation. 
1.2.3.5 Roles in the endocrine system 
Many reports indicated that P2X4 receptors are present at various sites of the endocrine 
system and contribute in the activities of gonadotrophin-releasing hormone neuron, 
thyroid gland, adrenal cortex, lactotrophs, and anterior pituitary gland, as reviewed by 
Bjelobaba et al. (2015). Despite its ubiquitous expression throughout the endocrine 
system, its role at various locations have been largely unexplored. Zemkova et al. 
(2010), among others, investigated the expression of P2X receptors in anterior 
pituitary cells using quantitative RT-PCR analysis and found that P2X4 was the most 
abundant in the cells. The receptors were suggested to trigger secretory pathways 
involving thyrotropin-releasing hormone-responsive cells and lactotrophs by initiating 
and regulating the electrical activity and recruiting calcium influx. 
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1.2.4 P2X4 and tactile allodynia 
Tactile allodynia, as understood so far, is a type of neuropathic pain which is believed 
to be resulted from peripheral nerve injury (PNI). This disease is primarily 
characterised by persistent pain or recurrence of pain independent of stimulus (Murphy 
et al., 2017). Pain experienced by patients includes a feeling of burning, and shooting 
pain. The sufferers are highly sensitive to pain, that in some extreme cases, even a light 
touch can result in a great pain. The aetiology and mechanism by which this disease 
occurs are largely unexplained. It might be caused by a collection of mechanisms or 
one mechanism that could lead to many conditions (Scholz & Woolf, 2002; Woolf & 
Mannion, 1999). However, numerous outstanding discoveries over the past decade 
have produced a mutual consensus that the PNI causes microglial activation which 
leads to its pathogenesis. The underlying mechanisms on the process of microglial 
cells activation and subsequent cascades are the interesting issues that demand further 
exploration. 
 
The first association between P2X4 and tactile allodynia was demonstrated by Tsuda 
et al. (2003). A non-selective P2X4 antagonist, TNP-ATP, was used to demonstrate 
that inhibition of P2X4 receptor reduces the hypersensitivity in animals with nerve 
injury. They also ruled out the involvement of other P2X receptors using low 
concentration of PPADS which was sufficient to block other P2X receptors. They 
found that PPADS failed to attenuate pain hypersensitivity in the animals used, 
indicating P2X4 was the only receptor responsible for hypersensitivity.  
 
There were many other studies that revealed historical findings in understanding tactile 
allodynia development which will be discussed in the next three sections. The first 
section will discuss on the signalling cascades that lead to P2X4 receptor upregulation, 
the second section will scrutinise the downstream pathway resulted from P2X4 
upregulation, and the third section will summarise the first two sections. 
1.2.4.1 Signals which upregulate P2X4 
There are several studies have been done to elucidate the possible processes that lead 
to the upregulation of P2X4 receptors. One such study was carried out by Zhang and 
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De Koninck (2006). They demonstrated that chemoattractant protein-1 (MCP-1), also 
known as CCL2, was responsible for microglial cell activation after PNI. CCL2 was 
induced in a few parts of the spinal cord that is ipsilateral to the injury site and the 
induction subsequently leads to the activation of microglial cells, which is confirmed 
through the morphological changes of microglia and antibody-labelled P2X4 receptors. 
Later, they asserted that the interaction between CCL2 and its receptor, CCR2, is 
essential during the microglial activation, not only on the resident microglia at the 
spinal cord, but also macrophages/monocytes that migrated into the spinal cord, 
proliferated, and differentiated into microglia. The CCR2-deficient model (native 
receptor for CCL2) did not display the symptoms of neuropathic pain or even 
microglial activation when the CCL2 was injected intrathecally. Moreover, 
neutralising CCL2 also inhibited the infiltration of macrophages into spinal cord 
(Zhang et al., 2007). 
 
Kim et al. (2007) explained another component that might be involved in the 
progression of tactile allodynia. They showed the participation of toll-like receptor 2 
(TLR2) during the activation of glial cells, which is vital for the development of 
allodynia. They also showed that the expression of interleukin-1β, interleukin-6, 
tumour necrosis factor-α (TNF-α), and inducible nitric-oxide synthase (iNOS) were 
induced in spinal cord glial cells after sensory neurons were damaged. Later, the same 
group further investigated the involvement of TLR2 in tactile allodynia. They 
demonstrated that the receptor was also responsible for the upregulation of NADPH 
oxidase 2 (Nox2) (Lim et al., 2013) and interferon regulatory factor (IRF8) (Lim et al., 
2016). 
 
Nox2 has been shown to be induced in spinal cord microglia after PNI. The induction 
of Nox2 in turn stimulates the production of reactive oxygen species (ROS) which is 
required for microglia activation and pain hypersensitivity (Lim et al., 2013). 
Meanwhile, IRF8 is a main transcription factor in microglial activation after PNI. They 
discovered the TLR2 knock-out mice did not display the upregulation of IRF8, and 
potentiating the TLR2 with an agonist marked an increase in IRF8 transcription (Lim 
et al., 2016). Earlier, the importance of IRF8 in microglial activation was implicated 
by Masuda et al. (2012) who proposed that the IRF8 is an important transcription factor 
that increases the transcription of genes required for activated microglia. 
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In addition to IRF8, Masuda et al. (2014) also found another transcription factor that 
is crucial for P2X4 receptor upregulation, namely interferon regulatory factor-5 
(IRF5). It was reported that its expression was induced after PNI and that it bound 
directly to the promoter region of P2RX4 gene. Observation on IRF5-deficient mice 
proved that P2X4 was not upregulated after PNI and that hypersensitivity was 
compromised. Moreover, they demonstrated a relationship between the two 
transcription factors where IRF8 regulated the expression of IRF5 in microglia. 
Together, IRF5 and IRF8 are two major transcription factors that are directly 
responsible for upregulating the P2X4 receptors in microglia. 
 
Tsuda et al. (2008b) found that the Src-family kinases (SFK), particularly Lyn, was 
key players in the development of allodynia. Lyn was the most abundant SFK in the 
central nervous system. Lyn expression was found to be confined to microglia and 
increased after PNI. Apart from that, Lyn knock-out mice also displayed reduced 
upregulation of P2X4 receptor expression following PNI, indicating that the kinases 
were one of many possible signals in causing the P2X4 receptor upregulation. 
 
The same group also delineated the involvement of fibronectin/integrin in P2X4 
upregulation at the spinal cord after PNI. Fibronectin is a molecule in the extracellular 
matrix and it has been shown to regulate the microglial functions. The receptor for 
fibronectin is integrin, which can be a heterodimer between 18 α subunits and 8 β 
subunits (Campbell & Humphries, 2011). In case of tactile allodynia, fibronectin was 
found to upregulate the expression of P2X4 receptor (Tsuda et al., 2008a). The 
blockade of integrin using echistatin in an in vivo study revealed failed upregulation 
of P2X4 receptors, while introduction of fibronectin into normal rats induced P2X4 
upregulation prior to development of tactile allodynia. 
 
Later, the same team made another discovery regarding the possible cytokine or 
receptor which involved in microglia activation. They unearthed the involvement of 
cytokine IFN-γ together with its receptor (IFN-γR). The receptors are present in naïve 
microglia and upon activation of receptors, the microglia become activated and tactile 
allodynia develops. Meanwhile, the IFN-γR knock-out mice exhibited reduced 
sensitivity of some microglia (not all) to PNI. This might be explained through the fact 
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that microglia activation is not a result of IFN-γ/IFN-γR signalling alone, rather it 
involves a collection of mechanisms that can lead to its activation. Interestingly, the 
activation of IFN-γR also increases the expression of Lyn tyrosine kinase and P2X4 
receptors, which indicates that the IFN-γ/ IFN-γR cascade occurs during the pre-SFK 
activation (Tsuda et al., 2009).  
 
Besides, Biber et al. (2011) elucidated another molecule that is important in P2X4 
receptor upregulation. CCL21 expression was found to be induced at the nerve injury 
site and it is transported to their central terminals in the dorsal horn. In CCL21 knock-
out mice, the P2X4 receptor expression level remains unchanged after nerve injury, 
and injection of CCL21 into CCL21 knock-out model induces the overexpression of 
P2X4 receptor. CXCR3 and CCR7 are the receptors for CCL21, however this study 
indicated that neither is crucial for CCL21 cascade signalling since knock-out mice of 
either receptor produced similar reduction in paw withdrawal threshold (PWT), a 
characteristic of model with hyperalgesia. This finding presented a direct evidence that 
CCL21 is indeed a very crucial factor during the upregulation of expression of P2X4. 
1.2.4.2 Signalling downstream of P2X4 
Tsuda et al. (2004) associated tactile allodynia with the activation of p38 mitogen-
activated protein kinase (p38MAPK) in spinal microglia of rat model (Tsuda et al., 
2004). Immunofluorescence assay revealed that this protein kinase is overexpressed in 
the dorsal horn at the injury site, particularly in microglia, but not in the opposite side. 
Moreover, the use of a p38MAPK inhibitor, 4-(4-fluorophenyl)-2-(4-
methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) inhibited the 
development of nerve injury-associated tactile allodynia.  
 
Coull et al. (2005) addressed another remarkable finding in understanding neuropathic 
pain development. They found that activated microglia following PNI changes the 
anion reversal potential (Eanion) in spinal lamina I neurons, and that application of 
brain-derived neuropathic factor (BDNF) to a naïve rat model resembles the Eanion 
changes. The receptor for BDNF, TrkB, has been shown to interact with BDNF that 
subsequently causes Eanion changes. In addition, under normal condition, GABA (γ-
amino butyric acid) causes the inhibition of action potentials which results in the 
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inhibition of nociceptive signals. However, in this case, GABA through its receptor 
(GABAR) causes the opposite outcome, instead of being inhibitory, it excites action 
potentials and sequentially transmits more pain signals. This was observed on some, 
but not all, lamina I neurons when GABA is applied. 
 
In agreement with previous discovery by Coull et al. (2005), Ulmann et al. (2008) 
identified additional knowledge on the consequence of P2X4 receptor upregulation. 
They presented direct evidence showing that the P2X4 upregulation and activation by 
ATP subsequently cause the release of BDNF, which has been indicated to be a vital 
signalling molecule between activated microglia and neurons in hypersensitivity cases. 
The release of BDNF from microglia is likely to mediate the downregulation of K+/Cl− 
cotransporter KCC2 in inhibitory neurons, which results in allodynia. 
 
Trang et al. (2009) further investigated the process of BDNF release from microglia 
upon P2X4 receptor stimulation by ATP. They made several interesting discoveries in 
their study. Upon activation of P2X4 receptor by ATP, the influx of calcium in turn 
activates p38MAPK, a signalling mechanism as implicated by Tsuda et al. (2004). The 
p38MAPK activation then causes the upregulation of BDNF expression as well as the 
release of BDNF from microglia. They also found that the BDNF release occurs 
through soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) 
receptor (SNARE)-dependent exocytosis. These findings are also in agreement with 
Xiaodi et al. (2010) who found the same signalling cascade in rat model with 
mechanical hypersensitivity. 
 
In addition to that, Slack et al. (2005) demonstrated the presence of TrkB, a high-
affinity receptor for BDNF in spinothalamic tract, a route where nociceptive 
information was transmitted in the spinal cord. The presence of TrkB supports 
previous findings which stated that the BDNF was crucial in neuropathic progression. 
Microinjection of BDNF and capsaicin introduction to naïve rats stimulate the PNI and 
subsequently produce BDNF, both cause the activation of extracellular signal-
regulated protein kinase (ERK) phosphorylation in TrkB containing neurons. 
Induction of ERK phosphorylation was earlier observed by Ji et al. (1999) (as cited in 
Slack et al. (2005)) as an important sequential event in hyperalgesia development. 
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Next, Katsura et al. (2006) documented another possible signalling mechanism in the 
tactile allodynia development. They reported PNI stimulated the activation of SFK, 
including Src, Lck, and Lyn at the microglia of spinal dorsal horn. The activation in 
turn rises the phosphorylation of ERK and contributes to the pathogenesis of 
mechanical hypersensitivity. Blocking SFK with 4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine (PP2) signifies a halt on the activation of ERK and 
mechanical hypersensitivity caused by nerve injury, but not by cold and heat. 
1.2.4.3 Summary of tactile allodynia signalling cascade 
After extensive in-depth studies about the disease over decades, a unifying mechanism 
for its development was proposed by Beggs and Salter (2010) and Trang and Salter 
(2012). After PNI, several proteins and cytokines such as CCL2, CCL21, IFN-γ, and 
fibronectin are upregulated and activated. Although some studies argued against the 
hypothesis of CCL2 upregulation since its receptor (CCR2) is absent in microglia, its 
involvement during the development of nerve-injury induced neuropathic pain is 
evident (Biber & Boddeke, 2014). The involvement of CCL21 was clear based on 
several convincing evidences that link the CCL21 with P2X4 receptor upregulation 
although its receptors (CCR21 and CXCL3) are not important in the process. Instead, 
it was proposed that it could be another unknown CCL21 receptor that is activated 
during this signalling mechanism (Biber & Boddeke, 2014). Meanwhile, the binding 
of IFN-γ to its receptor, IFN-γR, subsequently activates the SFK signalling (Lyn 
particularly) cascade and phosphorylation of ERK (Tsuda et al., 2009). 
 
Fibronectin, on the other hand, has been quite well elaborated. Its binding to its 
receptor, integrin, stimulates microglia to their activated form and that upregulates the 
IRF5 expression. In addition to that, the activation of TLR2 by an unknown protein 
upregulates another transcription factor, IRF8. The upregulation of IRF5 is controlled 
by IRF8, which then induces the upregulation of de novo expression of P2X4 receptors 
by directly binding to promoter region of P2X4R gene. Together, the CCL2, CCL21, 
IFN-γ, and fibronectin are all being stimulated in response to PNI and the stimulation 
activates microglia with the upregulated P2X4 receptor expression (Trang & Salter, 
2012). 
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Following the upregulation of P2X4 and its activation by ATP, presumably released as 
neurotransmitter, P2X4 activates p38MAPK. The activation of p38MAPK induces 
synthesis and release of BDNF via SNARE exocytosis. The BDNF then binds to its 
high affinity receptor, TrkB on the neurons and further causes changes in Eanion. The 
changes in anion reversal potential might be due to the downregulation of KCC2 which 
causes the accumulation of Cl− in neurons. High neuronal [Cl−] causes the impairment 
in GABA receptor function which, under normal condition, plays its role to 
compensate the loss of Cl− by extrusion through KCC2 and accordingly causes 
inhibition in transmission. The impairment, however, disinhibits the transmission and 
rather potentiates the nociceptive transmission that turns innocuous stimuli into 
noxious stimuli, which consequently results in tactile allodynia (Beggs & Salter, 2010; 
Stokes et al., 2017; Trang & Salter, 2012). 
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Figure 1.6 Schematic presentation of signalling involved in hypersensitivity 
The figure illustrates signals involved in the process of hypersensitivity. Several cytokines are released in response to PNI and act on their respective 
receptors on microglia cells. The activation of those receptors causes the P2X4 to be upregulated, particularly TLR2 that has been directly associated 
with upregulation of IRF8 and IRF5. Both regulate the transcription of P2X4R gene. Increased calcium influx through upregulated P2X4 receptors 
in turn activates the p38MAPK, that subsequently causes overexpression of BDNF in addition to release BDNF through SNARE-dependent 
exocytosis. BDNF interacts with its receptor (TrkB) which then downregulates the KCC2 and causes alteration on membrane properties of dorsal 
horn lamina 1 neuron. This change can then potentiate the firing of impulse through NMDAR potentiation which eventually leads to 
hypersensitivity.
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1.2.5 P2X4 subcellular localisation and trafficking 
P2X receptors are continuously recycled between the plasma membrane and 
intracellular compartments. It was postulated that this is the way the cells control the 
up or downregulation of receptors. The seven members of P2X receptors show 
different cellular distribution due to different receptor trafficking properties. The 
receptors are predominantly localised at the plasma membrane or within endosomes 
and lysosomes while some are localised within the endoplasmic reticulum (Bobanovic 
et al., 2002; Qureshi et al., 2007; Robinson & Murrell-Lagnado, 2013).  
 
The investigation on P2X4 subcellular distribution revealed that the predominant 
distribution of P2X4 receptors is within the late endosomes and lysosomes. The ability 
of P2X4 receptors to resist proteolytic environment of the lysosomes is attributed to N-
linked glycans which can be found within the intra-luminal loop of the receptor 
(Bobanovic et al., 2002; Boumechache et al., 2009; Qureshi et al., 2007). The receptors 
are rapidly internalised from the plasma membrane through a dynamin-dependent 
mechanism as an evidence showed that mutated dynamin-1 increases the surface 
expression of P2X4 as well as ATP-evoked response (Bobanovic et al., 2002). In 
macrophages, P2X4 receptors in the lysosomes are exocytosed to the plasma 
membrane, stimulated by intracellular calcium increase and this has been hypothesised 
to be a mechanism of which surface P2X4 is upregulated (Qureshi et al., 2007). 
 
Molecular studies showed that the internalisation involves a non-canonical tyrosine-
based endocytic motif of the form YXXGL at C terminal of the P2X4 receptor which 
interacts with a clathrin- and AP2-dependent pathway (Royle et al., 2002, 2005). 
Recently, Xu et al. (2014) generated mouse P2X4 carrying a pHluorin tag that shows 
the same characteristics with wild-type P2X4. This can greatly facilitate the research 
of P2X4 trafficking through live imaging experiments. 
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1.2.6 Pharmacology 
1.2.6.1 Agonists 
All homomeric and heteromeric P2X receptors are activated by ATP but the affinity 
for ATP is receptor-specific with the EC50 values ranging from nanomolar to 
submillimolar concentrations (Coddou et al., 2011). At the rat P2X4 heterelogously 
expressed in Xenopus oocytes, ATP acts as the most potent agonist with an EC50 value 
of 10 µM and this is followed by ATPγS, 2-methylthio ATP (2meSATP), ADP, and 
αβ-methylene ATP (the last two have similar potency) (Bo et al., 1995). A subsequent 
study by Soto et al. (1996) using rat P2X4 also revealed a similar potency order of ATP 
> 2meSATP ≥ CTP > α,β-meATP > dATP but no response was evoked by ADP, AMP, 
GTP, adenosine, or β,γ-methylene-ATP analogue. The concentration-response 
analysis displayed an EC50 value of 6.9 ± 0.8 µM for ATP. Early studies of the human 
P2X4 receptor expressed in Xenopus oocytes demonstrated a similar agonist potency 
order of ATP > 2meSATP ≥ CTP > α,β-meATP > dATP and a similar value of ATP 
EC50 value, i.e., 7.4 ± 0.5 µM (Garcia-Guzman et al., 1997). A study using three P2X4 
orthologues (human, rat, and mouse) expressed in HEK293 displayed EC50 values of 
5.5 µM, 1.5 µM, and 2.3 µM, respectively (Jones et al., 2000). BzATP has also been 
discovered to be a partial agonist of rat and human P2X4 receptors (Stokes et al., 2017). 
1.2.6.2 Positive modulators 
Positive allosteric modulators are the compounds that increase response by binding to 
an allosteric site of a receptor. One of the best positive allosteric modulators for P2X4 
is ivermectin (IVM). Ivermectin is a derivative of a macrocyclic lactone which is 
highly lipophilic. It has long been used as an antiparasitic and anthelmintic drug but it 
has also been reported to positively modulate several ligand-gated ion channels 
including GABAAR (Kru˚šek & Zemkova´, 1994) and α7 neuronal nicotinic 
acetylcholine receptor (Krause et al., 1998). Ivermectin’s potentiation at P2X4 was 
recorded to be attributed via two effects; it slowly deactivates the receptor and 
increases the magnitude of agonist-evoked response (Khakh et al., 1999). Ivermectin 
was reported to be selective to P2X4 (Khakh et al., 1999) but recently, Norenberg and 
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co-authors (2012) found that IVM can also positively modulate human P2X7, but not 
mouse P2X7. 
 
The IVM mechanism of action has been extensively elaborated by numerous 
researches. There are several theories explaining its mechanism of action. Priel and 
Silberberg (2004) stated that IVM binds allosterically to outer region of the P2X4 
receptor and there are two possible allosteric sites for IVM binding, identified as higher 
and lower affinity sites based on their EC50 values. It was postulated that IVM at the 
higher affinity site reduces channel desensitisation and thereby increases the current 
magnitude, while IVM at the lower affinity site stabilises the open state of the receptor 
and thereby slows the deactivation time. This hypothesis was progressively supported 
by later studies that discovered, rather than acting on the outer region of P2X4 receptor, 
that IVM enters the bilayer plasma membrane through lateral fenestration of the open 
state receptor, binds, and jams the opening of P2X4 receptor at allosteric site in 
transmembrane helices. This allows more calcium to enter and slows the decay 
kinetics. (Jelínková et al., 2006; Silberberg et al., 2007). 
 
In agreement with previous findings, Jelínkova et al. (2008) brought more evidence 
showing the action of IVM is indeed through the binding with transmembrane domain. 
Their cysteine-scanning mutagenesis study revealed that IVM was not sensitive at 
P2X4 with mutations at one of these residues: Arg33, Gln36, Leu40, Val43, Val47, 
Trp50 of TM1 and Asn338, Gly342, Leu346, Ala349, Cys353, Ile356 of TM2. 
Comparing the residues with the topological structure of P2X4 receptors, those 
residues appeared to line the outer helical side of transmembrane domain in addition 
to principally a hydrophobic-nonpolar region. These two statements provide more 
evidence that hydrophobic IVM binds to the transmembrane domain. In addition to 
this, Zemkova and colleagues (2014) also proposed that the binding of IVM may 
involve two neighbouring subunits, inferred from the fact that a single mutation of the 
abovementioned residues failed to totally diminish IVM action in the previous study. 
 
In contrary to Silberberg et al. (2007), Toulmé et al. (2006) earlier reported a slightly 
different view for the mechanism. The P2X4 receptors are continuously cycled 
between the intracellular environment and the plasma membrane. In their experiment, 
it was demonstrated that IVM acted by increasing the surface expression of P2X4 
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receptors due to a mechanism that involves a constitutive AP2/clathrin-dependent 
internalisation, and the potentiation characteristic of IVM (in comparison to untreated) 
is absent when the clathrin-dependent endocytosis mechanism is compromised. 
However, IVM still causes delayed deactivation in deficient clathrin-dependent 
internalisation model. Thus, they proposed that IVM potentiates magnitude of P2X4 
response via increasing surface expression of P2X4 receptors. In congruity with 
Toulmé et al. (2006), Stokes (2013) observed the same finding in a study. It was 
suggested that the action of IVM is indeed dependent on the internalisation 
mechanism. 
 
Nevertheless, the two findings did not oppose each other, but are rather 
complementary. Stokes (2013) stated that IVM may bind to the transmembrane region 
of P2X4 receptor and stabilise the open state. This in turn may prevent the endocytosis 
of receptors into the cytosol. On the other hand, P2X4 receptors are continually 
reinserted into the plasma membranes. Together, these situations — prevention of 
internalisation of IVM-bound P2X4 receptors and the continuous reinsertion of P2X4 
receptors — may be interpreted as increased surface expression. 
 
In short, IVM potentiates P2X4 response during an open state and it alone cannot cause 
channel activation. Once P2X4 receptor is activated, IVM enters the membrane lipid 
bilayer through lateral opening and binds to transmembrane domain between two 
neighbouring subunits. The hydrophobic regions of TM1 and TM2 are the most 
possible binding site for IVM as the compound is lipophilic and the molecular structure 
configuration of both transmembrane region and IVM complement each other 
(Jelínkova et al., 2008). Once bound to the higher affinity binding site, it increases the 
response, while binding to the lower affinity region prolongs deactivation time by 
blocking the closure of receptor. It is also possible to deduce that the binding of IVM 
also prevents the internalisation of surface receptor while reinsertion of the receptors 
causes elevated surface P2X4 receptor expression. 
 
Ivermectin was also reported to antagonise the ethanol effect of P2X4 receptor 
expressed in Xenopus oocytes. The electrophysiology data showed that IVM can 
overcome the inhibition by ethanol (Asatryan et al., 2010). Yardley et al. (2012) also 
found that when IVM is injected into mice, it can reduce their alcohol intake and 
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preference. Recent findings showed that an analogue of IVM, moxidectin, could also 
potentiate the P2X4 response and antagonise the inhibition of ethanol as well as 
alleviate alcohol intake by mice (Huynh et al., 2017). Other IVM analogues that have 
been reported to potentiate the P2X4 responses include avermectin, doramectin, and 
emamectin (Silberberg et al., 2007). Avermectin showed comparable potentiation to 
IVM while the last two compounds displayed potentiation to a lesser extent (Silberberg 
et al., 2007). 
1.2.6.3 Non-selective antagonists of P2X4 
The research into P2X4 has been hampered due to the lack of selective antagonists. 
The scientists depend on broad-spectrum antagonists such as suramin, PPADS, and 
brilliant blue G (BBG) together with other inhibitory techniques such as divalent 
cations, pH, and several drugs (anti-depressants and statins). Table 1.3 shows the 
summary of non-selective antagonists identified so far. 
1.2.6.3.1 Broad-spectrum antagonists 
It has been demonstrated that 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate 
(TNP-ATP) competitively blocked the activation of human P2X4 receptor with an IC50 
value of 15.0 μM, however it is at least 2000-fold more potent at P2X1, P2X3, and 
P2X2/3 (Hernandez-Olmos et al., 2012; Virginio et al., 1998). Suramin is another 
broad-spectrum antagonist of purinergic receptors and it shows a very weak inhibition 
at human, mouse, and rat P2X4 orthologues. Jones et al. (2000) reported that the 
inhibition was only 11 – 35 % across the P2X4 orthologues when 100 µM suramin was 
used. In addition to this, human and mouse P2X4 were reported to be sensitive to 
PPADS with IC50 values of 9.6 µM and 10.5 µM, respectively but relatively less 
sensitive at rat P2X4 with an inhibition of ~50 % when 100 µM PPADS was used. 
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Table 1.3 The list of P2X4 antagonists 
Name IC50 value (µM) 
(Species) 
Type of 
expressing cells 
Mode of action Selectivity (human 
paralogues) 
Reference 
5-BDBD 
0.5-1.2 (human, current) 
0.35 (human, calcium) 
3.47 (rat, calcium) 
2.04 (mouse, calcium) 
HEK293 Competitive Not reported 
(Abdelrahman et al., 
2017; Balazs et al., 
2013; Fischer et al., 
2004) 
Paroxetine 
1.87 (human, calcium) 
2.45 (rat, calcium) 
Human 
astrocytoma 
Noncompetitive Not reported (Nagata et al., 2009) 
N,N-diisopropyl-5H-
dibenz[b,f]azepine-
5-carboxamide 
3.44 (human, calcium) 
54.6 (rat, calcium) 
14.9 (mouse, calcium) 
Human 
astrocytoma 
Noncompetitive 
>1.5-fold (P2X1, P2X3) 
>30-fold (P2X2) 
>27-fold (P2X7) 
(Tian et al., 2014) 
PSB12054 
0.19 (human, calcium) 
2.10 (rat, calcium) 
1.77 (mouse, calcium) 
Human 
astrocytoma 
Allosteric 
>34-fold (P2X1) 
>50-fold (P2X2, P2X3, P2X7) 
(Hernandez-Olmos 
et al., 2012) 
PSB12062 
1.38 (human, calcium) 
0.93 (rat, calcium) 
1.76 (mouse, calcium) 
Human 
astrocytoma 
Allosteric 
>50-fold (P2X1, P2X2, P2X3, 
P2X7) 
TNP-ATP 15.2 (human, current) HEK293 Competitive 
More potent at P2X1, P2X2, 
P2X2/3 and P2X3 (IC50 <2 µM) 
>2-fold (P2X7) 
(Hernandez-Olmos 
et al., 2012; Virginio 
et al., 1998) 
NP-1815-PX 0.26 (human, calcium) 
Human 
astrocytoma 
Not reported 
>100-fold (P2X1, P2X2/3, P2X7 
>28-fold (P2X2) 
 
(Matsumura et al., 
2016) 
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BX430 
0.55 (human, current) 
1.89 (zebrafish, current) 
HEK293 Noncompetitive 
>10-fold (P2X1, P2X2, P2X3, 
P2X4, P2X5) 
>100-fold (P2X7) 
(Ase et al., 2015) 
Duloxetine 1.59 (human, calcium) 
Human 
astrocytoma 
Not reported 
Not reported (Yamashita et al., 
2016) 
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1.2.6.3.2 Divalent cations and pH 
Several divalent cations have been shown to cause modulation on ATP-evoked 
response at P2X4 receptors. Zn
2+ was reported to potentiate ATP-evoked response at 
low concentrations (0.1 – 10 µM) but it inhibited the response at higher concentrations  
 (30 µM – 1 mM) (Acuña-Castillo et al., 2000; Garcia-Guzman et al., 1997; Wildman 
et al., 1999). Further investigation on other transition metals from the same group in 
the periodic table as Zn2+ revealed that Cd2+ demonstrated slightly less potentiation 
compared to Zn2+, while Cu2+ and Hg2+ inhibited the ATP-evoked response (Acuña-
Castillo et al., 2000). In addition to this, the ATP-evoked response of P2X4 was also 
affected by pH. A high concentration of H+ (pH 6.5 and pH 5.5) progressively reduced 
the potency of ATP in evoking the response and the efficacy was also reduced at pH 
6.5 (Clarke et al., 2000) and pH 5.5 (Wildman et al., 1999). 
1.2.6.3.3 Antidepressants 
Nagata and co-researchers (2009) investigated some antidepressant drugs to observe 
the ability of those drugs to inhibit P2X4. This was due to the clinical evidences that 
showed the drugs were effective in modulating pain. They tested paroxetine, 
fluoxetine, maprotiline, and clomipramine on 1321N1 cells stably expressing human 
P2X4 receptor. It was observed that those drugs inhibited the P2X4 activity and 
paroxetine showed the most potent inhibition with an IC50 value of 1.87 μM. This was 
also supported by a recent study that showed paroxetine has a direct inhibition on P2X4 
(Abdelrahman et al., 2017). However, another study claimed that those four 
antidepressants did not significantly inhibited the P2X4 receptor even at high 
concentrations up to tens of micromolars, tested on activated mouse cerebellar 
immortalised microglial C8-B4 cell line. Nonetheless, it was noticed that the 
antidepressants (at small concentration of 500 nM) reduced the upregulation of cell 
membrane P2X4 receptor by impairing lysosomal function and subsequently lead to 
smaller response (Toulme et al., 2010). These contradictory results might be explained 
by the fact that the cell systems used in both experiments were different. The 1321N1 
cells may be more susceptible to the antidepressants and thus, cause reduced 
upregulation of cell membrane P2X4. 
  
57 
 
1.2.6.3.4 Statins and cholesterol depleting agents 
An HMG-CoA reductase inhibitor, fluvastatin, was discovered by Li and Fountain 
(2012) to inhibit the activation of P2X4 through a calcium-based assay on 
heterologously expressed P2X4 in HEK293 cells and native P2X4 in human THP-1 
monocytes. The inhibition of P2X4 was postulated to occur through cholesterol 
depletion that might interfere with the receptor trafficking. 
1.2.6.4 Selective antagonists 
The researchers have been using the non-selective antagonists of P2X4 such as suramin 
and TNP-ATP for a considerable amount of time. This has impeded the development 
of pharmacological insight into P2X4 receptors. Since 2006, there have been several 
novel compounds identified, which are selective to P2X4 and this has provided a new 
avenue for scientists to selectively target P2X4. Table 1.3 shows the summary of 
selective antagonists identified so far. 
1.2.6.4.1 Carbamazepine derivatives 
A total of 47 carbamazepine derivatives including 32 novel compounds were 
investigated for P2X4 receptor antagonists study. A compound, N,N-diisopropyl-5H-
dibenz[b,f]azepine-5-carboxamide, was reported to potently and allosterically block 
P2X4 activity with an IC50 value of 3.44 μM. The compound was not fully selective 
for P2X4 as it showed a considerable blockade at P2X1 and P2X3, but was selective 
versus P2X2 and P2X7 which indicates that more optimisation is needed. The 
compound was found to be less potent at mouse and rat (IC50 values: 14.9 µM and 54.6 
µM, respectively) (Tian et al., 2014). 
1.2.6.4.2 N-substituted phenoxazine 
Two phenoxazine derivatives were reported to exhibit potent inhibition at P2X4 which 
were PSB12054 (N-(Benzyloxycarbonyl)phenoxazine (II)) with IC50 value of 0.189 
μM and PSB12062 (N-(pMethylphenylsulfonyl)phenoxazine) with IC50 value of 1.38 
µM, at the human P2X4 receptor expressed in human astrocytoma cells (Hernandez-
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Olmos et al., 2012). The former compound was reported to be less potent on rat (IC50 
value of 2.1 µM) and mouse (IC50 value of 1.77 µM) P2X4 and the latter is similarly 
potent at all P2X4 orthologues tested (IC50 values: rat = 0.928 µM, mouse = 1.76 µM). 
PSB12054 blocks noncompetitively and is highly selective for the human P2X4 
receptor with over 50-fold selectivity against P2X2, P2X3, and P2X7 and over 30-fold 
against P2X1. PSB12062 is also an allosteric blocker with 35-fold selectivity towards 
P2X4 versus P2X1, P2X2, P2X3, and P2X7. 
1.2.6.4.3 BX430 
Ase et al. (2015) recently revealed a novel compound that negatively modulates P2X4 
receptor. The discovery was a consequence of high throughput screening of a 
compound library of 26,240 compounds. The compound, known as BX430, was 
claimed to have an IC50 value of 0.54 µM. Further testing on other P2X paralogues 
unearthed its selectivity for P2X4 only, with effective dose at other P2Xs about 10 – 
100 times to its IC50 value at P2X4. However, BX430 was proven to inhibit the zfP2X4 
and hP2X4, but not rP2X4 and mP2X4 despite their high similarity in amino acid 
sequence among all those orthologues. 
1.2.6.4.4 NP-1815-PX 
A recent discovered antagonist of P2X4 receptor, NP-1815-PX (5-[3-(5-thioxo-4H-
[1,2,4]oxadiazol-3-yl)phenyl]-1H-naphtho[1, 2-b][1,4]diazepine-2,4(3H,5H)-dione), 
was identified from a high throughput screening of a chemical library using calcium-
based assay on human astrocytoma cells stably expressing human P2X4 receptor with 
an IC50 value of 0.26 µM. The compound was claimed to fit some characteristics that 
previous compounds did not, in which it is highly potent, selective, and effective across 
P2X4 orthologues, as well as high water solubility and in addition, has been shown to 
be effective in attenuating pain on chronic pain mouse model (Matsumura et al., 2016). 
1.2.6.4.5 Duloxetine 
Yamashita et al. (2016) discovered another antagonist of P2X4 receptor as a result of 
high throughput screening of 1,979 compounds obtained from Drug Discovery 
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Initiative, University of Tokyo. The compound, duloxetine, was reported to have an 
IC50 value of 1.59 µM at P2X4 and was also found to ameliorate pain hypersensitivity 
on spinal nerve injury rat model but did not completely remove the mechanical 
allodynia. The identified P2X4 antagonists and their characteristics are listed in Table 
1.3. 
1.2.6.4.6 5-BDBD 
5-BDBD was first reported by Fischer et al. (2004) in a form of commercial patent but 
no information was found in any scientific report. It was only recorded academically 
through a review article by Donnelly-Roberts et al. (2008). However, there was no 
additional information about the compound other than the stated IC50 value of 5-BDBD 
as in the patent, which is 0.5 µM. The experiment was done on Chinese hamster 
ovarian (CHO) cell. Other than that, the detailed report about the characteristics of the 
compound are not available neither in the patent nor the article. Also, 5-BDBD has 
long been claimed to be selective for P2X4 but there is no evidence to prove that (Ase 
et al., 2015; Jacobson & Müller, 2016). 
 
Since then, there were several studies that incorporated 5-BDBD in their experiments 
involving P2X4 inhibition such as Wu et al. (2011). They used 30 µM of 5-BDBD on 
ECs of spiral ligament (SL) capillaries to prove the existence of P2X4 receptor in these 
cells. Later, Kwon (2012) discovered that P2X4 was the main P2 receptor involved in 
pre-chondrogenic condensation, which was a vital process in skeletal patterning, using 
10 µM of 5-BDBD to revoke the pre-chondrogenic condensation. Besides, Norenberg 
et al. (2012) also used 5-BDBD on HEK293-stably-expressing human P2X4 receptor 
cell line. They found that it was effective for P2X4 by inhibiting 70 % of normal 
response at 5 µM and that it did not cause any modulation on human P2X7. 
 
Hung et al. (2013) used 50 µM of 5-BDBD on human immortalised gingival 
keratinocyte to explain the role of P2X4 in the production of reactive oxygen species 
in response to microbial infection. So far, 5-BDBD has been used in studies involving 
various types of cells at various concentrations. In addition to that, there was also a 
study (Vavra et al., 2011) that claimed that the compound did not inhibit P2X4, at least 
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on endogenously expressed P2X4 receptors after 3 and 30 µM of 5-BDBD were tested 
on primary supraoptic neuron that were freshly isolated from rat brain slices.  
 
Until this point, the use of 5-BDBD is only focused on its application on various 
settings of experiments but none of the studies offers any insight on the compound 
behaviour. Thus, Balazs et al. (2013) explored the potency and mode of inhibition of 
5-BDBD. They identified the IC50 value of 1.2 µM when tested on human P2X4 
overexpressing HEK293 cells and the inhibition was due to competitive inhibition. 
Their electrophysiology data also showed that 5-BDBD blocked the ion current. 
Another observation made was that 5-BDBD and TNP-ATP have similar potency on 
the tested cell line. 
 
A recent article on 5-BDBD by Abdelrahman et al. (2017), however, contradicted the 
previous finding. It is widely and commonly accepted that 5-BDBD blocks P2X4 
competitively. Nevertheless, this team unveiled a quite surprising finding that the 
inhibition of P2X4 by 5-BDBD was noncompetitive rather than competitive. They 
made use of a radioligand [35S]ATPγS that binds to the active site of P2X4. They 
measured the displacement of the radioligand as an indication for the type of binding. 
Interestingly, 5-BDBD did not displace the radioligand and that suggested 5-BDBD 
binds to an unknown allosteric site on the P2X4 receptor, not at the orthosteric site. Up 
until now, there is a limited knowledge on 5-BDBD despite it is being widely used in 
various studies.  
  
61 
 
1.2.7 Structure activity relationship study 
To date, there have been two structure activity relationship (SAR) studies of the P2X4 
antagonists performed by the same group (Hernandez-Olmos et al., 2012; Tian et al., 
2014). In the first study, a total of 54 compounds were synthesised based on the parent 
compounds of phenoxazine and acridone, as well as 47 carbamazepine derivatives in 
the second study. The modification of the derivatives involved the substitution with 
different functional groups including amide, amine, urea, and carbamate. As a result 
of the studies, three novel compounds were identified to potently inhibit the activation 
of P2X4 which were PSB12062, PSB12054 (Hernandez-Olmos et al., 2012), and N,N-
diisopropyl-5H-dibenz[b,f]azepine-5-carboxamide (Tian et al., 2014).  
1.3 Objectives 
Assessing the current situations, two gaps have been identified in P2X4 research. 
Firstly, there is a lack of selective and potent inhibitors of P2X4 that impacts the 
development of P2X4 receptor-related studies. Another gap identified is the lack of 
information about 5-BDBD. Despite this it is being used in numerous studies involving 
P2X4, very little information is available. Hence, this project aimed to solve these two 
recognised gaps in existing knowledge. The first major objective of this study was to 
search for a potential inhibitor of P2X4 that can be used as a therapeutic tool in research 
and as a template to design more potent and selective inhibitors which could be used 
therapeutically in the future. The second main objective was to study the structure 
activity relationship of 5-BDBD derivatives at P2X4 receptor. Throughout this project, 
several specific objectives were hoped to be achieved as follows: 
1. To produce 1321N1 cells stably expressing human and mouse P2X4 and human 
P2X7. 
2. To screen the NCI diversity set and natural product library (1,710 compounds), 
and identify hit compounds in a receptor activity assay with P2X4 
overexpressing cells. 
3. To characterise a lead compound to understand its properties, selectivity, and 
mechanism of action. 
4. To produce chemical orthologues of 5-BDBD in order to explore its structure 
activity relationship of a known antagonist at P2X4. 
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5. To use in silico docking for generating hypothesis of 5-BDBD binding sites in 
human P2X4 receptor.   
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CHAPTER 2  
MATERIALS AND METHODS 
2.1 Materials 
All general salts, reagents, and solvents were purchased from Sigma-Aldrich or 
Thermo Scientific unless otherwise stated. All buffers were prepared in deionised 
water unless otherwise stated. All screened compounds were obtained from National 
Cancer Institute library, except for 5-BDBD analogues which were purchased 
commercially and synthesised in-house. Tables below provide the lists of materials 
used in this study. 
 
Table 2.1 P2 receptor ligands. 
Compound 
Target 
receptor 
Function Supplier Vehicle 
Final 
concentration 
(µM)  
5-BDBD P2X4  Antagonist Tocris DMSO 0.03 – 30  
ATP All P2 
receptors 
except 
P2Y6 and 
P2X7 
Agonist Abcam DI 0.01 – 100  
BzATP P2X7 Agonist SA DI 0.01 – 500  
UDP P2Y6 Agonist SA DI 0.01 – 30  
IVM P2X4 Positive 
allosteric 
modulator 
Tocris DMSO 0.01 – 10  
PPADS P2X4 Antagonist SA DI 0.01 – 100  
PSB12062 P2X4 Antagonist SA DMSO 10  
Note. DMSO = dimethyl sulfoxide, DI = deionised water, SA = Sigma Aldrich 
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Table 2.2 Antibodies. 
Antibody Epitope Host 
Target 
species 
Supplier 
Goat anti-Rabbit IgG 
(H+L) Secondary 
Antibody, Alexa Fluor 
488 
- Goat R Invitrogen 
P2X4 antibody Intracellular Rabbit H, M, R Alomone 
P2X4 antibody Extracellular Rabbit H, M, R Alomone 
Rabbit (DA1E) mAb 
IgG XP® Isotype 
Control 
- - - CST 
Human BD Fc blocker - - H 
BD 
Pharmingen 
Note. H = human, M = mouse, R = rat, CST = Cell Signalling Technology 
 
Table 2.3 Other calcium pathway mediators. 
Compound Function Supplier Vehicle 
Final 
concentration 
(µM) 
Carbachol 
It causes phosphatidylinositol 
hydrolysis resulting in 
calcium release from 
intracellular store (Chough et 
al., 1993) 
SA DI 100  
Ionomycin Ionophore that allows 
calcium gets into the cell 
(Caridha et al., 2008) 
SC DMSO 1 
Note. DMSO = dimethyl sulfoxide, DI = deionised water, SC = Santa Cruz 
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Table 2.4 Starting molecules for 5-BDBD analogues syntheses.  
Compound Supplier 
Molecular 
weight (g/mol) 
Purity 
(%) 
2-hydroxy-5-trifluoromethylbenzonitrile Fluorochem 187.12 95 
3-(trifluoromethyl)phenacyl bromide Fluorochem 267.05 98 
3-bromophenacyl bromide Fluorochem 277.94 97 
3-chlorophenacyl bromide Fluorochem 233.49 90 
3-fluorophenacyl bromide SA 217.04 97 
5-bromo-2-hydroxybenzonitrile Fluorochem 198.02 98 
5-chloro-2-hydroxybenzonitrile SA 153.57 NM 
5-fluoro-2-hydroxybenzonitrile Fluorochem 137.11 95 
Ammonia, 0.5M solution in 1,4-dioxane FS 17.03 99 
Bromoacetyl bromide AG 201.84 98 
Sodium ethoxide SA 68.05 95 
Note. SA = Sigma Aldrich, AG = Acros Organics, FS = Fisher Scientific, NM = not 
mentioned 
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Table 2.5 List of 5-BDBD analogues that available commercially. 
Compound 
Catalogue 
number 
Molecular 
weight (g/mol) 
Purity 
(%) 
5-(4-bromophenyl)-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
STK775918 355.19 > 90 
5-Phenyl-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
STK045532 276.30 > 90 
5-(4-methylphenyl)-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
STK027946 290.32 > 90 
5-(4-fluorophenyl)-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
STK747973 294.29 > 90 
9-bromo-5-phenyl-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
STK731427 355.19 > 90 
9-methoxy-5-phenyl-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
STK864662 306.32 > 90 
5-(4-chlorophenyl)-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
STK079751 310.74 > 90 
2-benzoyl-5-chloro-1-benzofuran-3-
amine 
STK021512 271.70 > 90 
*All compounds were purchased from Vitas-M Laboratory and dissolved in DMSO. 
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2.2 Methods 
2.2.1 Cell culture 
The main cell line used for this study was the human 1321N1 cells which was readily 
available in-house. This astrocytoma cell line was previously isolated from 1181N1 
line, a subline of parent U-118 MG (Pontén & Macintyre, 1968). The cells have been 
tested and showed no response upon nucleotide stimulation in calcium-based 
experiments (Communi et al., 1996). The two other types of cell line used were the 
HEK293T/17 and murine microglial (BV2) cell lines. 
 
All cell types were cultured in Dulbecco’s Modified Eagle Medium containing 0.6 g/L 
L-Glutamine and 4.5 g/L glucose (DMEM, Lonza) supplemented with 10 % (v/v) 
Foetal Bovine Serum (FBS, HyClone) and 1 % (v/v) penicillin-streptomycin (Gibco) 
solution containing 50 units/mL of penicillin and 50 μg/mL of streptomycin (this will 
be referred as cell culture medium from hereon). All cell lines were the adherent type, 
cultured in vented T75 flasks (Nunc), and were kept in a humidified incubator (Nuaire) 
at 37 °C with 5 % of CO2. When the cells were 80 – 90 % confluent, they were rinsed 
with 5 mL PBS (Lonza) and subsequently detached from bottom of the flask by 
incubating the cells with 3 mL Trypsin EDTA (Lonza) containing 170,000 U trypsin/L 
at 37 °C for 3 minutes. After incubation, the flasks were tapped gently to ensure all 
cells were detached and afterwards, 7 mL of cell culture medium was added into the 
flask to stop the enzymatic reaction. The cells were then centrifuged at 805 × g for 7 
minutes at room temperature and supernatant was discarded. The pellet was 
resuspended with 10 mL of cell culture medium and utilised for further experiments, 
which was either reseeded into a new T75 flask or cryopreserved. 
 
Cryopreservation is a technique to preserve cells for future use without causing loss of 
viability. The cryopreservation mixture constituted of 45 % cell culture medium with 
cells (~1 – 2 million cells), 45 % of FBS, and 10 % of DMSO which were added 
together in a 1.8 mL cryotube (Thermo Scientific). The cryotubes were then placed in 
a freezing container (Sigma Aldrich) to allow slow freezing and the container was 
stored at −80 °C for one day and later were transferred to a liquid nitrogen facility. 
When the cryopreserved cells were to be used, the cells were thawed by swirling the 
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tube in lukewarm water and immediately transferred the suspension into a falcon tube 
containing 10 – 15 mL of cell culture medium. The cells were washed twice by 
centrifugation and resuspension before they were seeded in a new flask per 
requirement. 
2.2.1.1 Activation of BV2 cells 
BV2 cells were used to model primary microglial cells under physiological and 
inflamed conditions. Henn et al. (2009) made a comparison between BV2 cells and 
primary microglial cells in vitro and in vivo in terms of their response towards bacterial 
lipopolysaccharide (LPS, E. coli 0127:B8, Sigma). It was found that BV2 cells respond 
similarly to primary microglia and thus the cells serve as a good model for primary 
microglia. The cells in the physiological state was termed as quiescent cells and used 
as it were after splitting. On the other hand, to render the cells from quiescent state to 
pathological state (termed as activated), the LPS was used. After being seeded, the 
cells were exposed to 1 µg/mL LPS in cell culture medium for 24 hours and incubated 
at 37 °C humidified with 5% of CO2. After the incubation, the cells were ready to be 
used for further experiment. 
2.2.2 Generation of DNA recombinant plasmid 
P2X4 recombinant DNA in pcDNA3.1 vector was available in-house. The recombinant 
DNA was restricted and the DNA was ligated into pLVX-IRES-mCherry vector for 
transfection. The pLVX-IRES-mCherry is a lentiviral expression vector based on HIV-
1 which allows its expression in most mammalian cell types. It is a bicistronic vector 
that can carry two DNA sequences; one is the DNA of interest and another is DNA for 
fluorescing mCherry protein. The use of mCherry protein was useful because it could 
be used to indicate the transfection success and sort the transfected cells. Figure 2.1 
shows the map for the vector and its multiple cloning sites. BamHI was chosen as the 
restriction enzyme as it was also present in the pcDNA3.1 vector as shown in Figure 
2.1 and Figure 2.2. The whole procedure for generation of P2X4 recombinant plasmid 
is described below. 
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Figure 2.1 pLVX-IRES-mCherry vector map and multiple cloning sites (MCS) 
This bicistronic vector was used to express P2X4 together with mCherry protein for 
selection purpose. The vector was restricted using BamHI for inserting the P2X4 DNA. 
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Figure 2.2 pcDNA3.1 (+/-) vector map and multiple cloning sites (MCS). 
In-house human P2X4 DNA was in pcDNA3.1 vector. Therefore, the DNA was 
restricted using BamHI and further ligated into pLVX-IRES-mCherry. Both 
pcDNA3.1 and pLVX-IRES-mCherry vectors contained BamHI restriction sites, 
hence the BamHI was selected. 
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2.2.2.1 Restriction analysis of P2X4 DNA 
The P2X4 recombinant DNA in pcDNA3.1 and pLVX-IRES-mCherry vectors were 
both digested using the restriction enzyme, BamHI, in two separate tubes. The 
digestion mixture consisted of 20 units (1 µL) of BamHI restriction enzyme, 5 µL of 
10X CutSmart buffer, 5 µg of plasmid (1 µg for pLVX-IRES-mCherry vector), and 
molecular grade water (topped up to 50 µL). The mixtures were mixed by gentle 
tapping and incubated at 37 °C for two hours. Afterwards, the restricted pLVX-IRES-
mCherry vector was purified using E.Z.N.A Cycle Pure Kit (OMEGA bio-tek) 
according to manufacturer’s protocol. The resulting product was quantified using a 
NanoDrop (Thermo Scientific) and stored at −20 °C until further use.  
 
For P2X4 DNA in pcDNA3.1, the digestion mixture was run on an agarose gel using 
electrophoresis (will be discussed in Section 2.2.2.6). After visualising the gel under 
UV light, the corresponding size of DNA was carefully excised from gel and weighed. 
The DNA in the excised gel was extracted and purified using gel extraction kit 
(OMEGA bio-tek) per manufacturer’s protocol. The resulting product was quantified 
and stored at −20 °C until further use. 
2.2.2.2 Insertion of DNA into selected vector 
Two products generated following the process mentioned in Section 2.2.2.1 were 
thawed on ice and used in the ligation process to produce a recombinant plasmid. 
Ligation mixture consisted of 400 units (1 µL) of T4 DNA ligase (BioLabs Inc.), 1 µL 
of 10X T4 DNA ligase buffer (BioLabs Inc.), 50 ng of P2X4 DNA, 50 ng of vector 
(pLVX-IRES-mCherry), and molecular grade water (topped up to 10 µL). The ligation 
mixture was mixed by flicking and briefly centrifuged to collect remaining liquid from 
the tube wall, and then incubated at 16 °C overnight (up to 24 hours). After overnight 
incubation, the product was proceeded to the next step.  
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2.2.2.3 Transformation of recombinant plasmid 
The product obtained (as described in Section 2.2.2.2) was promptly followed by 
transformation. This step was done to allow E. coli to uptake the recombinant DNA 
for the multiplication of DNA copies. Prior to this process, the ligation reaction from 
previous section was chilled on ice while the Super Optimal broth with Catabolite 
repression (SOC) outgrowth medium (BioLabs Inc.) and LB agar (Sigma) plates (with 
100 μg/mL ampicillin) were warmed up to 37 °C. A vial of commercially available 50 
μL of high efficiency competent E. coli (BioLabs Inc.) was thawed on ice. Then, 5 μL 
of recombinant plasmid was added into the E. coli vial, mixed by gentle tapping, and 
incubated on ice for 30 minutes. Afterwards, the vial was heat-shocked at 42 °C for 30 
seconds and immediately returned to ice for 2 minutes. Subsequently, 250 μL of pre-
warmed SOC outgrowth medium was added into the vials which were then placed into 
universal tubes and shaken at 225 rpm for an hour at 37 °C. After shaking, 200 μL and 
50 μL of the culture were plated on separate pre-warmed agar plates, respectively and 
then incubated at 37 °C in an upside-down position overnight. Colonies were observed 
on the agar following overnight incubation. Eight single colonies were selected and 
inoculated in 10 mL of LB broth (with 100 μg/mL ampicillin, Sigma) to increase the 
possibility of getting successful ligation. Next, the cultures were incubated overnight 
at 37 °C on a shaker at 225 rpm. This procedure was done in a sterile environment. 
2.2.2.4 Purification and confirmation of recombinant plasmid 
After the incubation, 750 µL from each culture tube and 250 µL of glycerol (Sigma) 
were added into separate cryotubes (Thermo Scientific) in a sterile setting and stored 
at −80 °C. These glycerol stocks were intended for future use if more recombinant 
plasmids were required. The remaining cultures were centrifuged at 805 × g for 10 
minutes at room temperature and the supernatant was discarded. The remaining pellet 
was then purified using E.Z.N.A Plasmid Mini Kit I (OMEGA bio-tek) according to 
manufacturer’s protocol. The obtained recombinant plasmids from bacterial culture 
were then quantified. All plasmids were then run on a gel to determine whether these 
plasmids contained the DNA of interest. This was confirmed by comparing the size of 
the bands on the gel. If the plasmid size was larger than the unrestricted pLVX-IRES-
mCherry vector, this might be an indication of successful ligation. This was further 
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confirmed with DNA sequencing using CMV promoter and pIRES reverse primers. 
Successful recombinant plasmid was then carried forward for the next procedure 
which was the generation of P2X4 overexpressing cell line. 
2.2.2.5 LB broth and agar preparation 
LB broth and agar powder (both from Sigma) were dissolved using distilled water 
according to manufacturer’s recommendation and then autoclaved to sterilise the 
solution. The autoclaved solution was stored at room temperature until future use. For 
making culture, 10 mL of broth was added into a universal tube and 10 µL of ampicillin 
from 100 mg/mL stock (final concentration = 100 µg/mL) was added into broth and 
mixed. These cultures were freshly prepared before use. Meanwhile, for making agar 
plates, LB agar was liquefied by heating it in microwave. Then, 12 µL of ampicillin 
from 100 mg/mL stock (final concentration = 100 µg/mL) was placed at the centre of 
the petri dish and 12 mL of lukewarm LB agar was added into the petri dish and mixed 
with ampicillin. Bubbles were removed as much as possible. The plates were left to 
solidify at room temperature and then stored at 4 °C in an upside-down position, and 
it can be used within two weeks. All steps were done under a sterile condition. 
2.2.2.6 Gel electrophoresis 
Gel electrophoresis is a procedure to separate DNA of different sizes. With the help of 
electricity through an electrophoretic system, DNA fragments are separated based on 
their size, where bigger fragment will travel slower than the lighter fragments. Three 
main ingredients were needed to make a gel, 1X Tris-Acetate-EDTA (TAE) buffer, 1 
% agarose, and ethidium bromide (Sigma, 10 mg/mL). 1X TAE buffer was prepared 
by diluting 50X TAE solution (Fisher Scientific) with deionised water. The 1 % 
agarose gel was prepared by dissolving and heating 1 g of agarose (Fisher Scientific) 
with 100 mL of 1X TAE buffer. When the gel solution was lukewarm, 4 µL of 
ethidium bromide (final concentration = 40 ng/mL) was added as the intercalation dye 
to enable gel visualisation under UV light. 
 
The 1 % agarose gel solution was poured into a cast with the desired comb and allowed 
to solidify (approximately 20 minutes). To start the electrophoresis, the gel was 
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transferred into the gel electrophoresis system and 1X TAE buffer was added into the 
system until the surface of solidified gel was fully submerged. Samples were prepared 
by mixing them with 6X blue loading dye at a ratio of 1:6 (dye:sample) and then loaded 
into the wells of the gel. One of the wells was filled with a 1 kb ladder which was 
mixed with the loading dye. The ladder served as the reference for DNA size. The gel 
electrophoresis was run for approximately an hour at 95 V and the gel was visualised 
under UV illumination using a ChemiDoc™ XRS visualiser (Bio-Rad). 
2.2.3 Generation of P2X4 overexpressing cell lines 
The DNA product (obtained following process explained in Section 2.2.2.4) was used 
to generate the P2X4 overexpressing cell line in a process called transfection. 
Transfection is a process whereby transfected cells take up the recombinant DNA, 
incorporate it into its genome, and starts expressing the protein. There are many ways 
of transfecting DNA into cells which are categorised into three classes, which are 
biological, chemical, and physical (Kim & Eberwine, 2010). In this study, the 
biological way of transfection was employed which involved the packaging of 
recombinant DNA into lentiviral particles. Subsequently, the virus infected human 
astrocytoma cells and plasmid DNA were incorporated into human astrocytoma cells’ 
DNA. 
2.2.3.1 Production of lentiviral particles 
The production of lentiviral particles was achieved by co-transfecting the three 
plasmids, namely lentiviral vector coding the viral genome with the transgene, 
psPAX2 containing a robust CAG promoter for packaging protein expression, and 
pMD2.G which encoded the Vesicular Stomatitis Virus (VSV) envelope glycoprotein. 
Those three plasmids were co-transfected into the HEK293T/17 cells. 
 
On Day 0, nine million HEK293T/17 cells were seeded into a 150 mm culture dish in 
20 mL cell culture medium and incubated at 37 °C overnight, supplemented with 5 % 
of CO2. On Day 1, two Eppendorf tubes were filled with 1.2 mL of Opti-MEM® 
Reduced-Serum Medium (Gibco) each. The three plasmids; 9 µg of transgene DNA, 
12 µg of psPAX2 packaging vector, and 3 µg of pMD2.G envelope vector (a total of 
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24 µg DNA) were added into one of the tubes while 36 µL of transfection reagent 
Lipofectamine 2000 (Invitrogen, 1 mg/mL stock) was added into the other tube. Both 
tubes were then incubated at room temperature for 5 minutes. Afterwards, the tubes 
were mixed together and incubated at room temperature for 20 minutes. In the 
meantime, the medium in HEK293T/17 culture dish from the Day 0 was replaced with 
20 mL DMEM (Lonza) supplemented with 1 % (v/v) FBS (will be referred as virus 
collection medium from hereon). After 20 minutes, the plasmids and transfection 
reagent mixture were added in a drop-wise manner into the HEK293T/17 cells culture 
dish. The cells were incubated at 37 °C for 6 hours, supplemented with 5 % CO2. After 
6 hours, the medium was replaced with 20 mL of virus collection medium and 
incubated at 37 °C overnight with 5% of CO2 supplementation.  
 
On Day 2 until 4, 20 mL of virus collection media in the culture dish was collected 
each day and passed through a 0.45 µm polyethersulfone (low protein binding) filter 
(Whatman) to remove cells/debris. The filtered media was stored at 4 °C. After each 
collection, 20 mL fresh virus collection medium was added to the HEK293T/17 cells. 
On Day 4 after the last day of media collection, there was 60 mL of virus-containing 
media in total. The media was split into two falcon tubes containing 30 mL each. The 
virus was then concentrated by adding 10 mL of Lenti-X Concentrator (Clontech 
Laboratories) into each tube. The mixture was mixed thoroughly by gentle inversion 
and kept for 72 hours at 4 °C. After three days, the tubes were centrifuged at 1500 × g 
for 45 minutes at 4 °C. After centrifugation, an off-white pellet of virus was visible. 
The supernatant was carefully removed, taking care not to disturb the pellet. The pellet 
was then gently resuspended in 0.5 mL of DMEM and the suspension was quantified. 
The remaining suspension was aliquoted and stored at −80 °C. 
2.2.3.2 p24 ELISA and determination of viral titre 
The lentivirus produced (as described in Section 2.2.3.1) was quantified using 
QuickTiter™ Lentivirus Titer Kit (Lentivirus Associated HIV p24) according to 
manufacturer’s protocol (Cell Biolabs Inc.). The kit can only quantify lentivirus 
associated with p24 protein but not free p24 generated by HEK293T/17 cells during 
transfection and thus, it was an accurate kit for measuring viral titre. The kit has a 
detection sensitivity limit of 1 ng/mL HIV p24, or about 10,000 to 100,000 TU/mL 
  
76 
 
VSVG-pseudotyped lentivirus samples. The lentivirus p24 formed complexes with 
ViraBind™ lentivirus reagents while free p24 remained in the supernatant and 
lentivirus associated p24 were measured by a HIV p24 ELISA. The antibodies were 
reacted with FITC-conjugated anti-p24 monoclonal antibody and subsequently HRP-
conjugated anti FTIC-monoclonal antibody. The absorbance was measured using a 
FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices) at 450 nm. 
2.2.3.3 Transfection of P2X4 into human astrocytoma cells 
The transfection procedure was used to introduce the P2X4 recombinant plasmid into 
human astrocytoma cells. Prior to transfection, the polybrene reagent was prepared. 
Polybrene is a cationic polymer that facilitates more efficient gene transfer into target 
cells, i.e., astrocytoma cells (Davis et al., 2002). This was done by dissolving the 
hexadimethrine bromide (or polybrene, Sigma) in deionised water to a concentration 
of 100 mg/mL. The solution was then filtered using sterile 0.20 µm polyethersulfone 
filter (Whatman) in a sterile environment and aliquoted (1 µL per tube). The 1 µL 
aliquot was subsequently diluted with 61.5 µL of cell culture medium, yielding 1.6 
µg/µL of polybrene concentration which was stored at −20 °C until further use. 
 
The transfection process began with the splitting of human astrocytoma cells as 
described in Section 2.2.1 and the cell suspension was diluted to a concentration of 5 × 
105 cells/mL. Then, 400 µL of the cell suspension (final cell count of 2 × 105 cells) 
was added into a 15 mL falcon tube containing 1.6 mL of cell culture medium and 10 
µL of polybrene (final concentration = 8 µg/mL). Finally, 10 µL of virus media 
(obtained from the steps explained in Section 2.2.3.1) was added into the tube. The 
mixture was then spinoculated at 1400 × g for 1 hour at 37°C. The supernatant was 
discarded and disposed of accordingly, and the pellet was resuspended with 1 mL of 
cell culture medium. The suspension was then transferred into T25 flask containing 4 
mL of cell culture medium. The flask was incubated at 37 °C supplemented with 5 % 
CO2 until the cells fluoresced brightly as observed with a fluorescence microscope 
with the TRITC filter. The cells were then sorted according to the intensity of their 
mCherry fluorescence. Cell that strongly produced mCherry indicated the high 
expression of P2X4 receptors. 
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2.2.3.4 Sorting the P2X4 highly expressing cells 
Not all cells are able to successfully express the protein of interest. Hence, the highly 
expressed cells are required to be sorted according to their expression of protein of 
interest. The cells with high expression of mCherry, i.e., that fluoresced brightly, were 
physically selected BD FACSAria III Sorter and collected in a tube whereas the cells 
with low expression were discarded. 
 
Briefly, the transduced cells (obtained from steps done in Section 2.2.3.3) were split 
and the cell suspension was diluted with cell culture medium to a concentration of 1 × 
106 cells/mL. A clean tube with 1 mL of cell culture medium was prepared for cell 
collection purpose. The cells were then passed through the instrument, excited at 587 
nm wavelength, and emitted at 610 nm wavelength. The highest 1 % of fluorescing 
cells were then selected and collected into the collection tube. The collected cells were 
added into a T75 flask containing 20 mL of cell culture medium and incubated at 37 °C 
with 5 % CO2 until the cells reached 80 – 90 % confluency. When it reached 
confluency, the cells were split and remaining cells were cryopreserved as described 
in Section 2.2.1. 
2.2.4 Measurement of intracellular calcium responses 
2.2.4.1 Calcium indicator 
Indicators can be classified into two groups; single wavelength such as Fluo-4 and 
ratiometric dye such as Fura-2. The advantage of ratiometric dye over the other class 
is that it circumvents common problems associated with chemical calcium indicators 
which include photobleaching, uneven dye loading and cell thickness, leakage, and 
changes in cell volume (Paredes et al., 2008).  
 
Fura-2 is a membrane impermeable indicator but when it is esterified with 
acetoxymethyl (AM) group, it becomes more lipophilic and cell permeant. Once Fura-
2 AM (used in this study) enters the cytosol, the AM group is cleaved by intracellular 
esterases, leaving Fura-2 trapped in the cells to bind with free intracellular calcium 
(Hirst et al., 1999; Tsien, 1981). The Fura-2 was initially synthesised from a 
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combination of stilbene fluorophore and calcium chelator, ethylene glycol tetraacetic 
acid (EGTA). When Fura-2 bound with calcium, its excitation spectra shifts in peak 
fluorescence from λex = 362 nm in unbound states to λex = 335 nm in calcium-bound 
states while the emission wavelength remains the same (λem = 510 nm) (Grynkiewicz 
et al., 1985). It has high affinity towards calcium compared to other cations with a Kd 
value of ~145 nM (Paredes et al., 2008). 
2.2.4.2 Buffer preparation 
The buffer used in this experiment was HEPES-buffered physiological saline (HBPS). 
The buffer contained 137 mM of sodium chloride (NaCl), 4 mM of potassium chloride 
(KCl), 10 mM of HEPES, 8 mM of D-glucose, 1.2 mM of magnesium chloride 
(MgCl2), and 1.5 mM of calcium chloride (CaCl2) in deionised water. The buffer was 
pH-adjusted using sodium hydroxide (NaOH) to pH of 7.4. The buffer was then used 
to make the loading buffer, i.e., a buffer used to load Fura-2 AM into the cells. To 
make the loading buffer, 0.02 g of Pluronic F-127 was weighed and dissolved in 200 
mL of HBPS (0.01 % w/v). Pluronic helped with the internalisation of Fura-2 AM by 
making the plasma membrane more permeable. Both buffer solutions were stored at 
4 °C and used within one week of preparation. 
2.2.4.3 Concentration-response experiments 
2.2.4.3.1 ATP concentration-response experiment 
The ATP concentration-response relationship experiment was done to describe the 
intracellular calcium change in the human P2X4 overexpressing cells upon stimulation 
with ATP. The data could also be used to plot a concentration-response relationship 
curve in which, the EC50 value could be determined. The EC50 value is the 
concentration of ATP that causes the 50 % activation, i.e., half of the maximum 
response recorded, at the P2X4 receptor. In this study, the ATP EC50 value was used 
for compound screening experiment so that the screening would not exclude the 
potential competitive inhibitors that might not be able to compete with ATP. The 
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response of P2X4 receptors upon activation by ATP was assessed by measuring the 
fluorescence from Fura-2, which was the indicator for calcium influx into the cells. 
 
The human P2X4 overexpressing cells were split and seeded in a 96-well clear flat 
bottom black plate (Molecular Devices) at a density of 25,000 cells/well in 200 μL of 
cell culture medium, and incubated overnight in a 37 °C incubator supplemented with 
5 % of CO2. The following day, Fura-2 AM (TEFLabs) was mixed with loading buffer 
(final concentration = 2 µM, 0.2 % DMSO) and warmed at 37 °C. The seeded cells 
were then taken out of the incubator, washed gently with 200 μL of pre-warmed HBPS 
once, and then loaded with 200 μL of the prepared loading buffer containing Fura-2 
AM. Next, the plate was wrapped with aluminium foil because Fura-2 was 
photosensitive and can be bleached by prolonged exposure to light; and incubated at 
37 °C for an hour. 
 
During the 1 hour incubation, the ATP solution was prepared by dissolving ATP 
disodium salt (Abcam) with deionised water to make up 50 mM of stock solution. The 
stock was further diluted with HBPS into 14 concentrations; 500, 300, 150, 50, 30, 15, 
5, 3, 1.5, 0.5, 0.3, 0.15, 0.05, and 0.03 μM. Then, each of the different concentrations 
of ATP was added into a clear round bottom plate in triplicate. After the 1 hour 
incubation, the cells were washed gently with HBPS twice and loaded with 200 μL of 
HBPS. Both plates were then placed in the FlexStation3 at 37 °C. ATP solution (50 
mL) was added to each column using the instrument at 17th second (final ATP 
concentration was one fifth of the concentrations prepared) and the fluorescence was 
recorded for 250 seconds. The data obtained were analysed using Origin® version 9.1. 
 
With regards to the instrument, there were two excitation wavelengths set up because 
Fura-2 is excited at two wavelengths which are 340 nm and 380 nm, and emits at 510 
nm light. The ratio of readings from the two wavelengths will give an accurate 
measurement of calcium influx. This ratiometric reading provides accurate reading 
because it is independent of Fura-2 concentration loaded into the cells (Kong & Lee, 
1995).  
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2.2.4.3.2 Inhibitor concentration-response experiment 
This experiment aimed to observe the inhibition potency of a compound. The cells 
splitting, Fura-2 loading, and FlexStation3 set-up followed the same procedure as 
described previously. However, only the first six columns of the 96-well plate were 
used. While the cells were loaded with Fura-2, different concentrations of an inhibitor 
were prepared using DMSO, HBPS, and vehicle control. The compounds were usually 
dissolved in final concentration of 0.1 % DMSO but some hydrophobic compounds 
were dissolved in 1 % DMSO. After final wash following Fura-2 loading, the 96-well 
and compound plates containing different concentrations of inhibitor were placed in 
FlexStation3. The compound (10 µL) was injected into column 1 until 6 using the 
instrument and the fluorescence of each column was recorded for 250 seconds. These 
took 30 minutes for the compound delivery. Immediately after, the cells were injected 
with 0.6 µM of ATP (in the case of human P2X4 overexpressing cells) into column 1 
until 6 and fluorescence was recorded for 250 seconds for each column. This was done 
to ensure a constant 30 minute-incubation time for the inhibitor of each column. 
2.2.4.3.3 Statistical analysis 
In all calcium-based experiments, peak responses were recorded and used for statistics. 
Peak responses are the maximum peak recorded after ATP was added. The value was 
in the form of F ratio which was the ratio of fluorescence from two wave lengths 
(340/380 nm). Meanwhile, for the inhibitor concentration-response curve, the 
percentage of response was normalised to the peak response of the vehicle control. 
 
Data from the calcium experiments was presented in two forms, which are the 
concentration-response curve establishment and decay kinetics. The concentration-
response curves were fitted using the Hill equation as follows: 
 
𝑦 = 𝐴1 +
𝐴2 − 𝐴1
1 + 10(𝐿𝑜𝑔𝑥0−𝑥)𝑝
 
where; 
A1 = bottom asymptote 
A2 = top asymptote 
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Logx0 = centre of curve 
p = Hill slope 
 
The IC50 or EC50 values was the value of Logx0 as the value represented the centre of 
the curve, which also corresponded to the half of maximal response concentration. To 
get the x value (concentration of ATP in log10) at any magnitude of response, the 
above equation was rearranged and y was substituted accordingly, and the value was 
base-10 anti-logged to get a value in molar. 
 
 
𝑥 = −1
(
 
√
𝐴2 − 𝐴1
𝑦 − 𝐴1 − 1
10
𝑝
+ 𝐿𝑜𝑔𝑥0
)
  
 
Decay kinetics was measured in the form of tau value (τ). Tau value is defined as the 
time constant of a single exponential decay fitted to the desensitisation phase. It was 
determined using the exponential decay 1 function in Origin software and the equation 
was: 
 
𝑦 = 𝑦0 + 𝐴1𝑒
−(𝑥−𝑥0) 𝑡1⁄  
where; 
y0 = offset 
x0 = centre 
A1 = amplitude 
t1 = time constant 
2.2.5 High throughput screening 
2.2.5.1 Compound library 
The compounds for high throughput screening were obtained from the National Cancer 
Institute (NCI). It is the primary agency for cancer research and training under the 
federal government of United States of America and is a part of the National Institute 
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of Health. It is located at Rockville Pike, Bethesda, Maryland, USA. Generally, as its 
name implies, it manages programs related to cancer by conducting and supporting 
research, managing health-related issues of cancer, and continuing to take care of 
cancer sufferers as well as their families (NCI, n. d.-a). 
 
One example of the programs operated by the institute is the Development 
Therapeutics Program (DTP). This programme was first established in 1955 by 
Congress. It aims to help academic and private-sector researchers in their research and 
development by providing services and resources to facilitate drug discovery and 
development. Since then, more than 40 compounds have been developed and licenced 
in the USA as anti-cancer agents with the support of DTP. This would not be achieved 
without the close relationship and collaborations between DTP, academics, 
biotechnological industries, and pharmaceutical companies. Among the licensed anti-
cancer agents are paclitaxel, romidepsin, eribulin, sipuleucel-T, and dinutuximab 
(NCI, n. d.-b). 
 
DTP also holds a big library of compounds comprised of synthetic and natural 
compounds. The library consists of more than 200,000 compounds either submitted by 
third parties for biological assessment or synthesised under DTP protection. They are 
available to be used by researchers for research purpose (NCI, 2015). Some of those 
compounds are available in plates which are classed into four sets — Approved 
Oncology Drugs Plated, Diversity, Mechanistic, and Natural Products Sets. During the 
commencement of this study, the Natural Products Set was in the third version (current 
version is fourth), which lacks 302 compounds compared to the fourth version (NCI, 
2016). All compounds in those sets were supplied in 96-well plates, dissolved in 20 
µL DMSO at 10 µM, and shipped in a frozen state. 
2.2.5.1.1 Diversity Set V (DSv) 
In this study, the Diversity Set V (DSv) was used for compound screening in the search 
for potential inhibitors of human P2X4 receptor. Out of 140,000 compounds available 
in DTP, 1,594 compounds were extracted based on few parameters and categorised 
into the DSv. The parameters include the drug-like criteria as outlined by Lipinski’s 
research team (1997) and as a result, compounds that were relatively rigid, with 5 or 
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fewer rotatable bonds, with tendency to be planar, one or less chiral centres, and 
pharmacologically desirable features were included into the set. All compounds 
included in this set have a purity of > 90 % as analysed by LCMS (NCI, 2016). 
2.2.5.1.2 Natural Products Set III (NPiii) 
As opposed to the currently available Natural Products Set IV, this study used NPiii 
which was available at the beginning of the study. It differed in terms of the number 
of compounds where the latter set contains 302 more compounds than the previous set. 
Set III came with 117 compounds while set IV had 419 compounds. This set was also 
extracted from 200,000 compounds that meet certain criteria. The first criterion was 
that the compounds must be extracted from natural sources. Other criteria were that 
the compounds must have > 90 % purity and correct mass ion, depending on the 
compound structural diversity, and availability of the compound itself. This set was 
established in response of growing enthusiasm among researchers for various scaffold 
structures having multiple functional groups for drug discovery purposes, as observed 
in natural products (NCI, 2016). 
2.2.5.1.3 Studies involving DTP compound plates 
Several studies were carried out using these DTP compound libraries. Li et al. (2004) 
screened, in silico and in vitro, the NCI diversity set to search for 5-aminoimidazole- 
4-carboxamide ribonucleotide (AICAR) transformylase inhibitors. They found 19 
compounds with inhibitory properties at AICAR which can be a good 
template/scaffold to design more potent compounds. Another cancer-related study was 
done by Sukkurwala et al. (2014) in which they screened 879 compounds from the 
Mechanistic Diversity Set. They tested the compounds for the ability to enhance 
immunogenic cell death (ICD). They unveiled one lead compound, septacidin which 
is an antifungal antibiotic produced by Streptomyces fibriatus, that can act as an ICD 
inducer and regulate anti-tumour effect. Other than that, NCI libraries have also been 
reported in an antimicrobial study by Feng and co-researchers (2015). They tested 
Diversity Set V, Mechanistic Diversity Set II, and Natural Products Set III on a species 
of bacteria, Borrelia burgdorferi persisters, which is the cause of Lyme disease. From 
the screening, they discovered a few compounds from the libraries with the detrimental 
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activity on the non-growing stationary and growing phases of B. burgdorferi cultures. 
Yet, there were no studies that used the NCI compound libraries in the purinergic 
receptor field. Thus, this study was the first to use the compound library from NCI to 
see if any compounds has a modulation potency at P2X4 receptor. 
2.2.5.2 Compound screening experiment 
The compounds obtained from NCI were in 100 % DMSO with a concentration of 10 
mM. Prior to the experiment, the compounds were diluted with HBPS to reach a 
concentration of 210 µM (DMSO concentration = 2.1 %). This experiment followed 
the same procedure as the ATP concentration-response experiment (Section 2.2.4.3), 
but there were few differences. After the cells were treated with Fura-2 AM and 
washed, 10 μL of 210 μM compound (final concentrations of sample and DMSO were 
10 µM and 0.1 %, respectively) was added into each well. The delivery of the 
compound into each well was automatically performed by FlexStation 3 at 37 °C. The 
instrument delivered compound into a column of wells each time and the fluorescence 
of respective column was recorded for 120 seconds. This action was repeated for 10 
columns. By the end of compound delivery process, the first column of wells was 
incubated with the compound for 30 minutes. Immediately after the compound 
delivery process, 50 µL of 3.12 µM of ATP (final concentration = 0.6 µM) was added 
to the cells using Flexstation 3 at 37 °C and the fluorescence was recorded for 120 
seconds (the same time interval with compound delivery). The rationale of this 
arrangement was to ensure that the cells were incubated with the compounds at a 
constant duration of 30 minutes across the plate. A schematic presentation of the plate 
layout is shown in Figure 2.3 (top panel). The peak responses recorded for each 
compound were normalised to the vehicle control responses in order to evaluate the 
response modulation. 
2.2.6 Reversibility experiment 
This experiment aimed to determine the reversibility of thaspine blockade. The plate 
layout is shown in Figure 2.3 (lower panel). The experiment consisted of two parts. 
The first part was performed according to the procedure for compound screening 
experiment except that the maximal ATP concentration was used (final concentration 
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= 3 µM) and the recording time was extended to 250 seconds (instead of 120 seconds) 
for both compound delivery and ATP addition. After the first part of the experiment, 
the wells were washed twice with HBPS. This was done to remove thaspine and ATP 
from the buffer. After washing, the plate was incubated at 37 °C for 5 minutes. Then, 
the cells in the first column were stimulated with ATP for the second time by adding 
50 µL of 15.6 µM ATP (final concentration = 3 µM) using Flexstation 3 and the 
fluorescence was recorded for 250 seconds. This was repeated until column number 6. 
The arrangement allowed a gradual 5 minutes increase in the incubation time across 
the plate which meant that the last column was incubated for 30 minutes after washing. 
The peak response for each well was recorded and used for statistics. 
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Figure 2.3 The layout of 96-well plate for compound screening and reversibility 
experiment. 
The top panel shows the layout of 96-well plate used for compound screening. V was 
the vehicle control, C1 – C20 were the different compounds in triplicate, P and N were 
both positive controls for positive modulators (IVM) and antagonists (PPADS), 
respectively. Each plate consisted of 20 different compounds. Meanwhile, the lower 
panel shows the plate layout for reversibility experiment. V represented the vehicle 
control (0.1 % DMSO) and T represented thaspine (10 µM). 
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2.2.7 Flow cytometry 
This experiment was done to test the hypothesis of thaspine causing the internalisation 
of surface P2X4 receptors that resulted in the decrease of calcium response. This was 
done by tagging the external epitope of membrane-bound P2X4 receptor with rabbit 
anti-human P2X4 (extracellular epitope) (Alomone) and then coupled with a secondary 
antibody carrying fluorophore that was excited at 488 nm wavelength, namely goat 
anti-rabbit Alexa Fluor 488 (Thermo Fisher). The fluorescence was then measured 
using a CytoFLEX Flow Cytometer (Beckman Coulter). 
 
The highly expressing human P2X4 receptor cells were split and diluted in PBS to a 
concentration of 1 × 107 cells/mL. Next, 100 µL of the cell suspension (1 million cells) 
was added into two suitable tubes. Afterwards, thaspine or DMSO (test and vehicle 
controls, respectively) were added into each of tubes to reach a final concentration of 
10 µM or 0.1% DMSO, respectively. Both conditions were accompanied with their 
own negative control, which was the rabbit isotype control. The concentration of 
thaspine was chosen based on calcium experiment data. The tubes were then incubated 
at 37 °C for 30 minutes. Following incubation, the cells were washed by adding 3 mL 
of PBS into each tube and centrifuged at 400 × g for 5 minutes at room temperature. 
Supernatant was removed and pellet was resuspended with 100 µL of PBS. 
 
Subsequently, 5 µL of human Fc blocker (BD Bioscience) was added into each tube 
to block all Fc receptors to avoid the non-specific binding. This was incubated for 10 
minutes at room temperature before 1 µL of rabbit anti-human P2X4 (extracellular) 
(1/100 dilution, 0.85 mg/mL stock) was added into each tube. For isotype control, a 
rabbit monoclonal antibody IgG (0.85 µg) was added into each tube. After 1 hour 
incubation at room temperature, the cells were washed in the same way as described 
earlier. The pellet was then resuspended with 500 µL of PBS and then 1 µL (1/500 
dilution) of secondary antibody was added. The tubes were incubated in dark condition 
for 1 hour. Later, the cells were washed twice (as previously described) and 
resuspended in 500 µL of PBS. 
 
CytoFLEX Flow Cytometer was then used to measure the fluorescence of antibody. 
The cells were kept in dark during transport to avoid bleaching of the fluorophore. The 
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excitation and emission wavelengths used were 490 and 525 nm, respectively and 
FITC filter was applied. The fluorescence was recorded for 10,000 events for each 
condition. The data were then analysed using CytExpert Software and student t-test 
was used for statistics. 
2.2.8 Synthesis of 5-BDBD analogues 
Ten analogues were synthesised based on parent compound, 5-BDBD to study the 
structure relationship between 5-BDBD and P2X4. The general formula for the 
synthesised compounds is shown in Figure 2.4, in which R1 and R2 differed in each 
compound. The analogues synthesised are listed in Table 2.6. 
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Figure 2.4 General formula of synthesised 5-BDBD analogue. 
The chemical formula shows the backbone of the analogue investigated in this study. 
There were two sites of chemical modification, which were R1 and R2, which are either 
H, F, Cl, Br, or CF3. 
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Table 2.6 List of synthesised compounds with chemical variabilities. 
Compound 
ID 
Compound name 
R1 R2 
IA1 
5-(3-chlorophenyl)-1,3-dihydro-2H-
benzofuro[3,2-e]-1,4-diazepin-2-one 
H Cl 
IA2 
9-bromo-5-(3-bromophenyl)-1,3-dihydro-
2H-[1]benzofuro[3,2-e][1,4]diazepin-2-one 
Br Br 
IA3 
5-(3-trifluoromethyl)-1,3-dihydro-2H-
benzofuro[3,2-e]-1,4-diazepin-2-one 
H CF3 
IA4 
9-trifluoromethyl-5-(3-
trifluoromethylphenyl)-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
CF3 CF3 
IA6 
9-fluoro-5-phenyl-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
F H 
IA7 
9-trifluoromethyl-5-phenyl-1,3-dihydro-
2H-[1]benzofuro[3,2-e][1,4]diazepin-2-one 
CF3 H 
IA8 
9-chloro-5-(3-chlorophenyl)-1,3-dihydro-
2H-[1]benzofuro[3,2-e][1,4]diazepin-2-one 
Cl Cl 
IA9 
9-chloro-5-phenyl-1,3-dihydro-2H-
[1]benzofuro[3,2-e][1,4]diazepin-2-one 
Cl H 
IA10 
9-fluoro-5-(3-fluorophenyl)-1,3-dihydro-
2H-[1]benzofuro[3,2-e][1,4]diazepin-2-one 
F F 
IA11 
5-(3-fluorophenyl)-1,3-dihydro-2H-
benzofuro[3,2-e]-1,4-diazepin-2-one 
H F 
Note. Br = bromine, Cl = chlorine, H = hydrogen, F = fluorine, CF3 = trifluoromethyl 
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2.2.8.1 Compound synthesis 
The synthesis of ten compounds was performed by two persons. I synthesised three 
compounds (IA1, IA2, and IA3) and the rest were synthesised by Dr Marco Cominetti, 
a postdoctoral researcher in School of Pharmacy and Chemistry, University of East 
Anglia. The synthesis which consisted of four major steps were based on methods 
outlined by Fischer et al. (2004). Two starting materials were required to synthesise 
each compound which were purchased from either Sigma-Aldrich or Fluorochem. The 
general chemical structure for the starting materials is shown in Figure 2.5. The 
following procedure is the example of IA2 synthesis. 
 
In Step 1, 4 mmol (1.11 g) of 3-bromophenacyl bromide (compound 1) and 4 mmol 
(0.792 g) of 5-bromo-2-hydroxybenzonitrile (compound 2) were weighed and put into 
a V-vial with silicone septa-equipped open top cap. Then, 4.4 mmol (0.445 g) of 
triethylamine (Sigma-Aldrich) was added into the vial and lastly 5 mL of 
dimethylformamide (Fischer Scientific) was added. All ingredients were stirred at 70 
°C for 2 – 3 hours. The reaction mixture was checked with thin layer chromatography 
(TLC) after 2 hours to check the extent of reaction. The solvent system used for TLC 
was ethyl acetate:hexane (3:7). After TLC indicated a complete reaction, the reaction 
mixture was washed with water and saturated sodium chloride solution. The reaction 
mixture was poured into a separating funnel, then 95 mL of ethyl acetate and 200 mL 
of water was added to it. The mixture was shaken to wash off impurities from the 
reaction mixture and allowed to stand until two distinct layers were formed; ethyl 
acetate containing product and water containing impurities. The water underneath was 
removed and another 200 mL of water was added again into the separating funnel, 
shaken, and removed. This was repeated three times and an additional two times with 
saturated sodium chloride solution. The organic phase was dried over sodium sulphate 
and the solvent was vaporised under reduced pressure. The product was then tested for 
1H-NMR to check its purity and chemical content. 
 
Next, 2.8 mmol (1.067 g) of product from Step 1 was added into V-vial and dissolved 
with 7 mL of ethanol (Fischer Scientific). Then, 3.08 mmol (0.210 g) of sodium 
ethoxide (Sigma-Aldrich) was added into the vial which was heated under reflux for 2 
– 3 hours. The reaction mixture was checked on TLC after two hours to determine the 
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extent of reaction. Solvent system used for TLC was dichloromethane:hexane (3:7). 
When the reaction was completed, the reaction mixture was washed with water and 
saturated sodium chloride solution for three and two times, respectively, and the 
remaining steps explained in previous paragraph were repeated. The dried product was 
weighed and the mole number was determined. The product was then tested for 1H-
NMR to check its purity and chemical content. 
 
In Step 3, 1.9 mmol (0.751 g) of product from Step 2 was dissolved in 60 mL of 
chloroform (Fischer Scientific) and stirred at 0 °C. Next, 2.09 mmol (0.422 g) of 
bromoacetyl bromide (Sigma-Aldrich) and 7.6 mmol (0.638 g) of sodium bicarbonate 
were added into the mixture to start the reaction. The reaction mixture was stirred for 
1 – 2 hours at 0 °C, with TLC checking after 1 hour of stirring. When the reaction was 
completed, the solvent was removed under reduced pressure and the dried product was 
redissolved with 50 mL of ethyl acetate. The solution was then washed with 100 mL 
of sodium bicarbonate solution and 100 mL of saturated sodium chloride solution, 
once each. The organic phase was dried over sodium sulphate and solvent was 
removed under reduced pressure. The dried product was weighed and mole number 
was determined. The product was then tested for 1H-NMR to check its purity and 
chemical content. 
 
Finally, 1.3 mmol (0.671 g) of product from Step 3 was dissolved in 30 mL diethyl 
ether (Fischer Scientific) and stirred at room temperature in a V-vial. Sodium sulphate 
(5.0 g) was also added into the reaction to absorb water formed during the reaction. 
The air in the V-vial was flushed with nitrogen gas to make the environment inert 
because dioxane can form explosive peroxide with prolonged exposure to air. Then, in 
an inert environment, 13 mmol (25.89 mL) of 0.5 M solution of ammonia in dioxane 
was added into the mixture to start the reaction and the reaction mixture was stirred at 
room temperature for 3 – 4 days. The mixture was checked on TLC after three days 
with solvent system of ethyl acetate:hexane (4:6). When the reaction was completed, 
30 mL of ethyl acetate was added to the reaction mixture and it was washed with 150 
mL of water and 150 mL of saturated sodium chloride for thrice and once, respectively. 
The organic phase was dried over sodium sulphate and the solvent was removed under 
reduced pressure. The final product was weighed and mole number was determined. 
The product was then tested for 1H-NMR to check its purity and chemical content. 
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Two modifications on the synthesis protocol were made to make the synthesis more 
efficient. Firstly, the duration for each reaction step was increased by up to 1 hour on 
top of reported duration (Fischer et al., 2004) for Step 1 – 3 and additional 1 – 2 days 
for Step 4. This was done because TLC test indicated that the reaction was incomplete 
at the end of reported reaction period, hence the reaction was allowed to proceed 
longer. Another modification made was the addition of anhydrous Na2SO4 into 
reaction vial during Step 4 because the reactions were reversible. Therefore, to prevent 
the product from hydrolysing, Na2SO4 was added to dry up water by-product. 
 
Secondly, the yield of final product from each synthesis was extremely low. From an 
initial amount of 4 mmol at the beginning of reaction, the yield decreased after each 
reaction step and the yield of final product was approximately 1 % of theoretical yield 
of each compound. This could be due to many factors; lack of competency in organic 
synthesis, incomplete reaction, but mostly due to sample being taken out after each 
step for analysis purposes. Another factor that contributed to low yield was the 
presence of impurities together with the compound that demanded purification using 
HPLC in which caused more product to lose. 
 
Basically, the main reactions involved throughout the synthesis were nucleophilic 
substitution and acid-base reactions. The detailed mechanism of each reaction step is 
shown in Scheme 2.1 to 2.4. 
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Figure 2.5 General chemical formula of starting materials. 
Compound 1 and 2 were reacted in certain conditions as a starting reaction to produce 
final products. R1 and R2 were determined based on required final product chemical 
structure. 
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Step 1 
 
Mechanism 
 
 
 
Scheme 2.1 Mechanism of reaction during Step 1 synthesis. 
Two starting materials were reacted in dimethylformamide in the presence of 
triethylamine at 70 °C for 3 hours. The hydroxyl group at Reactant 1 was deprotonated 
by triethylamine through acid-base reaction. The resulting nucleophilic phenoxy ion 
(O-) at Intermediate 2 attacked the electrophilic carbon at Reactant 3 which in turn 
caused Br− to leave through SN2 reaction to form Product 4. 
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Step 2 
 
Mechanism 
 
 
Scheme 2.2 Mechanism of reaction during Step 2 synthesis. 
The product from Step 1 was then reacted with sodium ethoxide in ethanol under reflux 
for 3 hours. Sodium ethanoate deprotonated the alpha carbon to carbonyl at Reactant 
1 and the resulting enolate was stabilised by resonance. The nucleophile at Resonant 
2b attacked the neighbouring electrophilic carbon through SN2 reaction to yield 
Intermediate 3. The nitrogen was then reprotonated by ethanol to give Intermediate 4. 
As in Step 1, deprotonation by enolate led to Intermediate 5. Subsequent 
rearrangement and proton transfer led to aromatization of the furan ring and restoration 
of neutrality (6). 
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Step 3 
 
Mechanism 
 
 
Scheme 2.3 Mechanism of reaction during Step 3 synthesis. 
The product from Step 2 was then reacted with bromoacetyl bromide in chloroform 
and sodium bicarbonate for 2 hours at 0 °C. Nucleophile at Reactant 1 attacked the 
electrophilic δ+ carbon of bromoacetyl bromide and caused Br− to leave through SN2 
reaction (2). The amide nitrogen at Intermediate 3 was then deprotonated by 
bicarbonate yielding the final Product 4.  
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Step 4 
 
Mechanism 
 
 
 
Scheme 2.4 Mechanism of reaction during Step 4 synthesis. 
Finally, the Step 3 product was reacted with ammonia in diethylether together with 
sodium sulphate, to absorb water by-product, for 3 days at room temperature. 
Nucleophilic ammonia attacked the electrophilic carbon at Reactant 1 and caused 
subsequent loss of Br−. Then, Intermediate 2 was deprotonated by ammonia. 
Nucleophilic amine at Intermediate 3 attacked the carbonyl and formed the 
benzodiazepinone ring. Proton transfer at Intermediate 4 led to the hydroxyl group at 
Intermediate 5, which was then eliminated to yield final Product 6. 
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2.2.8.2 Analysis and purification of synthesised compounds by HPLC 
Both the analysis and purification were performed by Dr Marco Cominetti. The 
analysis of final compounds was done using high performance liquid chromatography 
(HPLC, Agilent Technologies 1200 Series) using reverse phase column Agilent 
Eclipse XDB-C18 with a pore size of 5 µm and dimension of 4.6 ×150 mm, heated at 
40 °C. The eluted compounds were detected using UV light at 210 nm. The samples 
were eluted using a gradient system using solvent A (water added with 0.05 % 
trifluoroacetic acid) and solvent B (acetonitrile added with 0.05 % trifluoroacetic acid). 
Two gradient methods were used to analyse the compound, which were short and long. 
The short method was firstly used for all compounds. The long method was employed 
if there were the presence of integrated peaks, in order to obtain better peaks 
separation. Both gradient elution methods are shown in Table 2.7. Data analysis was 
performed using OpenLAB CDS ChemStation Edition by Agilent Technologies. The 
blank was subtracted from the signal of the analysis prior to integration. 
 
For purification, the compounds were purified using preparative HPLC (Agilent 
Technologies 1200 Infinity Series). The column used was the Agilent Eclipse XDB-
C18 with a pore size of 5 μm and dimension of 21.2 × 150 mm. The eluted compounds 
were detected using UV light at 210 nm. The sample was separated using a gradient 
system adjusted from the analytical HPLC gradient system but with slightly different 
solvents; Solvent A was water/acetonitrile 95/5 added with 0.05 % trifluoroacetic acid 
while Solvent B was water/acetonitrile 5/95 added with 0.05 % trifluoroacetic acid. 
The gradient elution system for purification is shown in Table 2.8. The fractions 
containing the product were collected and acetonitrile was removed by evaporation 
under reduced pressure. The remaining water was freeze dried to yield the dry product. 
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Table 2.7 Gradient elution system used for HPLC analysis.  
Time (min) 
Solvent A (%) Solvent B (%) 
Short method Long method 
0 – 2 0 – 3 100 0 
2 – 5 3 – 10 100 – 5 0 – 95 
5 – 10 10 – 15 5 95 
10 15 100 0 
 
 
Table 2.8 Gradient elution system used for HPLC purification.  
Time (min) Solvent A (%) Solvent B (%) 
0 – 3 100 0 
3 – 10 100 – 5 0 – 95 
10 – 15 5 95 
15 100 0 
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2.2.8.3 Other analyses for the synthesised compounds 
All final compounds were also analysed by Dr Marco Cominetti using 1H NMR, 13C 
NMR, 19F NMR (where applicable), melting point determination equipment (Stuart), 
and Fourier transform infrared spectroscopy (FTIR). The molecular weight of the 
compounds was determined using high resolution mass spectrometry (HRMS, Thermo 
Scientific LTQ Orbitrap XL) carried out by EPSRC UK National Mass Spectrometry 
Facility. 
2.2.9 Docking of 5-BDBD and its analogues 
Docking was done by Dr Marco Cominetti. The ligands were prepared for docking 
with UCFS Chimera (Pettersen et al., 2004) and AutodockTools4 (Morris et al., 2009), 
each one in two different conformations to account for flexibility of the diazepinone 
ring. The rotation of phenyl group was allowed. The human homology model of P2X4 
in its closed, resting state was kindly modelled by Associate Professor Dr Ralf Schmid 
from University of Leicester based on closed state of zfP2X4 (PDB ID: 4DW0) 
(Hattori & Gouaux, 2012). The protein was cleaned, hydrogens were added with UCFS 
Chimera (Pettersen et al., 2004), and relaxed with GROMACS 4.6.5 (Pronk et al., 
2013). The AutoDockTools4 (Morris et al., 2009) was used to convert the files for 
docking. The side chains of residues near the active site were made flexible. 
 
The homology model of human P2X4 receptor in its ATP-bound, open state was created 
using MODELLER 9.18 (Webb & Sali, 2014). The crystal structure of Danio rerio 
P2X4 (PDB: 4DW1) was used as template. Sequence alignments were obtained 
through BLASTP 2.6.1+ from the NCBI website (Altschul et al., 1997; Altschul et al., 
2005; National Institute of Health, n. d.). Due to the number of halogens present in the 
structures under investigation, docking was performed with AutoDock VinaXB 
(Koebel et al., 2016). Considering the competitive activity of these compounds with 
ATP, each compound was docked into the ATP binding pocket of protein in its closed, 
apo state. Considering the slight different conformation of three ATP binding pockets 
on P2X4, the process was repeated for each pocket to increase the sampling. 
 
All binding poses of every docked analogue were clustered hierarchically by the 
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RMSD relative to rigid, flat part of the molecule present in all analogues to identify 
the similar binding poses throughout the series of compounds. This was repeated for 
each of the three ATP binding pockets. The clustering was performed with the single-
linkage clustering method provided in MATLAB 8.5. The manual inspection of 
clusters led to the identification of a redundant binding mode across all three binding 
pockets. This mode was also presented a prevalence of active compounds versus non-
active compounds. The ability of the model to reproduce and explain the activity in 
relation to the different substitutions led to the proposal of this model as the binding 
mode. 
2.2.10 Statistical analysis 
All data were analysed using Origin® version 9.1 software (Origin Lab Corporation, 
USA). The distribution of data was determined using the Shapiro-Wilk test. If the data 
was normally distributed, statistical analysis was done using paired t-tests and if 
otherwise, the paired-sample Wilcoxon signed rank test was done. All experiments 
were repeated three times, at least, which was indicated by number of n. If n = 3, for 
instance, the experiment was done in three individual experiments, each in triplicates, 
using cells from three different flasks. The confidence interval was set at 95 % and 
statistical significance was labelled with asterisk where *p < 0.05, **p < 0.01, and 
***p < 0.001. All concentration-response curves were fitted using the Hill equation 
and desensitisation period (tau value (τ)) was determined using the exponential decay 
1 function in the Origin software. 
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CHAPTER 3  
IDENTIFICATION OF THASPINE AS A P2X4 
INHIBITOR THROUGH HIGH THROUGHPUT 
SCREENING 
3.1 Introduction 
A total of 1,710 compounds were used for screening and they came in two different 
sets namely Natural Products Set III (NPiii) and Diversity Set V (DSv) which were 
obtained from the NCI. The NPiii consists of 116 compounds; and the set is derived 
from DTP repository and put together by NCI based on their origin, purity, structural 
diversity, and availability of compound in the repository. However, this set was 
recently updated to Natural Products Set IV with additional compounds ("National 
Cancer Institute Development Therapeutics Program," 2016). Meanwhile, DSv 
consists of 1,594 compounds which are carefully selected from 140,000 compounds 
available in DTP repository, based on their pharmacophoric properties such as the 
number of hydrogen bond acceptors and donors, electric charge, and hydrophobicity. 
Another criterion for the selection is that the compounds should be relatively rigid, 
with five or less rotatable bonds, having tendency to be planar, having one or less chiral 
centres, and possessing pharmacologically desirable features; all of which contribute 
to the favourability of compounds to bind with biological proteins. Those properties 
are important because they represent drug-like properties, which are vital in this study. 
 
Before the screening experiment, a few steps were carried out for the preparation of 
compound screening. Stable P2X4 and other P2 receptor overexpressing cells were 
either generated in the lab or supplied by third parties as gifts. All overexpressing cells 
were characterised before being used in high throughput screening. After the stable 
P2X4 overexpressing cells were generated and characterised, the high throughput 
screening was performed of which its process is illustrated in Figure 3.18. The process 
started with screening of 1,710 compounds using a calcium response assay. Any 
compound that met two criteria (will be discussed later) were considered as hits which 
were then further characterised. After the hit characterisation, lead compound was 
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identified and taken forward for further investigation. In this study, thaspine was 
identified as the lead compound and investigated further for its pharmacological 
properties. 
3.2 Aim 
The main objective of this experiment was to find any potential compound with the 
potential of antagonising the human P2X4 receptor and to further characterise this lead 
compound. 
3.3 Results 
The results for section are divided into three sections. The first section will discuss the 
generation of stable P2X4 overexpressing cell line. The second section will describe 
on the high throughput screening while the third section will explain the 
characterisation of lead compound, thaspine.  
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3.3.2 Generation of stable cell lines 
3.3.2.1 Cloning of DNA 
To generate stable cell lines, the DNAs of interest were first introduced into pLVX-
IRES-mCherry vector. The DNAs were already available in-house with different 
vectors. Therefore, they were restricted using suitable restriction enzymes for insertion 
into the new vector. The size of DNAs was determined by running the DNA on gels. 
The DNAs were then inserted into pLVX-IRES-mCherry vector and transformed 
inside bacteria. The DNA extracted from bacterial colonies were then run on a gel to 
check for successful transformation. Based on Figure 3.1B, for mouse P2X4, the DNA 
from bacterial colony 1 was observed to travel less on gel compared to the uncut 
vector, which suggested that it contained the DNA of interest because theoretically it 
had a bigger size in comparison with the uncut vector and thus, travelled less. As for 
the human P2X7, all five colonies travelled less compared to uncut vector and it was 
deduced that all of them contained the human P2X7 DNA. The DNAs from colony 1 
from both mouse P2X4 and human P2X7 cloning were then sent for DNA sequencing 
and the data showed that they both contained the right sequence for mouse P2X4 and 
human P2X7, respectively, with correct orientation.  
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Figure 3.1 Gels showing bands after restriction and ligation. 
Panel A shows the bands of restricted mouse P2X4 DNA and human P2X7 DNA, and 
their vectors after restriction with EcoRI-HF and NotI-HF (for mouse P2X4), and NotI-
HF (for human P2X7). Mouse P2X4 and human P2X7 had a size of ~1.2 and ~1.9 kb, 
which were both confirmed by the gels. The bigger bands on top of DNA in both gels 
were the vectors. Gels in panel B show the size of circular DNA extracted from five 
colonies which had been transformed with DNA of interest. On the left, DNA from 
bacterial colony 1 travelled less than the uncut vector, indicating a successful ligation. 
On the right, the DNA from all bacterial colonies moved relatively less than uncut 
vector, which was an evident of successful ligation. The DNAs from colony 1 of both 
clones were verified further using DNA sequencing. 
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3.3.2.2 Transfection with Fugene HD 
Once the correct recombinant DNAs were obtained, they were transfected into the 
astrocytoma cells. To achieve that, a transfecting agent called Fugene HD was used. 
Optimisation experiments were done to determine the best Fugene HD (µL):DNA (µg) 
ratio, seeding density (two seeding densities chosen based on manufacturer’s protocol, 
i.e., 50,000 and 125,000 cells/well in a 24-well plate) and transfection duration. GFP-
tagged recombinant DNA was used in this experiment to assess the success of 
transfection by observing the fluorescence under a fluorescence microscope as well as 
a more accurate quantitative evaluation using FlexStation 3. Basically, the more 
fluorescence recorded indicated that more cells were being successfully transfected. 
  
Figure 3.2 shows the amount of fluorescence measured by FlexStation 3 at different 
Fugene HD:DNA ratio and seeding densities. At a ratio of 3:2, there was no 
fluorescence observed at low cell density and minimal fluorescence measured at high 
cell density after 48 and 72 hours. At 4:2 ratio, no or minimal fluorescence detected 
from cells at low seeding density at both time points. On the contrary, at high seeding 
density, the fluorescence was markedly higher with slightly more intense fluorescence 
after 72 hours compared to 48 hours. As the Fugene HD:DNA ratio increased to 5:2 
and 6:2, the fluorescence remained similar with that 4:2 ratio. 
 
However, at 7:2 ratio, the fluorescence was further reduced at high seeding density 
after 48 and 72 hours in relative to lower Fugene HD:DNA ratio, while fluorescence 
at low seeding density remained undetected. Again, the transfection was better when 
the cells were left with transfecting agent for 72 hours rather than 48 hours. 
Surprisingly, further ratio increase had turned down the fluorescence lower than 7:2 
ratio, with no or minimal detection of fluorescence at low seeding density. Based on 
the results, it was deduced that the optimum conditions for transfection using Fugene 
HD were 7:2 ratio (Fugene HD:DNA), 125,000 cells/well density and 72 hours 
incubation with Fugene HD. 
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Figure 3.2 Optimisation of Fugene HD:DNA ratio for transfection. 
The figure shows the optimisation process to determine the optimum condition for 
transfection using Fugene HD. The variables tested were Fugene HD:DNA ratio, 
duration of transfection, and seeding density. The tests were done in a 24-well plate. 
Black and dark grey bars represent the fluorescence measured after 48 and 72 hours of 
transfection duration, respectively, at low cell density. Light grey and white bars 
represent the fluorescence measured after 48 and 72 hours of transfection, respectively, 
at high cell density. (n = 1) 
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Afterwards, a kill curve experiment was carried out to determine the resistance of 
astrocytoma cells towards puromycin. This was important at later stages of the 
transfection process because puromycin was used to select the successfully transfected 
cells which carry the puromycin-resistant gene. The viable cells after puromycin 
selection were quantitated using an MTS assay as they can reduce MTS tetrazolium 
compound into a coloured formazan product which was subsequently measured by 
absorbance reading at a wavelength of 490 nm. Based on Figure 3.3, the cells 
multiplied on Day 1 of treatment except at 10 and 30 µg/mL of puromycin, where the 
cells died straight after puromycin treatment. Meanwhile at 1.0 µg/mL, the 
proliferation rate was greatly reduced to almost balance between cell proliferation and 
death. 
 
On Day 2, the cells at all concentrations started to die. Throughout four days of 
puromycin treatment, astrocytoma cells were only resistant towards 0.1 and 0.3 µg/mL 
of puromycin and survived. On the contrary, at higher concentrations, the cells died 
from Day 1 onwards. Generally, the rate of cell death gradually increased as the 
puromycin concentration increased. At 1.0 and 30 µg/mL, the cells did not survive 
after four days of puromycin treatment, whereas at 3.0 and 10 µg/mL, the cells died 
after three days of treatment. Consequently, it was deduced that the optimum condition 
for puromycin selection for post-transfection was 1.0 µg/mL for four days. 
 
After all this important information was retrieved from the experiments, the outcomes 
were used to transfect the recombinant DNA into blank astrocytoma cells. When the 
transfected cells were treated with 1.0 µg/mL puromycin, visually, 99 % cells died 
after five days. Only a few cells survived after five days and the remaining cells were 
maintained at the same puromycin concentration. However, the rate of multiplication 
was extremely slow. It took about a month to get a sufficient number of cells for the 
ATP concentration-response experiment which is shown in Figure 3.4. Based on the 
concentration-response, the calculated EC50 value was 6.64 µM with a maximal ATP 
concentration of 100 µM, which produced a response of 0.96 F ratio. 
 
However, the experiment was only performed once because the cells did not survive 
after subsequent splitting. That might have been caused by the low cell number after 
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splitting. That was also the cause for the inability to provide the standard error of mean 
for EC50 value. Afterwards, numerous attempts were done to repeat transfection 
process including up-scaling the transfection process but only resulted in numerous 
failures. Having continuous disappointment with the current technique of transfection, 
another technique was employed, which will be discussed shortly. 
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Figure 3.3 Puromycin kill curve on astrocytoma cells. 
The graph shows the absorbance of MTS-reagent after puromycin treatment on 
astrocytoma cells for 4 days. The absorbance represents the number of viable cells; 
higher absorbance indicates more viable cells. (n = 1) 
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Figure 3.4 ATP concentration-response of the human P2X4 puromycin-resistant 
overexpressing cell. 
Panel A shows the ATP concentration-response at human P2X4 puromycin-resistant 
overexpressing cells and panel B shows the representative trace when the cells were 
stimulated with 100 µM of ATP. (n = 1) 
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3.3.2.3 Viral transfection 
As the transfection using Fugene HD failed, the transfection strategy was changed to 
viral transfection. In this technique, the recombinant DNA was delivered into the blank 
astrocytoma cells using lentivirus. The number of lentiviral particles for each lentivirus 
produced was determined using p24 standard curve, as shown in Figure 3.5. The 
plasmid packaged in lentivirus contained mCherry gene that after being transcribed, 
would produce a fluorescent protein that emitted light when being excited at 587 nm 
wavelength. Thus, the selection of successfully transfected cells was based on the 
amount of fluorescence produced by the cells. The cells that highly fluoresced relative 
to non-transfected astrocytoma cells were sorted and grown in cell culture medium. 
 
Figure 3.6 shows the distribution of cell population and histogram of fluorescence for 
the transfected cells in flow cytometry. Dot plots show the size and granularity of the 
cells while the histograms show fluorescence of the transfected cells of (A) human 
P2X7, (B) mouse P2X4, and (C) human P2X4, respectively. Fluorescent cells were most 
likely to express the genes of interest although it was not guaranteed. The fluorescence 
histogram was divided into two regions, which P8 was the region that overlapped with 
fluorescence from non-transfected astrocytoma cells while P7 marked the fluorescence 
region outside non-transfected cell fluorescence. Cells that highly fluoresced and fell 
into P7 region were collected and cultured in flasks for future experiments. The 
percentage of highly expressing cells collected from the total population were 0.2, 2.3, 
and 1.0 % for human P2X7, mouse, and human P2X4, respectively. 
 
All sorted cells for each P2X subtype were then cultured, expanded, and 
cryopreserved. The growth of cells after sorting was relatively slow but when it 
reached about 50 % confluency, the growth became faster. After the first splitting, the 
cells proliferated at the same rate as non-transfected astrocytoma cells and still showed 
fluorescence under fluorescence microscope as indicated in Figure 3.7. 
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Figure 3.5 HIV p24 ELISA standard curve of recombinant HIV-1 p24 antigen. 
The amount of p24 associated particles of each lentiviral produced was calculated 
using this p24 standard curve and formula given by the manufacturer. The resulting 
figure was the amount of virus-containing gene in 1 mL of virus suspension. 
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Figure 3.6 Distribution of P2X overexpressing cells and mCherry fluorescence. 
These are the flow cytometry histograms of (A) human P2X4, (B) mouse P2X4, and 
(C) human P2X7. The left panel shows the distribution of cells being transfected for 
each transfected DNA. The target population was gated as P1 region and coloured in 
red and the small black population in the lower left side of the plot was regarded as 
dead cells. The right panel of the figure shows the fluorescence of mCherry protein. 
Since the vector used to carry the P2X DNAs also contained mCherry gene, the cells 
that were highly fluorescent indicated successful transfection. P7 region was regarded 
as the overexpressing cells and sorted for future experiments. 
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Figure 3.7 Images of overexpressing cells under fluorescence microscope 
The images show the non-transfected astrocytoma cells, mCherry overexpressing cells (positive control), human P2X4, mouse P2X4, and human 
P2X7 overexpressing cells under the fluorescence microscope post-sorting. The top panels are the bright-field images and bottom panels are the 
fluorescence images under TRITC laser. The scale bar represents 10 µm and magnification was 100x.
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3.3.2.4 Characterisation of overexpressing cells 
After the overexpressing cells were successfully generated, they were characterised 
for preparation to be used in high throughput screening. The performed 
characterisation tests comprised of the optimum seeding density determination, ATP 
concentration-response, determination of cell tolerability towards DMSO, PPADS 
inhibition concentration-response, and IVM potentiation concentration-response. All 
characterisation mentioned was only done on the human P2X4 overexpressing cells; 
and for the overexpressing cells of other receptors, only nucleotide concentration-
response was done. 
 
Figure 3.8 shows the data on the optimum seeding density for a maximal calcium 
response. Based on the data, it showed that the highest response (0.69 ± 0.04 F ratio) 
was observed at a density of 2.5 × 104 cells/well. The responses remained unchanged 
at the densities of ≤ 10 × 104 cells/well but significantly lower at density of > 10 × 104 
cells/well (p < 0.05, n = 3). Therefore, the optimum seeding density chosen for the 
next experiments was 2.5 × 104 cells/well. 
 
The potency of ATP on the human P2X4 overexpressing cell line was determined 
through the concentration-response experiment and the results are shown in Figure 3.9. 
The first significant response was recorded when the cells were applied with 0.1 µM 
of ATP which yielded a response of 0.042 ± 0.008 F ratio (p < 0.001, n = 12). The 
response exponentially increased to a plateau at 3 µM of ATP. The calculated EC50 
value was 0.56 ± 0.13 µM (n = 12 experiments). 
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Figure 3.8 Effects of seeding density on ATP-evoked calcium response on the 
human P2X4 overexpressing cells. 
Panel A shows the peak response recorded within a recording period of 250 seconds 
when the cells were stimulated with 0.6 µM ATP at different seeding cell density, and 
panel B shows representative at each seeding density. The lowest seeding density 
tested was 2.5 × 104 cells/well and the maximum was 20 × 104 cells/well. The 
statistical analysis was performed against the ATP-evoked response elicited at the cell 
density of 2.5 × 104 cells/well. (n = 3) 
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Figure 3.9 ATP concentration-response of the human P2X4 overexpressing cells. 
Panel A shows a complete ATP concentration-response at human P2X4 receptors and 
panel B shows its representative trace for 250 seconds when stimulated with a 
saturating concentration of ATP (3 µM). (n = 12) 
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Subsequently, various concentrations of DMSO were tested to determine its toxicity 
on the human P2X4 overexpressing cells. The cells were pre-incubated with various 
percentages of DMSO for 30 minutes and stimulated with 0.6 µM of ATP. This 
experiment was required because all compounds to be screened were dissolved in 
0.1 % DMSO (final concentration), however higher DMSO concentration might be 
needed if certain compounds were insoluble in 0.1 % DMSO. Figure 3.10 shows the 
effect of different DMSO percentages on ATP-evoked response. Up to 0.1 % of 
DMSO (final concentration), there was no significant change on the response in 
relation to the no DMSO control. However, at 0.3 % of DMSO, the response was seen 
to be potentiated significantly (32.6 ± 9.3 % potentiation, p < 0.05, n = 3) while at the 
highest concentration of 3 % of DMSO, it significantly reduced the response by 70.9 
± 17.7 % (p < 0.01, n = 3). Therefore, 0.1 % DMSO content was chosen to dissolve all 
compounds. However, in case of insolubility issue, the compounds were dissolved in 
1 % DMSO with proper controls. 
 
Figure 3.11 shows the inhibition concentration-response of PPADS on the human 
P2X4 overexpressing cells. It was shown that PPADS started to reduce the response at 
0.1 µM by 17.2 ± 5.2 % (p < 0.05, n = 3), and further inhibited until it abolished the 
response and reached plateau at 30 µM of PPADS. The IC50 value determined from 
the curve was 14.9 ± 5.2 µM (n = 3). Therefore, for high throughput screening, 100 
µM of PPADS was used as a positive control for inhibitor. Meanwhile, Figure 3.12 
shows the potentiation concentration-dependent curve of a selective positive allosteric 
modulator of P2X4, IVM. The value of EC50 determined from the curve was 1.7 ± 0.3 
µM (n = 3). From the curve, it was decided that 3 µM of IVM should be used for the 
positive control for the positive modulator. 
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Figure 3.10 Effects of DMSO incubation on ATP-evoked response. 
The bar chart shows the effect of DMSO on peak responses recorded within 250 
seconds when the cells were pre-incubated with different percentage of DMSO for 30 
minutes, and stimulated with 0.6 µM of ATP at human P2X4. All responses were 
normalised to mean of no DMSO. (n = 3) 
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Figure 3.11 PPADS inhibition concentration-response at human P2X4. 
The curve shows the PPADS inhibition concentration-response at human P2X4. 
Concentrations of PPADS used were from 0.01 to 300 µM, while the agonist ATP 
concentration was 0.6 µM, corresponded to EC50 value of the human P2X4 
overexpressing cells. All data were normalised against vehicle response. (n = 3) 
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Figure 3.12 Ivermectin potentiation concentration-response at human P2X4. 
The curve shows IVM potentiation concentration-response at human P2X4. 
Concentration of IVM used was from 0.01 to 300 µM, while ATP concentration was 
0.6 µM, corresponded to EC50 value of the human P2X4 overexpressing cells. All data 
were normalised against vehicle response. (n = 3) 
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3.3.2.4.1 Characterisation of P2X and P2Y overexpressing cell lines 
Concentration-response curves for agonists were performed on all available P2X and 
P2Y overexpressing cell lines to identify the maximal and EC50 concentrations 
required for the activation of receptors. ATP was used as the nucleotide for human 
P2X2, P2X2/3, P2Y2, and mouse P2X4 overexpressing cell lines while UDP and BzATP 
were used for human P2Y6 and P2X7 overexpressing cell lines, respectively. Although 
ATP is the physiological nucleotide for P2X7, BzATP was used as the agonist because 
P2X7 was only responsive to high concentration of ATP (millimolar range) (Bianchi 
et al., 1999) while the use of millimolar concentrations of ATP produced an 
endogenous response from non-transfected astrocytoma cells (data not shown), hence 
the ATP was replaced with BzATP. In the non-transfected astrocytoma cells, there was 
no response recorded at high BzATP (500 µM) concentration (data not shown).  
 
In the human P2X2 overexpressing cell line (Figure 3.13), ATP elicited a 
concentration-dependent increase in calcium level (EC50: 0.51 ± 0.1 µM, n = 3). The 
lowest ATP concentration that elicited response was 0.06 µM and the response 
plateaued at 3 µM. The maximal calcium influx was obtained from the application of 
3 µM of ATP which produced a magnitude of 1.77 ± 0.06 F ratio at 43.7 seconds. 
 
The human P2X2/3 receptor used in this study was a chimeric receptor. This was used 
because the instrument (FlexStation 3) could not detect any fluorescence from the 
activation of P2X3 expressing cell lines due to rapid desensitization. The amino acid 
sequence of the chimeric P2X2/3 ectodomain followed the sequence of P2X3 while the 
tail of C terminus followed the P2X2 residue segment. Therefore, activation of this 
chimeric P2X2/3 receptor followed the characteristic of P2X3 but desensitisation 
followed P2X2 behaviour because the tail of C terminus played a big role for 
desensitisation (Koshimizu et al., 1999). The use of ATP as an agonist in this 
overexpressing cell line produced a concentration-dependent influx of calcium (Figure 
3.14). The concentration-response curve revealed an EC50 value of 0.12 ± 0.03 µM (n 
= 3). The lowest concentration that receptor responded to was 0.06 µM and maximal 
concentration (1 µM) elicited a peak response of 1.54 ± 0.15 F ratio at 40.3 seconds. 
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The agonist BzATP elicited a concentration-dependent response in the human P2X7 
overexpressing cells (Figure 3.15). The first increase in intracellular calcium level was 
detected from the application of 10 µM of BzATP and the response plateaued at 300 
µM. The concentration-response curve revealed an EC50 value of 46.0 ± 4.0 µM (n = 
3). At the maximal concentration of 300 µM, the peak response recorded was 0.7 ± 
0.04 F ratio (n = 3) at 38.9 seconds. 
 
In the mouse P2X4 overexpressing cell line, the increase in calcium response was ATP 
concentration-dependent (Figure 3.16). The lowest response was detected with the 
application of 0.06 µM of ATP and the response plateaued at 1 µM. The calculated 
EC50 value was 0.22 ± 0.01 µM (n = 3). At the maximal concentration of 1 µM, the 
peak response recorded was 1.62 ± 0.06 F ratio (n = 3) at 40.4 seconds. 
 
Next, the ATP concentration-response for human P2Y2 is displayed in Figure 3.17. 
P2Y2 was more sensitive to ATP compared to P2X receptors tested in this study with 
a calculated EC50 value of 27.0 ± 7.3 nM (n = 3). The first response observed was 
when the cells were stimulated with 3 nM of ATP and the magnitude exponentially 
increased at higher ATP concentrations until it reached plateau at 0.3 µM. At a 
maximal concentration of 0.3 µM, the peak response recorded was about 1.5 ± 0.1 F 
ratio (n = 3) at 28.6 seconds.  
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Figure 3.13 ATP concentration-response of the human P2X2 overexpressing 
cells. 
The curve in panel A shows the concentration-response curve at human P2X2 receptor 
with ATP as an agonist and panel B shows the representative trace at super maximal 
concentration of 3 µM ATP. All responses were normalised to the mean peak response 
of vehicle control. (n = 3) 
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Figure 3.14 ATP concentration-response of the human P2X2/3 overexpressing 
cells. 
The curve in panel A shows the concentration-response curve at human P2X2/3 
receptor with ATP as an agonist and panel B shows the representative trace at super 
maximal concentration of 1 µM of ATP. All responses were normalised to the mean 
peak response of vehicle control. (n = 3) 
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Figure 3.15 BzATP concentration-response of the human P2X7 overexpressing 
cells. 
The curve in panel A shows the concentration-response curve at human P2X7 receptor 
with BzATP as an agonist and panel B shows the representative trace at super maximal 
concentration of 300 µM of BzATP. All responses were normalised to the mean peak 
response of vehicle control. (n = 3) 
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Figure 3.16 ATP concentration-response of the mouse P2X4 overexpressing 
cells. 
The curve in panel A shows the concentration-response curve at mouse P2X4 receptor 
with ATP as an agonist and panel B shows the representative trace at super maximal 
concentration of 1 µM of ATP. All responses were normalised to the mean peak 
response of vehicle control. (n = 3) 
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Figure 3.17 ATP concentration-response of the human P2Y2 overexpressing 
cells. 
The curve in panel A shows the concentration-response curve at human P2Y2 receptor 
with ATP as an agonist and panel B shows the representative trace at super maximal 
concentration of 0.3 µM of ATP. All responses were normalised to the mean peak 
response of vehicle control. (n = 3) 
  
  
131 
 
3.3.3 High throughput screening 
High throughput screening is a way to search for potential compounds that can be 
developed as the potential modulator, either positive or negative modulation. The flow 
of high throughput screening in this study is illustrated in Figure 3.18. The compounds 
obtained from NCI were screened in fluorescence-based assays using FlexStation 3. 
Subsequently, the hits were identified and several criteria were imposed to filter out 
the false positive hits. The hits were then characterised further before only one 
compound known as the lead was taken forward. 
 
Figure 3.19 shows the distribution of 1,710 compounds screened in this study in terms 
of response modulation. It was observed that most compounds lay in the region of 80 
– 150 % response, i.e., close to the 100 % mark of vehicle control. Since the screening 
was performed once in triplicate, the 80 – 150% region might be a result of variability. 
Thus, two filtering criteria were imposed to exclude the false positive results. The first 
criterion was the magnitude of potentiation or inhibition. Any compounds must have 
potentiated at least 75 % or inhibited at least 60 % of the control response to pass the 
first criterion. The control response was normalised to 100 % which was marked with 
a straight horizontal line in the figure. The potentiation percentage was calculated by 
subtracting the control response of 100 % from the remaining response displayed on 
the chart, while the percentage of inhibition was calculated by subtracting the 
remaining response displayed on the chart from 100 % control response. 
 
In the figure, the first criterion was marked with dashed lines (upper line for 
potentiation cut-off value and lower line for inhibition cut-off value). By applying the 
first criterion, 31 compounds were identified to potentiate the response while 56 
compounds showed the inhibitory properties. The three highest recorded potentiation 
were 1030.4 % (1130.4 % response), 534.1 % (634.1 % response), and 381.6 % 
(481.6 % response) which were recorded from the application of NSC179822, 
NSC375997, and NSC186067, respectively. The three biggest inhibition recorded 
were 97.5 % (2.5 % response), 96.7 % (3.3 % response), and 96.3 % (3.7 % response) 
(n = 1) which were recorded from the application of NSC122131, NSC639174, and 
NSC28080, respectively. 
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Figure 3.18 Flow chart of high throughput screening. 
The figure illustrates the process of high throughput screening from the testing of 1,710 
compounds until the discovery of lead compound and its characterisation.  
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Figure 3.19 Modulation of ATP-evoked calcium response in the human P2X4 
overexpressing cells treated with the screened compounds. 
The figure shows the distribution of all screened compounds in terms of their peak 
response in comparison to control response. The screening was done in triplicate. The 
solid line represents the control response normalised as 100 %. The long dash line 
represents the inclusion criterion for potential positive modulator. Compounds above 
the line (≥ 75 % potentiation) was regarded as potential positive modulators. 
Meanwhile, the short dash line represents the inclusion criterion for potential 
inhibitors. Compounds that had response below 40 % (i.e. ≥ 60 % inhibition) were 
carried forward for further experiments. In short, compounds between the long and 
short dashed lines were excluded from consideration. (n = 1)  
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The second criterion restricted the compounds that showed fluorescence baseline 
change after compound addition into the cells. This could be because of auto-
fluorescent compounds, quenching effect of compounds, and/or toxicity. To exclude 
those probabilities, the second criterion applied was that the compounds must not have 
altered the baseline ± 0.25 F ratio. The basis for selecting the value was that, a known 
human P2X4 blocker, PPADS, also shifted the baseline at a maximum of −0.25 F ratio. 
The second criterion is shown in Figure 3.20 where panel (A) shows the inclusion 
criterion for positive modulators and panel (B) for the inhibitors. The compounds 
populated in the figure were the compounds that passed the first inclusion criteria. The 
grey box highlights the compounds that passed the second criterion. 
 
As a result, eight positive modulator hits were identified: NSC9489, NSC14771, 
NSC27389, NSC34910, NSC211336, NSC48443, NSC369066, and NSC90749. The 
percentages of potentiation recorded were 81.04, 91.05, 77.20, 82.96, 85.76, 86.12, 
111.88, and 132.78% (n = 1), respectively. As for the modulation of baseline, all 
compounds did not cause baseline alteration except for two compounds: NSC34910 
and NSC211336 which shifted the baseline +0.2 and +0.06 F ratio, respectively. 
 
Meanwhile, the inhibitor hits identified were NSC345647, NSC116339, NSC50688, 
NSC17055, NSC5426, and thaspine, and their percentages of inhibition were 94.71, 
89.75, 65.18, 60.48, 81.40, and 69.96%, respectively. As for modulation shift, five 
from the six compounds altered the baseline. Compound NSC345647, NSC116339, 
NSC50688, NSC17055, and NSC5426 shifted the baseline by −0.15, −0.1, −0.25, 
+0.2, and −0.12 F ratio, respectively. Only thaspine indicated stable baseline upon 
compound addition. Thus, these eight positive modulator and six inhibitor hits were 
brought forward for preliminary testing. 
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Figure 3.20 Change in baseline fluorescence upon compound addition to the 
human P2X4 overexpressing cells. 
The dots in the figure represent the compounds that met the first criteria which was the 
percentage of potentiation and inhibition of more than 75 and 60 %, respectively (panel 
A and B, respectively). The y-axis represents the percentage of potentiation or 
inhibition while x-axis represents the fluorescence baseline alteration after compound 
addition, recorded at wavelength 340 and 380 nm excitation, and 510 nm emission. 
The acceptable value of baseline shift was within ±0.25 F ratio, which was set as the 
second inclusion criterion. The grey box marks the compounds that met both first and 
second criteria, known as hits. The hits were taken forward for further tests. 
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3.3.3.1 Preliminary characterisation of hits 
Further testing on the positive modulator hits revealed that none of the compounds 
tested potentiated the response more than 42 % despite the increasing concentration of 
the compounds (Figure 3.21), in contrast to the observation made in the high 
throughput screening. The highest significant potentiation observed among all the 
positive modulator hits was exhibited by NSC14771 which had 41.4 ± 12.6 % (p < 
0.05, n = 3) potentiation at a concentration of 0.5 µM. The data also showed that the 
potentiation was even lower at 10 µM which suggested that the potentiation was 
concentration-independent. This was also observed in other tested compounds. 
Therefore, further work on positive modulator hits were put to an end. 
 
While for the inhibitor hits, the results were more promising compared to positive 
modulator hits. Five out of six hits showed similar inhibition at 10 µM as observed in 
the screen, i.e., NSC345647, NSC116339, NSC17055, NSC5426, and thaspine. At 5 
µM, the reduction in response were 37.9 ± 5.7 % (NSC5426), 81.8 ± 1.3 % 
(NSC17055), 27.2 ± 7.3 % (NSC116339), 59.7 ± 7.7 % (NSC345647), and 29.1 ± 
12.8 % (thaspine) (n = 3). When the compound concentrations were reduced further, 
only NSC17055 still showed an inhibition of 46.5 ± 4.9 % and 26.6 ± 3.8 % at 1 and 
0.5 µM (n = 3), respectively. No inhibition was observed by all compounds at 0.1 µM. 
Overall, all compounds showed a concentration-dependent inhibition. Therefore, the 
lead compound, NSC17055, was selected for further characterisation as it showed the 
most potent inhibition at P2X4 receptor. 
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Figure 3.21 Concentration-response for compounds that went through second 
filter for positive modulators. 
The bar charts show the effects of eight positive modulator hits using five different 
concentrations: 0.1, 0.5, 1, 5, and 10 µM on the ATP-evoked response of the human 
P2X4 overexpressing cell. The concentration of ATP used was 0.6 µM, corresponded 
to EC50 value. All responses were normalised to the mean of vehicle response. 
Chemical structure of each compound is shown in Appendix I. Asterisks denote p-
value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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Figure 3.22 Concentration-response for compounds that went through second 
filter for inhibitors. 
The bar charts show the effects of six inhibitor hits using five different concentrations: 
0.1, 0.5, 1, 5 and 10 µM on the ATP-evoked response of the human P2X4 
overexpressing cell. The concentration of ATP used was 0.6 µM, corresponded to EC50 
value. All the responses were normalised to mean peak response of the mean peak 
response of vehicle control. Chemical structure of each compound is shown in 
Appendix II. Asterisks denote p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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3.3.3.2 Characterisation of NSC17055 
The first characterisation of NSC17055 was done to determine its inhibitory potency 
by establishing the inhibition concentration-response (Figure 3.23). The response 
elicited by the maximal concentration of ATP (3 µM) was blocked by NSC17055 in a 
concentration-dependent pattern. The fist inhibition was observed with the treatment 
of 0.3 µM of NSC17055 (6.9 ± 2.3 % inhibition, n = 3, p < 0.01) and a complete 
blockade was observed with 60 µM of NSC17055. From the concentration-response 
curve, the calculated IC50 value was 1.26 ± 0.08 µM. Based on the representative trace, 
it can be seen that the response magnitude was inhibited by 90.3 ± 0.6 % at 10 µM of 
NSC17055. 
 
The second characterisation was to determine its mode of inhibition, whether the 
blockade was competitive or noncompetitive. As shown in Figure 3.24, the inhibition 
from the treatment of 10 µM of NSC17055 was insurmountable regardless of 
increasing ATP concentration used which was up to 100 µM (13.9 ± 2.8 % response, 
n = 3) and the EC50 value of ATP was not significantly different between the untreated 
and treated cells (0.2 ± 0.03 µM versus 0.1 ± 0.01 µM, p > 0.05 n = 3). These indicated 
that the NSC17055 blocked the response noncompetitively and that the inhibition was 
an insurmountable antagonism. 
 
Looking at the potency of NSC17055, it was decided to look at its analogues to see if 
there were other variants that might inhibit better than NSC17055 while preserving its 
main backbone structure. The search for the analogues were done via MolPort web-
based server. The search was set up to show similar compounds with NSC17055 by 
0.8 similarity (Tanimoto index). Ten compounds with the highest similarity to 
NSC17055 and met drug-like properties as outlined by Lipinski et al. (2007) were then 
purchased from MolPort SIA and screened at 10 µM, and the chemical structure of 
each can be found in Appendix III. During the first replicate of experiment, there was 
a discrepancy in the data recording for STK331042. During the 250 seconds calcium 
response recording, there was no fluorescence detected and these were not observed 
in any other compounds. This raised a question whether the inhibition was an actual 
inhibition or just an artefact caused by the compound. Therefore, the experiment was 
put on hold and not replicated. 
  
140 
 
Figure 3.23 Inhibition concentration-response of NSC17055 at human P2X4. 
Panel A shows the complete inhibition concentration-response of NSC17055 on ATP-
evoked response of the human P2X4 overexpressing cells, plotted using peak response 
reading within 250 seconds recording post ATP activation. Panel B shows the 
representative trace with and without 10 µM NSC17055. (n = 3) 
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Figure 3.24 Determination of NSC17055 mode of action. 
The curve above displays the ATP concentration-responses with and without 10 µM 
of NSC17055. This experiment was aimed to study the mode of inhibition of 
compound, whether it was competitive or noncompetitive. Concentrations of ATP 
used were from 6 nM to 100 µM. The insurmountable inhibition by the compound 
indicated that it inhibited noncompetitively. (n = 3) 
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To verify whether NSC17055 was a true inhibitor, it was tested to check its effect on 
ionomycin- and carbachol-evoked responses. Ionomycin and carbachol are the 
compounds that can cause influx of calcium into the cytosol when they are applied on 
cells. However, ionomycin- and carbachol-evoked responses do not activate the P2X4 
receptor. Ionomycin was earlier hypothesised to physiochemically translocate the 
extracellular calcium into cells, but recent findings revealed that it also caused the 
release of calcium from intracellular store (Müller et al., 2013). Meanwhile, carbachol 
was reported to be an agonist for muscarinic acetylcholine receptors that mediated 
extracellular calcium influx through voltage-dependent calcium channels and also 
calcium release from intracellular store (Blackwood & Bolton, 1993). Therefore, both 
compounds can increase the level of calcium in the cytosol independent of P2X4 
receptor activation. 
 
In this experiment, ATP was replaced with either ionomycin or carbachol. It was 
hypothesised that the blockade of P2X4 receptor would not affect the ionomycin- and 
carbachol-evoked responses which are the results of activation of other receptors other 
than P2X4 activation. Therefore, the effect of NSC17055 treatment on the responses 
was investigated to ensure that the inhibition observed in P2X4 cell line was true. The 
cells were treated with 10 µM of NSC17055 for 30 minutes before being stimulated 
with 1 µM of ionomycin or 100 µM of carbachol.  
 
The data indicated that the antagonism of NSC17055 was not only specific to P2X4 
receptor since it significantly inhibited the ionomycin- and carbachol-evoked 
responses (Figure 3.25) by 87.2 ± 2.3 % and 81.0 ± 1.5 % (p < 0.001, n = 3), 
respectively. This may imply a possibility that NSC17055 was a fluorescence quencher 
that quenched Fura-2 fluorescence, and in turn gave low reading of F ratio. The 
quenching effect was also previously reported by Żamojć et al. (2014) who claimed 
that some coumarin derivatives caused the fluorescence quenching. Following the 
observed inhibition by NSC17055 on ionomycin- and carbachol-evoked response, the 
characterisation of NSC17055 was put to an end and the study turned back to other 
inhibitor hits. 
 
To avoid the same problem, all inhibitor hits were tested to observe their effects on 
ionomycin- and carbachol-evoked responses. The results (Figure 3.26) showed that 
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five out of six compounds inhibited the responses significantly. The percentage of 
inhibition ranged from 32.9 – 93.0 % for ionomycin and 17.8 – 81.2 % for carbachol, 
(p < 0.05, n = 3). These suggested that all potential inhibitor hits were false positives 
and that their inhibitory effect might be due to fluorescence quenching or via a non-
P2X4 mediated pathway, except for one compound, thaspine. Thaspine did not 
significantly cause a reduction in ionomycin- and carbachol-evoked responses 
compared to vehicle control. Therefore, thaspine was selected as the new lead 
compound as it showed 60 % inhibition of calcium-evoked response in the human 
P2X4 overexpressing cells at 10 µM in addition to its lack of effect on ionomycin- and 
carbachol-evoked responses. 
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Figure 3.25 Effect of NSC17055 on ionomycin- and carbachol-evoked response. 
The bar chart shows the responses of human P2X4 when challenged with 1 µM of 
ionomycin and 100 µM of carbachol in the presence and absence of 10 µM of 
NSC17055. Black bar represents the peak response of vehicle control recorded for 
each condition without the compound and the response was normalised to 100 %. 
Meanwhile, white bar shows the peak response of each condition when 10 µM of 
compound was present and the responses were normalised to control response. 
Asterisks denote p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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Figure 3.26 Effects of potential inhibitor hits on ionomycin- and carbachol-
evoked responses. 
The bar charts show the effect of all inhibitor hits on ionomycin- and carbachol-evoked 
responses of the human P2X4 overexpressing cells. The concentrations of ionomycin, 
carbachol, and potential compounds used in this experiment were 1, 100, and 10 µM, 
respectively. All responses were normalised to mean peak response of the vehicle 
control (0.1 % DMSO). The differences in percentage of responses between each 
compound and vehicle response were statistically calculated. Asterisks denote p-value: 
* = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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3.3.3.3 Characterisation of thaspine 
Several characterisation experiments on thaspine were done to fully understand its 
properties. The first characterisation done was the inhibition concentration-response 
to study its potency at inhibiting human P2X4 receptor. As shown in Figure 3.27, 
thaspine started to inhibit at a concentration of 3 µM, where it significantly inhibited 
33.0 ± 3.0 % (p < 0.001, n = 3) of the response elicited by 3 µM of ATP and at 100 
µM, it almost abolished the response (95.0 ± 1.1 % inhibition, p < 0.001, n = 3). From 
the data, the value of IC50 determined was 3.81 ± 0.2 µM (n = 3) and it could be clearly 
seen that thaspine only affected the magnitude of response while maintaining the decay 
kinetics, represented by tau value. The tau values for response with and without 
thaspine were not significantly different (106.8 ± 34.7 and 100.4 ± 10.3 seconds, 
respectively, [thaspine] = 10 µM, [ATP] = 3 µM, p > 0.05, n = 3). 
 
To test the dependency of thaspine inhibition on the cell system used for 
overexpressing the P2X4 receptors, it was tested on human P2X4 expressed in HEK293 
cells which were kindly donated by MedImmune. Due to HEK293 having endogenous 
P2Y receptors that were also responsive to ATP, cytidine triphosphate (CTP) was used 
as it only activates P2X4 and partially activates P2X1 (Roberts & Evans, 2004; Soto et 
al., 1996). Based on the data shown in Figure 3.28, it showed that thaspine blocked 
100 µM CTP-evoked response in concentration-dependent pattern. The first 
significant inhibition was observed when the cells were treated with 3 µM of thaspine 
(40.2 ± 8.0 % inhibition, p < 0.01, n = 3). At 30 µM of thaspine, the response was 
almost completely inhibited (92.4 ± 1.3 % inhibition, p < 0.001, n = 3). Its potency 
was also similar to that in 1321N1 cells overexpressing human P2X4 (IC50 value of 
3.99 ± 1.0 µM versus 3.81 ± 0.2 µM, p > 0.05, n = 3). These indicated that the 
inhibition of thaspine was not dependent on the use of nucleotide and cell system that 
overexpresses human P2X4. 
 
Next, thaspine was tested on mouse orthologue to see if it was also effective at 
blocking other P2X4 orthologue. Mouse P2X4 has an 88 % similarity with human P2X4 
in terms of amino acid sequence and thus, it was expected that thaspine would have 
similar effect. Figure 3.29 shows thaspine inhibition concentration-response at mouse 
P2X4 receptor (overexpressed in astrocytoma cells) and representative traces of 
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responses in the absence and presence of 10 µM of thaspine. The calculated IC50 value 
based on the curve was 3.53 ± 0.26 µM (n = 3) which was similar with the human 
P2X4 expressed in 1321N1 and HEK293 cells (p > 0.05, n = 3).  
 
The fourth characterisation was to determine the mode of inhibition. The result showed 
that the highest ATP concentration tested (30 µM) did not overcome the inhibition by 
10 µM of thaspine (Figure 3.30). The ATP EC50 values in the absence and presence of 
thaspine were also not significantly different (0.44 ± 0.1 µM versus 0.48 ± 0.2 µM, 
respectively, p > 0.05, n = 3). Together, the data suggested that the inhibition was 
noncompetitive. 
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Figure 3.27 Inhibition concentration-response of thaspine at human P2X4 
receptor overexpressed in astrocytoma cells. 
Panel A shows thaspine inhibition concentration-response at human P2X4. The lowest 
thaspine concentration was 10 nM and the highest was 30 µM. Panel B shows the 
representative trace of calcium response for 250 seconds recording with the presence 
and absence of 10 µM of thaspine. The cells were challenged with maximal agonist 
(ATP) concentration which was 3 µM. All responses were normalised to the maximum 
response of vehicle control. (n = 3) 
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Figure 3.28 Inhibition concentration-response of thaspine at human P2X4 
receptor overexpressed in HEK293 cells. 
Panel A shows thaspine inhibition concentration-response at human P2X4 receptor 
overexpressed in HEK293 cells. The lowest thaspine concentration was 10 nM and the 
highest was 30 µM. Panel B shows the representative trace of the response for 250 
seconds recording in the presence and absence of 10 µM of thaspine. The cells were 
challenged with a maximal CTP concentration which was 100 µM. All responses were 
normalised to the maximum response of vehicle control. (n = 3)  
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Figure 3.29 Inhibition concentration-response of thaspine at mouse P2X4. 
Panel A shows thaspine inhibition concentration-response at mouse P2X4 receptor. 
The lowest thaspine concentration was 10 nM and the highest was 30 µM. Panel B 
shows the representative traces of the response for 250 seconds recording between 
untreated and treated cells with 10 µM of thaspine. The cells were stimulated with a 
maximal concentration of 0.6 µM of ATP. All responses were normalised to the 
maximum response of vehicle control. (n = 3)  
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Figure 3.30 Determination of thaspine mode of inhibition. 
Panel A shows the ATP concentration-response at human P2X4 receptor with and 
without 10 µM of thaspine (open and closed squares, respectively). Panel B shows the 
representative trace of response when the cells were challenged with 3 µM of ATP in 
the absence and presence of 10 µM of thaspine for a period of 250 seconds. The 
inability of maximal ATP concentration to surmount thaspine inhibition and 
unchanged EC50 values were both the indicators of a noncompetitive antagonism. All 
responses were normalised to the response of vehicle control (without ATP). (n = 3) 
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Next, the bar chart in Figure 3.31 shows the effect of different pre-incubation periods 
of thaspine (10 µM) on ATP-evoked calcium response at human P2X4. The data 
showed that thaspine had no significant effect on the calcium response after 5 minutes 
pre-incubation where the inhibition was only 3.7 ± 4.5 % (p > 0.05, n = 3). The first 
significant inhibition was observed after 10 minutes pre-incubation with 19 ± 3.0 % 
inhibition (p < 0.001, n = 3) and the blockade was gradually increased as the pre-
incubation time increased. The maximum inhibition was observed after 40 minutes 
pre-incubation and the inhibition with periods longer than 40 minutes produced similar 
inhibition with that of 40 minutes (p > 0.05, n = 3). The incubation period versus 
percentage of inhibition were as follows: incubation period (minute) – percentage of 
inhibition (%): 10 – 19.1 ± 3.0, 15 – 21.3 ± 4.0, 20 – 30.5 ± 5.8, 25 – 37.4 ± 7.3, 30 – 
50.0 ± 8.4, 35 – 55.0 ± 9.1, 40 – 63.6 ± 9.1, 45 – 60.2 ± 10.3, 50 – 66.7 ± 6.5, 55 – 
70.0 ± 5.5, and 60 – 65.9 ± 4.5 (n = 3). The curve revealed that the time taken to 
produce 50 % of its inhibitory activity was 15.2 ± 11 (n = 3) minutes.  
 
Figure 3.32 shows the results of reversibility experiment. This was achieved by 
stimulating the cells with 3 µM ATP twice. Between the stimulations, the cells were 
washed with HBPS and incubated at 37 °C for 5 – 30 minutes. The hypothesis was if 
thaspine was a reversible inhibitor, it would be displaced from its binding site during 
the wash, and the second ATP stimulation should produce the same response between 
thaspine-treated cells and vehicle control. Based on the results, the second ATP 
stimulation of vehicle control yielded 41.0 ± 2.0 % (n = 3, normalised to the first ATP 
stimulation) after 5 minutes incubation. The percentage of response gradually 
increased as the incubation time increased and the highest response was recorded when 
the cells were incubated for 15 minutes after washing (61.9 ± 2.5 %, n = 3). The fitting 
of responses at each time point revealed that the receptors took 10.4 ± 1.0 minutes to 
achieve 50 % of its recovery fraction. 
 
However, the second ATP stimulation on thaspine-treated cells did not show the same 
magnitude of response as the vehicle control. After 5 minutes incubation, the 
percentage of response (normalised to the first ATP stimulation of vehicle control) 
recorded was only 8.2 ± 1.5 % (n = 3). The responses gradually increased as the 
incubation time increased and the highest point was recorded after 30 minutes 
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incubation (16.8 ± 2.1 %, n = 3). The percentage of responses after the second ATP 
stimulation between thaspine-treated cells and vehicle control was significantly 
different (p < 0.001, n = 3). This indicated that thaspine was not removed during the 
wash, and that it was a long-acting or irreversible inhibitor. 
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Figure 3.31 Effects of different thaspine incubation periods on calcium 
response. 
The bar chart represents the effect of different thaspine pre-incubation periods on the 
human P2X4 overexpressing cells after being stimulated with 3 µM of ATP. The 
shortest incubation period was 5 minutes and the period gradually increased by 5 
minutes up to 60 minutes. Black bar is the vehicle control response of untreated cells 
while white bar represents the response of treated cells. All responses were normalised 
to the vehicle control response at each time point. Statistics were calculated based on 
responses of untreated and treated cells at each respective time point. Black line is the 
curve fit of the treated cells data. The fitting revealed that the time taken to produce 
50 % of its inhibitory activity was 15.2 ± 11 minutes. Asterisks denote p-value: * = < 
0.05, ** = < 0.01, *** = < 0.001, n.s. = not significant. (n = 3) 
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Figure 3.32 Reversibility experiment of thaspine at human P2X4. 
The bar chart shows the amount of calcium response elicited by four conditions. Black 
bar represents the response of vehicle control in the first ATP stimulation while 
crossed bar represents the second ATP stimulation. White bar represents the response 
of thaspine-treated cells in the first ATP stimulation, while bar with horizontal lines 
shows the second ATP stimulation. The responses were normalised to the response of 
vehicle control in the first ATP stimulation (black bar). The x-axis represents the 
duration of incubation after washing, i.e., before the second ATP stimulation. The 
statistics show the difference in response magnitude in the second ATP stimulation 
between the vehicle control and thaspine-treated cells. The data shows that thaspine-
treated cells did not recover the response as high as the vehicle control. This shows 
that thaspine was not removed during the wash and the inhibition remained in the 
second ATP stimulation. Asterisks denote p-value: * = <0.05, ** = <0.01, *** = 
<0.001. (n = 3) 
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3.3.3.4 Effects of thaspine at P2X4 paralogues and P2Ys 
Then, thaspine was tested to determine its selectivity. Several P2X and P2Y 
overexpressing cell lines were tested with the compound. Figure 3.33 – 3.37 show the 
effect of thaspine treatment on each cell line: the human P2X2, P2X2/3, P2X7, P2Y2, 
and P2Y6, respectively. In the experiment, two concentrations were used, which were 
the EC50 and maximal agonist concentrations. 
 
At human P2X2, P2X2/3, and P2X7, there was no significant inhibition observed with 
the treatment of 10 µM of thaspine either at EC50 or maximal concentrations of agonist 
(p > 0.05, n = 3). On the other hand, the inhibition observed at human P2Y2 was 
significant either at EC50 or maximal concentrations of ATP with a magnitude of 79.9 
± 4.7 % and 74.4 ± 6.0 % (p < 0.001, n = 3), respectively. The inhibition was also 
observed at human P2Y6 with an inhibition of 19.1 ± 7.3 % (p < 0.05, n = 3) and 39.6 
± 5.7 % (p < 0.001, n = 3) when the cells were stimulated with 23 and 100 nM of UDP, 
respectively. 
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Figure 3.33 Effect of thaspine on ATP-evoked response at human P2X2. 
Panel A shows the effect of thaspine on ATP-evoked response at human P2X2 receptor 
when challenged with EC50 and maximal concentrations of ATP. The black bars 
represent the vehicle control peak response and white bars represent the peak responses 
of thaspine-treated cells. Panel B and C illustrate the representative trace for 250 
seconds when the cells were challenged with EC50 and super maximal ATP 
concentration, respectively. Close square is the trace for vehicle while the open square 
is for thaspine-treated cells. All responses were normalised to mean peak response of 
vehicle control for each concentration. n.s. = not significant. (n = 3) 
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Figure 3.34 Effect of thaspine on ATP-evoked response at human P2X2/3 
Panel A shows the effect of thaspine on ATP-evoked response at human P2X2/3 
receptor when challenged with EC50 and maximal concentrations of ATP. The black 
bars represent the vehicle control peak response and white bars represent the peak 
responses of thaspine-treated cells. Panel B and C illustrate the representative trace for 
250 seconds when the cells were challenged with EC50 and super maximal ATP 
concentration, respectively. Close square is the trace for vehicle while open square is 
for thaspine-treated cells. All responses were normalised to mean peak response of 
vehicle control for each concentration. n.s. = not significant. (n = 3)  
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Figure 3.35 Effect of thaspine on BzATP-evoked response at human P2X7 
Panel A shows the effect of thaspine on BzATP-evoked response at human P2X7 
receptor when challenged with EC50 and maximal concentrations of BzATP. The black 
bars represent the vehicle control peak response and white bars represent the peak 
responses of thaspine-treated cells. Panel B and C illustrate the representative trace for 
250 seconds when the cells were challenged with EC50 and super maximal BzATP 
concentration, respectively. Close square is the trace for vehicle while open square is 
for thaspine-treated cells. All responses were normalised to mean peak response of 
vehicle control for each condition. n.s. = not significant. (n = 3) 
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Figure 3.36 Effect of thaspine on ATP-evoked response at human P2Y2 
Panel A shows the effect of thaspine on ATP-evoked response at human P2Y2 receptor 
when challenged with EC50 and maximal concentrations of ATP. The black bars 
represent the vehicle control peak response and white bars represent the peak responses 
of thaspine-treated cells. Panel B and C illustrate the representative trace for 250 
seconds when the cells were challenged with EC50 and super maximal ATP 
concentration, respectively. Close square is the trace for vehicle while open square is 
for thaspine-treated cells. All responses were normalised to mean peak response of 
vehicle control for each concentration. Asterisks denote p-value: * = < 0.05, ** = < 
0.01, *** = < 0.001. (n = 3) 
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Figure 3.37 Effect of thaspine on UDP-evoked response at human P2Y6 
Panel A shows the effect of thaspine on UDP-evoked response at human P2Y6 receptor 
when challenged with EC50 and maximal concentrations of UDP. The black bars 
represent the vehicle control peak response and white bars represent the peak responses 
of thaspine-treated cells. Panel B and C illustrate the representative trace for 250 
seconds when the cells were challenged with EC50 and super maximal UDP (values 
based on Campwala (2015)) concentrations, respectively. Close square is the trace for 
vehicle while open square is for thaspine-treated cells. All responses were normalised 
to mean peak response of vehicle control for each condition. Asterisks denote p-value: 
* = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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To further investigate the potency of thaspine in inhibiting P2Y2 and P2Y6, an 
inhibition concentration-response was generated for both receptors which are shown 
in Figure 3.38. For P2Y2, there was no modulation of response observed at 
concentrations of lower than 10 µM. At only 10 µM, the response elicited by 100 nM 
of ATP was almost abolished (95.2 ± 0.8 % inhibition, n = 3) and the same effect was 
also observed at 30 µM of thaspine (96.1 ± 1.0 % inhibition, n = 3). On the other hand, 
there was a significant potentiation at 1 µM of thaspine (23.1 ± 13.6 % potentiation, p 
< 0.05, n = 3). At P2Y6, the UDP-evoked response was not changed with the treatment 
of ≤ 10 µM of thaspine (p > 0.05, n = 3), but it was significantly blocked with the 
application of 30 µM of thaspine by 94.7 ± 0.5 % (p < 0.001, n = 3). Together, the data 
showed that thaspine was not effective at human P2Y2 and P2Y6 at the concentrations 
of below 10 µM and 30 µM, respectively. 
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Figure 3.38 Thaspine inhibition concentration-response at human P2Y2 and 
P2Y6 receptors. 
The figure shows thaspine inhibition concentration-response at (A) human P2Y2 and 
(B) human P2Y6. Thaspine was ineffective at human P2Y2 at concentration of below 
than 10 µM and below than 30 µM at human P2Y6. The responses were normalised to 
the mean peak response of vehicle and the error bars show the standard error of mean. 
Asterisks denote p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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3.3.3.5 Effects of thaspine on microglial cells 
Up to this point, all characterisation experiments were performed on the stable 
overexpressing cell lines and this might not be reflected in primary cells or in vivo 
setting. To reflect the finding on primary cells, murine microglial cell line or BV2 cells 
were used. Although they were not the primary cells, Henn et al. (2009) proposed that 
BV2 cells behaved similar to primary microglial cells. Moreover, since thaspine also 
blocked ATP-evoked calcium response at mouse P2X4 as shown in Figure 3.29, BV2 
cell was a suitable model to examine such effect on mouse microglial cell line.  
 
Figure 3.39 shows the complete ATP concentration-response of BV2 cells. The 
calculated EC50 was 1.8 ± 0.65 µM and maximal concentration was 10 µM (n = 3). It 
is worth noting, however, BV2 cells contain other P2X and P2Y receptors and thus the 
observed response was a result of stimulation of multiple types of purinergic receptor 
(Gendron et al., 2003). 
 
To test whether thaspine had any effect on the response liberated by specifically P2X4 
receptors in BV2 cells, the cells were potentiated with IVM, which is a selective 
positive allosteric modulator. Theoretically, IVM will only potentiate the response 
yielded by P2X4 and if thaspine inhibits the P2X4 receptor, it will reduce the 
potentiated response by IVM. The tests were done on two states of cells, quiescent and 
activated cells. The activated cells were induced by LPS, of which increased the 
expression of P2X4 (Raouf et al., 2007). This was done to imitate the actual situation 
where hypersensitivity to pain was a consequence of overexpression of P2X4 receptors. 
The activity of thaspine was compared to a known P2X4 inhibitor, PSB12062, to see 
if they share common characteristics when exposed to BV2 cells. The concentration 
used for both compounds was 10 µM whereas 3 µM for IVM. 
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Figure 3.39 ATP concentration-response of BV2 cells. 
The curve in panel A shows the complete ATP concentration-response of BV2 cells 
challenged (25,000 cells/well) with multiple concentrations of ATP and panel B shows 
the representative trace at 100 µM of ATP which corresponded to saturated 
concentration. The EC50 value determined from the graph was 1.8 ± 0.65 µM. The 
error bars show the standard error of mean. (n = 3) 
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Figure 3.40 Effects of thaspine and PSB12062 on quiescent BV2 cells. 
Panel A shows the effect of thaspine and PSB12062 on ATP-evoked response of 
quiescent BV2 cells. The effects were measured in terms of percentage of peak 
response normalised to control response. The effects of both compounds were 
observed on normal ATP response and on IVM-potentiated response. Panel B shows 
the effects of IVM, thaspine, and PSB12062 on the representative traces of ATP-
evoked response while Panel C shows the effect of thaspine and PSB12062 on IVM-
potentiated representative traces. The concentration of compounds used in this 
experiment was 10 µM for thaspine and PSB12062, 3 µM for IVM, and 10 µM for 
ATP. Asterisks denote p-value: * = < 0.05, ** = < 0.01, *** = < 0.001, n.s. = not 
significant. (n = 6) 
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Figure 3.41 Effects of thaspine and PSB12062 on LPS-activated BV2 cells. 
Panel A shows the effect of thaspine and PSB12062 on ATP-evoked response of LPS-
activated BV2 cells. The effects were measured in terms of percentage of peak 
response normalised to control response. The effects of both compounds were 
observed on normal ATP response and on IVM-potentiated response. Panel B shows 
the effect of IVM, thaspine, and PSB12062 on the representative traces of ATP-evoked 
response while panel C shows the effects of thaspine and PSB12062 on IVM-
potentiated representative traces. The concentration of compounds used in this 
experiment was 10 µM for thaspine and PSB12062, 3 µM for IVM, and 10 µM for 
ATP. Asterisks denote p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. n.s. = not 
significant. (n = 6) 
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Figure 3.40 shows the effects of thaspine and PSB12062, as positive control, on 
quiescent BV2 cells. Ivermectin significantly potentiated the response by 42.8 ± 2.6 % 
(p < 0.001, n = 6) compared to control. In terms of representative trace, there was no 
difference in the decay kinetic (τ) between the vehicle control and IVM-potentiated 
response (16.5 ± 0.7 versus 16.7 ± 0.5 seconds respectively, p > 0.005, n = 6). In 
thaspine-treated cells, the response significantly increased by 11.9 ± 3.7 % (p < 0.01, 
n = 6) while there was no difference observed when the cells were treated with 
PSB12062. However, when IVM and thaspine or IVM and PSB12062 were co-treated, 
both inhibitors significantly reduced the response in comparison to IVM-potentiated 
response by 8.7 ± 2.6 % (p < 0.01, n = 6) and 33.6 ± 3.4 % (p < 0.001, n = 6), 
respectively.  
 
On the other hand, Figure 3.41 shows the effects of thaspine and PSB12062 on LPS-
activated BV2 cells. Similar pattern was observed as in quiescent cells except there 
was no effect on the response, in comparison with control, when the cells were treated 
with either thaspine or PSB12062. Ivermectin positively modulated the response by 
53.7 ± 5.6 % relative to control (p < 0.001, n = 6). When thaspine or PSB12062 was 
applied, there was no effect on the ATP-evoked response. Interestingly, when thaspine 
or PSB12062 was co-treated with IVM, both decreased the IVM-potentiated response 
by 56.9 ± 5.0 % and 40.6 ± 4.4 % (both p < 0.001, n = 6), respectively.  
 
Taken from the two sets of data of quiescent and LPS-activated cells, several 
deductions could be made. Ivermectin positively modulated ATP-evoked response on 
both cell conditions but there was a clear difference in the magnitude of potentiation 
between the two cell states. The potentiation in LPS-activated cells was significantly 
greater than quiescent cells (by 10.9 %, n = 6). That was in agreement with Raouf et 
al. (2007) who discovered that IVM-potentiation was stronger in activated cells and 
attributed to the increase in upregulated expression of P2X4 in activated cells. 
Meanwhile, there was no significant difference in response when PSB12062 was 
added to both cell conditions. However, the application of thaspine slightly potentiated 
the quiescent cells but did not affect LPS-activated cells. In terms of IVM-potentiated 
response, both thaspine and PSB12062 blocked the potentiation by IVM in both cell 
states. While the blockade strength by PSB12062 remained unchanged between the 
  
169 
 
two cell states (in relative to IVM-potentiated response), thaspine inhibition was 
stronger in activated cells. 
3.3.4 Understanding the mechanism of action of thaspine 
Subsequently, the mechanism of action of thaspine was investigated. Since thaspine 
was a slow acting compound, it was hypothesised that the reduction of response might 
not be due to a direct blockade of ATP binding. Rather, thaspine might cause the 
internalisation of P2X4 receptors from the plasma membrane and that resulted in less 
receptors on the surface. Consequently, less calcium channels were present on the 
membrane that led to less calcium influx into the cells. 
 
A flow cytometry experiment was used to test the hypothesis. In the experiment, the 
cells were labelled with an antibody that recognised extracellular epitope of P2X4 
receptors. The idea was to treat the cells with either 10 µM of thaspine or vehicle 
(0.1 % DMSO) to see the effect of the treatments. If the hypothesis were true, the 
fluorescence from the antibody would be less than the vehicle control, indicating a 
lower number of P2X4 receptors on the plasma membrane. 
 
To test the binding specificity of anti-P2X4 antibody used, the non-transfected 
astrocytoma cells were labelled with the antibody to see if there was fluorescence. 
Figure 3.42 (panel A) shows that there was a significant increase in the median 
fluorescence intensity (MFI) (p < 0.01, n = 3) of the labelled non-transfected cells 
relative to isotype control which suggested that there were non-specific bindings. 
However, the increase in the MFI of human P2X4 overexpressing cells was 
significantly higher than that of non-transfected cells (compare panel A and C of 
Figure 3.42, p < 0.05, n = 3) which suggested that the difference was the result of 
antibody binding to overexpressed P2X4 receptors.  
 
Figure 3.42 (panel C) shows the mean fluorescence intensity of isotype control and 
anti-P2X4 labelled human P2X4 overexpressing cells when treated with 0.1 % DMSO 
(vehicle control) or 10 µM of thaspine. In the presence of thaspine, the fluorescence 
was not significantly different from the vehicle control (p > 0.05, n = 3) which 
suggested that the number of P2X4 receptors on the plasma membrane was not 
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reduced. Figure 3.42 (panel E) represents the histogram of anti-P2X4 labelled human 
astrocytoma cells when treated with DMSO and thaspine. Both histograms overlapped 
each other indicating that the level of antibody binding was similar between the 
treatments. 
 
An alternative explanation for these results was that the effect of thaspine was 
overcome during the course of experiment as the antibody labelling process took 
approximately 3 hours. Therefore, another experiment was designed for FlexStation 3 
recording. The cells were treated and washed using the same protocol as the flow 
cytometry experiment, but they were challenged with ATP at the end of the procedure. 
This was to see if thaspine-treated cells regained their response as much as the control 
response because if the internalised receptors re-emerged, the inhibition would not be 
observed. Upon analysis, the results showed that the responses were still supressed 
compared to the control response even after 3 hours following thaspine treatment (36.3 
± 2.4 %, p < 0.001, n = 3), suggesting that the inhibition caused by thaspine was long 
term (Figure 3.43). Together, these suggested that thaspine did not alter the number of 
P2X4 receptors on the plasma membrane. 
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Figure 3.42 Flow cytometry of the non-transfected astrocytoma and human 
P2X4 overexpressing cells 
The charts summarise the fluorescence of the non-transfected astrocytoma and human 
P2X4 overexpressing cells when labelled with anti-P2X4 antibody. A) MFI of isotype 
control and anti-P2X4 labelled non-transfected astrocytoma cells, B) representative 
histogram of non-transfected astrocytoma cells where red curve is for isotype control 
and green is for anti-P2X4 labelled cells, C) MFI of the human P2X4 overexpressing 
cells that were treated with 0.1 % DMSO or 10 µM of thaspine, D) representative 
histogram of the human P2X4 overexpressing cells where red curve is for isotype 
control and green is for anti-P2X4 labelled cells, and E) representative overlaid 
histograms between DMSO- and thaspine-treated human P2X4 overexpressing cells 
where red is for DMSO treatment and green is for thaspine treatment. The experiments 
were repeated three times and the histograms are representative from one repetition.  
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Figure 3.43 ATP-evoked response of the human P2X4 overexpressing cells after 
being treated according to flow cytometry protocol. 
The bar chart shows the ATP-evoked response of thaspine-treated P2X4 
overexpressing cells after using the same protocol as the flow cytometry experiment 
and being stimulated with 3 µM of ATP at the end of the protocol. The results showed 
that the response was still inhibited after a 3 hours protocol. The response was 
normalised to control response. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** 
= < 0.001. (n = 3) 
 
  
  
173 
 
Another proposed mechanism was based on its chemical properties. It was found that 
it has an XLogP3 value of 2.8 which suggested that the compound was a moderately 
lipophilic compound. Therefore, it was postulated that thaspine diffused through the 
plasma membrane and subsequently bound to the P2X4 receptor on the internal epitope 
and changed the P2X4 structure conformation. The theory was also based on the fact 
that it was a slow-acting drug as shown in Figure 3.31. The idea behind this theory 
was that thaspine required certain amount of time to penetrate into the plasma 
membrane and bind to intracellular epitope of P2X4 before starting to effect the ATP-
evoked calcium response. 
 
To test this theory, thaspine was incubated with cells for 10 minutes in different 
percentages of DMSO. According to Williams and Barry (2012), increasing amount 
of DMSO made the plasma membrane more permeable, thus the penetration of 
thaspine could be easier and the effects of thaspine on ATP-evoked calcium response 
could be observed quicker. Figure 3.44 shows the inhibition observed at different 
percentages of DMSO. It could be clearly seen that the amount of inhibition increased 
as DMSO percentage increased. However, the data obtained was not substantial to 
draw a conclusive deduction if thaspine acted by crossing the plasma membrane and 
sequentially causing loss of calcium response.  
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 Figure 3.44 Effects of thaspine in different percentages of DMSO on ATP-
evoked concentration-response. 
The figure shows the effects of preincubation of 10 µM thaspine for 10 minutes on 
ATP-evoked response when thaspine was dissolved in different concentrations of 
DMSO prior to its treatment on cells. The amount of inhibition proportionally 
increased with DMSO percentage increment. The responses were normalised to 
control response for each condition. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, 
*** = < 0.001. (n = 3) 
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3.4 Discussion 
3.4.1 Identification of thaspine as a P2X4 inhibitor by high throughput 
screening 
The process of identification of thaspine began with the establishment of the human 
P2X4 overexpressing cells using astrocytoma. After its characterisation, high 
throughput screening was carried out using the overexpressing cells and hit 
compounds were further explored to finally choose one final compound as a lead, i.e., 
thaspine. Thaspine was further investigated in several experiments to elaborate more 
on its properties.  
3.4.1.1 Transfection of human P2X4 
The human P2X4 DNA was initially engineered into vector pIRESpuro3 and 
transfected using Fugene HD transfecting agent into astrocytoma cells. The bicistronic 
vector was a good vector because it could express two genes simultaneously, i.e., P2X4 
and puromycin resistant genes. The latter gene was very useful since it could be used 
to select cells that highly expressed P2X4 using puromycin and maintain high 
expression of P2X4 receptors. However, the transfection technique failed to establish 
a stable overexpressing cell line. One successful transfection out of several trials 
suggested that the transfection technique was not efficient as puromycin treatment 
caused the death of transfected cells. 
 
However, the viral transfection technique employed later showed success using 
pLVX-IRES-mCherry vector. Instead of carrying antibiotic resistance gene, the vector 
co-expressed mCherry fluorescent protein which was used as a marker for selection 
using BD FACSAria III Sorter. Throughout this study, the cells were constantly 
monitored to avoid over-confluency because the cells tended to switch off the 
expression of P2X4 under stress, as evidenced by reduced magnitude of calcium 
response and mCherry fluorescence. In addition, only cells passaged up to five times 
were used in this study to maintain high expression. Overall, these overexpressing cells 
— containing P2X4 DNA engineered into pLVX-IRES-mCherry and virally 
transfected — were a good model for high throughput screening. The high response 
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elicited by the cells (maximal response about 1.0 – 1.3 F ratio) made it more conducive 
for high throughput screening because the inhibition could easily be seen.  
3.4.1.2 Identification of thaspine through high throughput screening 
High throughput screening performed in this study has successfully narrowed 1,710 
compounds from NCI down to thaspine, which was found to be a potent inhibitor of 
P2X4 receptor. The method of screening by measuring calcium influx into the cells 
based on fluorescence was a good method for high throughput screening to discover 
P2X4 modulators. A handful of studies used the cytosolic calcium measurement as an 
indicator of P2X4 activity (Ase et al., 2015; Balazs et al., 2013; Hernandez-Olmos et 
al., 2012; Matsumura et al., 2016). When P2X4 receptors were activated by ATP, 
calcium entered the cells which would then bind to Fura-2 that was subsequently 
excited and emitted light for detection. This directly gave a reading on the amount of 
cytosolic calcium, representing the activation of P2X4 receptors. Excitation of Fura-2 
at two wavelengths, i.e., 340 and 380 nm, was a great advantage of this dye because 
resulting ratiometric reading cancelled out confounding variables such as cell 
thickness, uneven dye loading, and photobleaching (Tsien & Poenie, 1986). Fura-2 
also accurately measured calcium in the cytosol and did not take into account calcium 
that resided in intracellular stores such as nucleus and endoplasmic reticulum 
(Williams et al., 1985). Thus, it was a robust dye to detect influx of calcium into the 
cytosol in response to activation of P2X4 receptor by ATP. It is also worth mentioning 
that, to date, this was the first study that involved high throughput screening of a library 
of natural compounds for P2X4 receptor modulators.  
 
In the high throughput screening, two filters were applied to exclude false positives. 
The criteria for the first filter was that the screened compounds must have potentiated 
at least 75 % response or inhibited at least 60 % of the vehicle control responses. The 
criteria for the second filter was that the compounds must not have modulated the 
baseline of F ratio reading by ±0.25 F ratio after compound addition. Based on the 
screening of 1,710 compounds, a total of 87 compounds were identified to modulate 
ATP-evoked responses after primary filter. Thirty-one of them potentiated and 56 
compounds inhibited the response. Referring to Figure 3.19, the response of most 
tested compounds was seen to fluctuate around control response (100 %). Seeing a 
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large portion of responses were confined to one region, i.e., between 80 and 150 % 
response, it was suggested that the modulation within that region was a result of 
variability, due to various reasons including inadequate technical repeat, solubility of 
compounds, pipetting error, and uneven cell density. Therefore, the exclusion 
boundaries were set outside of the region to identify potential potentiators and 
blockers. 
 
Next, the observation on the Flexstation 3 data revealed that the addition of some 
compounds into the buffer distorted the Fura-2 fluorescence baseline signal and 
loading value. There was a trend observed in which when a compound caused a peak 
on the baseline and uncommonly high value of Fura-2 loading after addition of a 
compound, it would appear to potentiate the subsequent ATP-evoked response. 
Similarly, when a compound caused a sharp decline on the baseline and unusually low 
value of Fura-2 loading, the ATP-evoked response afterwards would be reduced. For 
example, compound NSC193043 caused a large peak in the baseline signal (8.3 F ratio, 
n = 1) and it potentiated ATP-evoked response by 87 %.  
 
The potentiation observed might be a result of auto-fluorescence of the compound that 
gave rise to the response which was a common disadvantage in fluorescence-based 
assay, as reported by Pope et al. (1999). Another explanation is that, maybe the 
compounds caused the increased permeability of plasma membrane which allowed 
calcium influx. Another deduction was that such compounds might lyse the cells that 
in turn released Fura-2 into extracellular environment that was highly concentrated 
with calcium. Another reason was that the compounds might have activated other 
calcium transporting signalling which resulted in calcium influx. On the other hand, 
dips observed on the baseline after addition of some compounds might be a result of 
quenching the fluorescence of Fura-2 or could also be a result of auto-fluorescence 
that interfered with emission light by Fura-2. While these deductions were made to 
explain the situation, there might be many other reasons that could have caused this 
discrepancy. Therefore, a second inclusion criterion was applied to reduce the amount 
of false positive results, which resulted in the recognition of eight positive modulator 
and six inhibitor hits, and subsequently NSC17055 was chosen as the lead compound. 
 
  
178 
 
However, further investigation revealed that the NSC17055 was also a false positive. 
One obvious indication was that one of its analogues (STK331042) did not show any 
fluorescence reading in an inhibition screening experiment whereas this was not 
observed in other compounds. Upon studying the structure activity relationship 
between NSC17055 and its analogues towards the P2X4 activity, it was found that 
there was a structural similarity in all compounds. All the “inhibiting” analogues 
contained a coumarin backbone and a polar functional group at carbon number 7 (R 
group, refer to Figure 3.45). Based on the tested analogues, only compounds with 
either acetate (7-acetoxy) or hydroxyl (7-hydroxyl) at R position were found to 
“inhibit” P2X4 activity. Substituting R group with methoxy (  ̶ CH3) or hydrogen 
completely eradicated the “inhibitory” characteristic. Findings by Sherman and Robins 
(1968) stated that the backbone of the compound, 7-hydroxycoumarin was a 
fluorescent molecule. Mostovnikov et al. (1977) also described the auto-fluorescence 
property of coumarin and its derivatives, particularly 7-hydroxycoumarin and 7-
acetoxycoumarin, which confirmed the findings in the present study. Their further 
investigation revealed that the excitation wavelength of the studied compounds 
overlapped with the excitation wavelength of Fura-2 but their emission wavelengths 
were different. Thus, it was postulated that NSC17055 and its analogues absorbed the 
excitation light and therefore reduced the excitation and emission of Fura-2. 
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Figure 3.45 Chemical structure of coumarin 
The chemical structure above is the backbone of NSC17055 and its analogues. The 
numbering was based on IUPAC numbering. The differences were some compounds 
had an additional functional group at carbon number 3 which did not affect the auto-
fluorescence characteristic. The vital functional group that affected auto-fluorescence 
was at carbon number 7, labelled as R. Polar functional group such as acetoxy and 
hydroxyl displayed auto-fluorescence characteristic while non-polar like methoxy did 
not. Carbonyl group at carbon number 2 was also crucial as when one compound that 
had carbonyl group at carbon number 4 instead at number 2, lost the auto-fluorescence 
property. 
 
  
  
180 
 
3.4.1.3 Verification of high throughput screening results 
To further discount false positives, an experiment using ionomycin and carbachol was 
employed. Ionomycin was reported as an ionophore that mobilises calcium through 
different pathways. It was suggested to translocate calcium across the plasma 
membrane (Liu & Hermann, 1978; Pressman & Fahim, 1982), to activate the native 
calcium channels that allow calcium influx, and to cause calcium release from 
intracellular store via phospholipase (Dedkova et al., 2000; Morgan & Jacob, 1994). 
Meanwhile, carbachol was reported to activate muscarinic acetylcholine receptors that 
mediate extracellular calcium influx through voltage-dependent calcium channels and 
also calcium release from intracellular stores (Blackwood & Bolton, 1993). Together, 
both ionomycin and carbachol action are deductively independent of P2X4 activation 
and therefore, it can be inferred that any compounds that cause modulation on 
ionomycin- or carbachol-evoked responses might do so via different pathways and not 
by directly inactivating P2X4.  
 
The outcomes of the experiment suggested that five of the six potential inhibitor hits 
significantly decreased both ionomycin- and carbachol-evoked responses including 
NSC17055. The magnitude of inhibition was also similar between ionomycin- and 
carbachol-evoked responses of each compound. Those compounds either acted on 
different pathways that affected calcium regulation intracellularly or interfered with 
Fura-2 fluorescence. For example, the backbone structure of NSC50688 was 2-naphtol 
which was reported to have an auto-fluorescence characteristic (Boyer et al., 1985; Wu 
& Hurtubise, 1993). This has left one compound that did not have a significant effect 
on the ionomycin- and carbachol-evoked responses, which was thaspine. 
 
Since the screening was performed once in triplicate, it was anticipated that the 
variabilities present in data would create false positives. Apart from that, it was also 
acknowledged that another caveat of this fluorescence-based screening method was 
that there would also be false negative results of which the exclusion criteria might 
have excluded the true potential modulators. Thus, fluorescence-based assay could be 
a good tool for high throughput screening if combined with additional tests to control 
the experiment, such as increasing technical repeats, applying strict cut off points, 
measuring baseline alteration after compound addition, observing Fura-2 loading 
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values after compound addition, and ionomycin and carbachol tests. It is also worth 
noting that the use of astrocytoma cells in this screening had advantage because the 
data obtained indicated astrocytoma cells had no endogenous ATP response up to 600 
µM, which was in parallel with Ballini et al. (2011). Therefore, the measured calcium 
response following ATP application on the human P2X4 overexpressing cells was 
exclusively due to the activation of P2X4 receptor alone.  
3.4.1.4 Thaspine characterisation 
The screening has successfully identified thaspine as an inhibitor of human P2X4 
receptor. Thaspine is an alkaloid extracted from the South American tree, Croton 
lechleri. It was reported to have anticancer activity by causing apoptosis on human 
colon carcinoma cell line. At a molecular level, it inhibited topoisomerase which are 
involved in cleavage and resealing of DNA strands during replication process and that 
results in apoptosis of cancerous cells (Castelli et al., 2013; Fayad et al., 2009). Apart 
from that, it was also shown to have an anti-inflammatory activity (Perdue et al., 1979). 
To date, it has not been reported in literatures other than cancer- and inflammation-
related studies. Following the identification, several characterisation experiments were 
carried out to understand its potency, mode of its inhibition, selectivity, reversibility, 
and mechanism of action. 
3.4.1.4.1 Thaspine inhibition concentration-response 
From the obtained data and analysis, it was shown that thaspine had an IC50 value of 
3.81 ± 0.2 µM at human P2X4 and 3.53 ± 0.26 µM at mouse P2X4. The shape of curves 
was also the same, suggesting that they had the same threshold concentration for 
thaspine to start taking effect. At 30 µM of thaspine concentration, the responses were 
completely abolished. Since human and mouse P2X4 share 87 % similarity in their 
amino acid sequence, it was predicted that thaspine would have similar potency at 
these two receptors. Tian et al. (2014) and Hernandez-Olmos et al. (2012) also 
observed the same pattern when their novel compounds acted on both human and 
mouse P2X4.  
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To exclude the possibility of thaspine action was cell-dependent, thaspine was then 
tested on human P2X4 which was overexpressed in different cell type, HEK293F. 
Since HEK293F also carries the endogenous P2Y receptors (Gerevich et al., 2007; 
Schachter et al., 1997), CTP — which does not activate P2Y — was used as the 
agonist. Thaspine’s potency at human P2X4 receptor in this cell line was comparable 
to astrocytoma cells, with an IC50 value of 3.99 ± 1.0 µM, suggesting that thaspine was 
active at inhibiting human P2X4 regardless of the cell system used. The use of CTP 
instead of ATP on this cell system also indicated that the effects of thaspine were 
independent of agonist. Further comparison analysis of representative traces of ATP-
evoked response with and without thaspine (Figure 3.27) revealed that thaspine only 
affected magnitude of peak response, but not decay kinetics. 
3.4.1.4.2 Mode of inhibition 
In an experiment to determine thaspine mode of inhibition, the highest concentration 
of ATP used (100 µM) failed to overcome thaspine inhibition and produce calcium 
response as high as the vehicle control, in addition to unaltered values of EC50 (0.44 ± 
0.1 µM and 0.48 ± 0.2 µM for vehicle control and thaspine-treated cells, respectively). 
Together, these evidences were in line with common characteristics of a 
noncompetitive antagonism, as explained by Hollinger (2007), who stated that such 
noncompetitive antagonism can be a result of either two occurrences: 1) compound 
binding to orthosteric site irreversibly or pseudo irreversibly (a very small dissociation 
constant) which disallows the binding of agonists; or 2) compound binding to allosteric 
site which then may alter the binding motif of orthosteric site for agonists. But the 
latter mode can be excluded by the fact that allosteric noncompetitive inhibitor could 
totally diminish the agonist response. And this was the case based on the 
concentration-response curve, where thaspine totally abolished the ATP-evoked 
response, indicating that it was an allosteric inhibitor. 
3.4.1.4.3 Reversibility of thaspine 
Thaspine was found to be a noncompetitive inhibitor since the increasing amount of 
agonist could not surmount thaspine inhibition. Noncompetitive inhibitors are mostly 
irreversible due to their covalent binding with receptors (Foreman & Johansen, 2003; 
  
183 
 
Katzung et al., 2012). Washing the cells with thaspine-free buffer was expected 
displace thaspine from its binding, and the change in response to the agonist 
application could have been observed. However, the data from reversibility 
experiment showed that the second stimulation by ATP could not restore the response 
as high as the vehicle control. The results suggested that thaspine was not displaced by 
washing and thus, remained the binding and inhibited the receptors. 
3.4.1.4.4 Thaspine inhibition was slow-acting 
Next, experimental data demonstrated that the action of thaspine was slow-acting. The 
data showed that pre-incubation of thaspine prior to ATP stimulation for 5 minutes did 
not cause a significant reduction in ATP-evoked response. Longer pre-incubation 
period progressively and significantly decreased the response. The first significant 
inhibition was observed after thaspine pre-incubation for 10 minutes, relative to the 
vehicle control. As the pre-incubation period increased, the inhibition became stronger 
with 40 minutes pre-incubation being the most optimum period for maximum 
inhibition. Its slow-acting effect might suggest two hypotheses pertaining to its 
mechanism of action: 1) thaspine did not directly affect P2X4, but rather caused the 
internalisation of P2X4 receptors. As previously described, P2X4 receptors are 
continuously cycled in and out between the plasma membrane and lysosomes and late 
endosomes (Bobanovic et al. 2002), so it could be that thaspine inhibited the 
reinsertion of P2X4 into the plasma membrane or promoted the internalisation of P2X4, 
or both, and consequently reduced the number of activated P2X4 receptor, calcium 
influx, and eventually fluorescence reading; or 2) thaspine diffused through the plasma 
membrane. Having an XLogP3 value of 2.8 (PubChem database), thaspine is relatively 
hydrophobic and that might help it diffuse through hydrophobic tail of the 
phospholipid bilayer. Once inside the cells, it might act on P2X4 intracellular epitope 
or interfere with other calcium intracellular signalling pathways. 
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3.4.1.4.5 Mechanism of action 
To determine its mechanism of action, the two hypotheses were tested. The first 
hypothesis was tested by quantitating the number of P2X4 receptors present on the 
plasma membrane in response to treatment of thaspine or vehicle control for 30 
minutes. This was achieved by labelling the extracellular epitope of P2X4 receptor with 
P2X4 antibody which was then labelled with AF488-conjugated secondary antibody. 
The fluorescence of AF488 was subsequently detected using flow cytometry 
technique. The results suggested that pre-incubation of thaspine did not markedly 
reduce the cell surface expression of P2X4 receptors compared to the vehicle control. 
Nevertheless, it was argued that the result might be partly due to the lengthy procedure 
of antibody labelling which might cause the re-emergence of P2X4 receptors on the 
plasma membrane. The data from Figure 3.32 and Figure 3.43, however, suggested 
that thaspine inhibition was irreversible. Therefore, the data together suggested that 
thaspine might not cause the internalisation of P2X4 receptors though more 
experiments are required to come to a solid conclusion. 
 
In regards to the second hypothesis, Williams and Barry (2012) mentioned that DMSO 
could enhance the drug penetration through the plasma membrane by decreasing the 
barrier resistance. Therefore, to test the second hypothesis, different percentages of 
DMSO was used to dissolve thaspine to reflect thaspine penetration level and thaspine 
was pre-incubated for only 10 minutes. Theoretically, a higher DMSO percentage 
would increase magnitude of inhibition since more thaspine could penetrate the plasma 
membrane in a limited time. Based on analysis, it showed that it was the case. The 
inhibition with 0.5 and 1 % DMSO was significantly higher than 0.1 % which was the 
amount of DMSO used in any thaspine experiment in this study. However, it could 
also be argued that the increase in inhibition along with the increase in DMSO 
percentage might be due to thaspine being more soluble in higher DMSO percentage 
and thus, the compound delivery to receptors was more efficient. Therefore, more 
experiments should be employed to reach a conclusive remark. In short, the results 
obtained were incomplete to explain the mechanism of action for thaspine. 
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3.4.1.4.6 Selectivity study 
Meanwhile, the selectivity study revealed that 10 µM of thaspine was P2X4-selective 
versus P2X2, P2X7, and heteromer P2X2/3. Meanwhile, at P2Y2 and P2Y6, thaspine 
was inactive at concentrations of 10 µM and 30 µM, respectively but it abolished the 
response at concentrations above those. The concentration-independent inhibition of 
thaspine at the P2Y receptors might be due to thaspine interfere with later stages of 
P2Y signalling pathways. 
3.4.1.4.7 Effect of thaspine on BV2 cells 
Thaspine was also tested on primary cell model, BV2 cell (murine microglial cell line) 
which are known to express metabotropic P2Y and ionotropic P2X receptors (Ferrari 
et al., 1996; Haas et al., 1996; Walz et al., 1993). The response elicited by ATP 
stimulation in this experiment was a collective contribution of those receptors. By 
comparing the representative traces of quiescent and LPS-activated cells (Figure 3.40 
and 3.41), it could clearly be seen that the magnitudes of potentiation by IVM between 
the two cell states were significantly different (p < 0.05, n = 6). This was because LPS 
induced inflammatory response and in LPS-activated cells, the expression of P2X4 
receptor was upregulated (Raouf et al., 2007). This in turn caused more P2X4 receptors 
available on cell surface that could be activated by ATP. Being a selective P2X4 
positive allosteric modulator, IVM therefore could potentiate more P2X4 receptors that 
in turn gave higher rise in the potentiation in the LPS-activated cells. 
 
In terms of inhibition, PSB12062 (a known P2X4 inhibitor) did not affect the ATP-
evoked response in both quiescent and LPS-activated cells. This could be that the 
response recorded was largely due to purinergic receptors other than P2X4 receptor. 
But when PSB12062 was co-treated with IVM, the inhibitor significantly suppressed 
the ATP-evoked response which suggested that IVM potentiated P2X4 receptors that 
were subsequently inhibited by PSB12062. Meanwhile, thaspine did not affect the 
ATP- response of LPS-activated cells but interestingly potentiated the response of 
quiescent cells. It was likely that thaspine potentiated other purinergic receptors in the 
quiescent cells. On the other hand, when thaspine was co-treated with IVM, the 
inhibition in activated cells was larger than quiescent cells. This could be explained by 
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the fact that there were more P2X4 receptors in the activated cells than quiescent cells, 
hence the inhibition became larger. 
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CHAPTER 4  
STRUCTURE ACTIVITY RELATIONSHIP STUDY OF 
5-BDBD AND P2X4 RECEPTOR 
4.1 Introduction 
In 2004, Fischer et al. discovered a novel compound, known as 5-BDBD, that potently 
inhibited P2X4 receptor heterologously expressed in Chinese hamster ovary cells. The 
group claimed that 5-BDBD has the potential to treat arteriosclerosis and restenosis in 
human and animals via the blockade of P2X4 receptor. However, the reports were in 
the form of a commercial patent and there were no other elaborative reports on the 
characterisation of the compound. A decade later, Balazs and co-researchers (2013) 
made an extensive study on the compound as well as a known P2X inhibitor, TNP-
ATP, which is less sensitive at P2X4 receptor than P2X1 and P2X3 (Jarvis & Khakh, 
2009). They studied the inhibitory effects of both antagonists in two ways, i.e., by 
measuring intracellular Ca2+ signals and whole cell ion currents in P2X4 
overexpressing HEK293 cells. They found that 5-BDBD and TNP-ATP inhibited the 
P2X4-mediated Ca
2+ influx in a concentration-dependent manner in both methods and 
their IC50 values were 1.2 µM and 1.5 µM, respectively. In addition, their data showed 
that 5-BDBD blocked P2X4 competitively based on the increased ATP EC50 values 
when the cells were treated with 2 µM and 20 µM of 5-BDBD. On the other hand, in 
a more recent study, Abdelrahman et al. (2017) reported that the inhibition was 
noncompetitive which indicated that 5-BDBD bound to an allosteric site on the 
receptor. The proposed mode of action was determined using a radiolabelled ATP 
analogue, which was not being displaced by the increasing concentration of 5-BDBD. 
 
The lack of information and discrepancy about 5-BDBD mode of inhibition 
highlighted a gap that needed to be filled. Ten compounds were synthesised in 
laboratory and eight compounds were purchased commercially. The list of compounds 
used in this study is tabulated in Table 2.5 and 2.6. The analogues manipulated three 
substitution sites, numbered from 1 to 3 to assist explanation (as shown in Figure 4.1). 
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The basis on the selection of substitution sites were according to the original patent by 
Fischer et al. (2004) who described that substitutions at either site 1 and 3 produced 
similar magnitude of inhibition for P2X4 receptor. Firstly, the sites were substituted 
with halogens other than bromine to see if the size of halogen plays any role in the 
inhibition potency. Secondly, it has been widely reported that trifluoromethyl can 
enhance the activity of a molecule. The history of the advantages of fluorine-
containing compounds was first reported by Lehmann (1928) (as reviewed by Yale 
(1959)) who found that benzotrifluoride positively affected the central nervous system 
of frogs. Later, the success of molecules containing trifluoromethyl group was reported 
in numerous articles which were reviewed by Yale (1959). Thus, it was decided to 
substitute site 1 and 3 with trifluoromethyl group to see if the substitutions can also 
enhance the inhibition. Thirdly, it was also interesting to see if a simultaneous halogen 
substitution at site 1 and 3 will affect the inhibition potency. Lastly, apart from the 
synthesis of modified compounds, it was also decided to look at the readily available 
analogues of 5-BDBD. The search for the analogues were done via MolPort web-based 
server, which was set up to show similar compounds with 5-BDBD by 0.8 similarity 
based on the Tanimoto index. 
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Figure 4.1 Sites of chemical modification of 5-BDBD backbone 
The chemical structure in the figure shows the backbone structure of 5-BDBD. Three 
sites were manipulated to study the relationship between P2X4 receptor and 5-BDBD. 
Substitution site 1 is meta-positioned at phenyl, substitution site 2 is para-positioned 
at phenyl and substitution 3 is at carbon number 9 of benzofurodiazepinone. If there is 
no substitution, it means that the substitution sites are filled with hydrogens. The red 
box indicates the diazepinone, a seven-membered heterocyclic compound with two 
nitrogen atoms and a ketone functional group (R – O – R) attached to the ring, which 
was absent in one of the purchased analogues (STK021512). 
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To investigate the structure–activity relationship between 5-BDBD and P2X4 receptor, 
pharmacological and in silico investigations were employed. In terms of 
pharmacological investigation, the potency and mode of action of compounds were 
determined to see if structural variation caused the significant effect on their potency 
and mode of action, relative to 5-BDBD. These experiments were performed using the 
same protocol as in the previous chapter. To study the binding at structural level, 5-
BDBD and its analogues were docked virtually (experiment performed by Dr Marco 
Cominetti). This technique has become feasible with the findings of Hattori and 
Gouaux (2012), where crystal structures of zfP2X4 in closed (PDB ID: 4DW0) and 
open state ATP-bound (PDB ID: 4DW1) state were solved. The protein sequence 
similarity between human and zebrafish is 67 %, based on the comparison between 
accession number AAF06661.1 (human, from NCBI database) and 4DW0_A 
(zebrafish, from PDB). 
 
The crystal structure of the closed, resting state P2X4 (4DW0) was used as a template 
to simulate the binding of 5-BDBD into its binding pocket (homology modelling to 
build human P2X4 was done by Associate Professor Dr Ralf Schmid). This was based 
on pharmacological protocol conducted in this study where 5-BDBD was pre-
incubated for 30 minutes prior to ATP stimulation, which suggested 5-BDBD could 
bind to the closed state P2X4 and block the stimulation by ATP. Although there were 
concerns regarding the crystal structure because of truncation of both termini, it was 
shown that it only affected the gating mechanism and pore opening but not the binding 
itself (Habermacher et al., 2015; Mansoor et al., 2016). Since this simulation only 
involved the docking between the compounds at orthosteric site, so the closed, resting 
state crystal structure was used. The experiment was carried out to study the possible 
docking poses that can explain the position of 5-BDBD in the pocket, and recognise 
important amino acids on P2X4 receptor and functional groups on 5-BDBD that play 
a role in binding. 
4.2 Aims 
The aim of this study was to pharmacologically investigate the structure activity 
relationship between human P2X4 and 5-BDBD and its analogues, identify important 
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functional groups for antagonistic action, and predict the binding modalities using 
molecular modelling.  
4.3 Results 
4.3.1 Pharmacological characterisation of 5-BDBD 
Before investigating the effects of altering 5-BDBD structure, 5-BDBD was first 
investigated to compare its characteristics with the altered compounds. The potency 
and mode of inhibition of 5-BDBD were first determined. Figure 4.2 displays the 
inhibition concentration-response curve for 5-BDBD. Based on three experiment 
repeats on the human P2X4 overexpressing cells, the calculated IC50 value was 1.6 ± 
0.63 µM (n = 3) which was close to the reported value of 1.2 µM (Balazs et al., 2013). 
The peak response started to decrease when 0.3 µM of 5-BDBD was applied and 
reached a plateau at 10 µM. The strongest inhibition was observed at 10 µM, which 
was 54.6 ± 10.8 % relative to the peak response of control.  
 
Figure 4.3 shows the ATP concentration-response with and without 5-BDBD. In the 
presence of 5-BDBD, the calcium response reached the same maximal magnitude as 
without 5-BDBD, but at a slower rate, which shifted the calcium response curve to the 
right. This also made the EC50 value of ATP for the treated cells significantly higher 
than the untreated (1.9 ± 0.10 µM versus 0.6 ± 0.08 µM, respectively (p < 0.05, n = 4). 
Taken together, these suggested that the mode of inhibition of 5-BDBD was 
competitive, which was in agreement with Balazs et al. (2013). 
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Figure 4.2 Inhibition concentration-response for 5-BDBD at human P2X4 
receptor. 
Panel A shows the inhibition concentration-response curve for 5-BDBD (0.03 – 30 
µM) when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows the representative traces in the absence and presence of 30 µM of 5-
BDBD dissolved in 1 % DMSO. All responses were normalised to mean peak response 
of vehicle response. The inset shows the chemical structure of 5-BDBD. (n = 3)  
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Figure 4.3 ATP concentration-response in the absence and presence of 5-BDBD. 
The plots show the ATP concentration-response curves of untreated (close square) and 
5-BDBD-treated (open square) human P2X4 overexpressing cells. The concentrations 
used were 0.03 to 100 µM for ATP and 1.6 µM for 5-BDBD. The difference between 
each data point was statistically calculated. The responses from both cell conditions 
were significantly different at 0.3, 1, and 3 µM of ATP before both equalled at 10 µM 
of ATP. The difference between both EC50 values was also significant (p < 0.05). The 
right shift of ATP concentration-response curve and significant increase in EC50 of 
ATP for treated cells compared to the vehicle control indicated a competitive mode of 
antagonism. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 4) 
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4.3.2 Potency determination of 5-BDBD analogues 
To further investigate the effects of manipulating substitution sites on the potency of 
5-BDBD analogues, their IC50 values were determined by establishing the inhibition 
concentration-response curves. Varying concentrations of compound were used: 0.03, 
0.1, 0.3, 1, 3, 10, and 30 µM, to plot the inhibition concentration-response curves while 
ATP concentration used was 0.6 µM, corresponded to ATP EC50 value. The curves 
were plotted using the values of mean peak response of each compound concentration, 
which were normalised to mean peak response of vehicle control. 
4.3.2.1 Halogen substitution at site 1 or 3 
To investigate the effect of substituting site 1 or 3 with other halogens (5-BDBD has 
bromine at site 1), chlorine and fluorine were chosen. Figure 4.4 presents the inhibition 
concentration-response curve for STK731427 and its representative traces of 
responses. In terms of chemical structure, this compound had its substitution site 3 
replaced with bromine. Calculated IC50 value was 1.0 ± 0.43 µM, not significantly 
different (p > 0.05, n = 3) compared to 5-BDBD. However, the maximum inhibition 
recorded at 30 µM was 47.1 ± 14.4 % which was significantly lower than 5-BDBD by 
8.9 % (p < 0.05, n = 3). The first inhibition in peak response was noted when the cells 
were treated with 0.3 µM compound and the inhibition plateaued at 10 µM of 
STK731427. 
 
Figure 4.5 shows the inhibition concentration-response curve for IA1 and its 
representative trace of response in the absence and presence of 30 µM of IA1. This 
compound had its substitution site 1 substituted with chlorine. The inhibition was first 
recorded at 0.1 µM compound, exponentially increased at higher concentrations, and 
plateaued at 10 µM. From the curve, the calculated IC50 value was 2.3 ± 0.28 µM, not 
significantly different (p > 0.05, n = 3) from 5-BDBD. The maximum inhibition 
measured was 55.3 ± 3.8 % when 30 µM of compound was applied, which was similar 
to 5-BDBD maximum inhibition (p > 0.05, n = 3).  
 
  
195 
 
Next, Figure 4.6 shows the inhibition concentration-response curve for IA9 and its 
representative trace of response. IA9 had a chlorine substitution at position 3. The IC50 
value obtained from the curve was 1.1 ± 0.65 µM, not significantly different (p > 0.05, 
n = 3) from that of 5-BDBD. The strongest inhibition observed at the highest 
concentration of IA9 (30 µM) which was not significantly different from 5-BDBD 
(72.9 ± 6.2 %, p > 0.05, n = 3). 
 
Meanwhile, Figure 4.7 shows the inhibition concentration-response curve for IA6 and 
its representative trace when 30 µM of IA6 was added. Structurally, site 3 of this 
compound was substituted with fluorine. The compound started to inhibit at 0.1 µM 
and it progressively reduced the response until it reached its maximum inhibition at 3 
µM. The calculated IC50 value was 1.2 ± 0.18 µM and the maximal inhibition recorded 
was 55.0 ± 2.9 % when the cells were treated with 30 µM of IA6, which were both not 
significantly different (p > 0.05, n = 4) from that of 5-BDBD.  
 
Lastly, Figure 4.8 shows the inhibition concentration-response curve for IA11 and its 
representative trace of response from treated and untreated cells. Structurally, IA11 
had its position 1 substituted with fluorine. From the curve, the inhibition was only 
observed when the cells were treated with 3 µM and it plateaued at 10 µM. The 
maximum inhibition was recorded at 30 µM which was 51.9 ± 2.6 %, not significantly 
different (p > 0.05, n = 3) from 5-BDBD. On the other hand, the IC50 value was 
significantly increased compared to 5-BDBD, 4.5 ± 0.63 µM (p < 0.05, n = 3). 
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Figure 4.4 Inhibition concentration-response for STK731427 at human P2X4 
receptor. 
Panel A shows the inhibition concentration-response curve for STK731427 (0.03 – 30 
µM) when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of STK731427. (n = 3) 
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Figure 4.5 Inhibition concentration-response for IA1 at human P2X4 receptor. 
Panel A shows the inhibition concentration-response curve for IA1 (0.03 – 30 µM) 
when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of IA1. (n = 3) 
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Figure 4.6 Inhibition concentration-response for IA9 at human P2X4 receptor. 
Panel A shows the inhibition concentration-response curve for IA9 (0.03 – 30 µM) 
when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of IA9. (n = 3) 
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Figure 4.7 Inhibition concentration-response for IA6 at human P2X4 receptor. 
Panel A shows the inhibition concentration-response curve for IA6 (0.03 – 30 µM) 
when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of IA6. (n = 4) 
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Figure 4.8 Inhibition concentration-response for IA11 at human P2X4 receptor. 
Panel A shows the inhibition concentration-response curve for IA11 (0.03 – 30 µM) 
when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of IA11. (n = 3) 
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4.3.2.2 Substitution with trifluoromethyl at site 1 or 3 
Figure 4.9 illustrates the activity of IA3. In terms of chemical structure, its substitution 
site 1 was replaced with trifluoromethyl. This compound was significantly less potent 
than 5-BDBD as the inhibition concentration-response curve showed that its IC50 value 
was significantly higher than 5-BDBD, 9.6 ± 1.55 µM (p < 0.05, n = 3). The first 
significant inhibition (p < 0.01, n = 3) was observed when 10 µM of IA3 was applied 
and 30 µM of IA3 only inhibited to 38.0 ± 2.2 % of control, significantly lower than 
5-BDBD (p < 0.01, n = 3).  
 
Next, the inhibition concentration-response of IA7 is shown in Figure 4.10 together 
with its representative traces in the absence and presence of 30 µM of IA7. 
Structurally, IA7 was similar with IA3 in terms of substituent but IA7 had its position 
3 substituted with trifluoromethyl. Similar to IA3, the first significant inhibition was 
observed when the cells were treated with 10 µM of IA7 and at 30 µM, IA7 produced 
similar magnitude of inhibition (37.6 ± 3.5 %) which was significantly lower (p < 0.05, 
n = 3) than 5-BDBD. The calculated IC50 value was 2.7 ± 0.96 µM, not significantly 
different (p > 0.05, n = 3) than that of 5-BDBD. 
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Figure 4.9 Inhibition concentration-response for IA3 at human P2X4 receptor. 
Panel A shows the inhibition concentration-response curve for IA3 (0.03 – 30 µM) 
when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of IA3. (n = 3) 
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Figure 4.10 Inhibition concentration-response for IA7 at human P2X4 receptor. 
Panel A shows the inhibition concentration-response curve for IA7 (0.03 – 30 µM) 
when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of IA7. (n = 3)  
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4.3.2.3 Multiple substitutions at site 1 and 3 
Since Fischer et al. (2004) suggested that substitution at either site 1 or 3 could inhibit 
the activity of P2X4 receptors, it was interesting to see if substitutions at both positions 
would affect the inhibitory action. Each analogue had the same constituent at both 
sites, either fluorine, chlorine, bromine, or trifluoromethyl. 
 
In terms of chemical structure, IA8 had site 1 and 3 substituted with chlorine. Its 
inhibition concentration-response curve and representative trace of responses at 30 µM 
are shown in Figure 4.11. Based on the inhibition concentration-response curve, the 
calculated IC50 value was 1.1 µM ± 0.28 µM, not significantly different (p > 0.05, n = 
3) from that of 5-BDBD. The maximum peak inhibition response was 73.9 ± 3.9 %, 
significantly higher (p < 0.05, n = 3) than 5-BDBD.  
  
However, for compound IA2, IA4, and IA10 which had bromine, trifluoromethyl, and 
fluorine substitution respectively; the modification of these analogues greatly reduced 
the potency compared to 5-BDBD. For IA2, the first significant inhibition was 
observed after 0.3 µM of IA2 treatment (10.6 ± 3.3 % inhibition, p < 0.01, n = 3) and 
the inhibition magnitude remained unchanged at higher concentrations of IA2 (Figure 
4.12). The strongest inhibition was also significantly lower than 5-BDBD (p < 0.01, n 
= 3). While for IA4 (Figure 4.13) and IA10 (Figure 4.14), no inhibition was observed 
except at 30 µM of compound treatment, which resulted in 13.8 ± 4.8 % and 29.5 ± 
4.5 % inhibition, respectively. Both were significantly lower than 5-BDBD (p < 0.001, 
n = 3 and p < 0.01, n = 3, respectively).  
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Figure 4.11 Inhibition concentration-response for IA8 at human P2X4 receptor. 
Panel A shows the inhibition concentration-response curve for IA8 (0.03 – 30 µM) 
when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of IA8. (n = 3)  
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Figure 4.12 Effect of IA2 treatment on ATP-evoked response of the human P2X4 
overexpressing cells 
The bar chart illustrates the effects of different concentrations of IA2 (0.3 – 30 µM) 
treatment on ATP-evoked response of the human P2X4 overexpressing cells. The 
concentration of ATP used was 0.6 µM. All responses were normalised to mean peak 
response of vehicle control. The top panel shows the chemical structure of IA2. 
Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
  
  
207 
 
 
 
 
 
 
 
 
Figure 4.13 Effect of IA4 treatment on ATP-evoked response of the human P2X4 
overexpressing cells 
The bar chart illustrates the effects of different concentrations of IA4 (0.3 – 30 µM) 
treatment on ATP-evoked response of the human P2X4 overexpressing cells. The 
concentration of ATP used was 0.6 µM. All responses were normalised to mean peak 
response of vehicle control. The top panel shows the chemical structure of IA4. 
Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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Figure 4.14 Effect of IA10 treatment on ATP-evoked response of the human 
P2X4 overexpressing cells. 
The bar chart illustrates the effects of different concentrations of IA10 (0.3 – 30 µM) 
treatment on ATP-evoked response of the human P2X4 overexpressing cells. The 
concentration of ATP used was 0.6 µM. All responses were normalised to mean peak 
response of vehicle control. The top panel shows the chemical structure of IA10. 
Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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4.3.2.4 Commercially available analogues 
Apart from that, the commercially available analogues were also investigated. Some 
of the purchased compounds allowed the investigation on the effect of site 2 
substitution. First, Figure 4.15 shows the inhibition concentration-response of 
STK045532 and its representative traces of response with and without 30 µM of 
compound. Structurally, this compound did not have any substitutions at all sites. A 
significant inhibition was first observed with 0.3 µM of STK045532 treatment (13.5 ± 
3.3 % inhibition, p < 0.05, n = 3) and it exponentially amplified at higher 
concentrations before reaching a plateau at 10 µM. The calculated IC50 value was 1.9 
± 0.31 µM, insignificantly different to 5-BDBD IC50 value (p > 0.05, n = 3). The 
highest blockade of 74.5 ± 7.7 % was recorded when 30 µM compound was applied, 
which was significantly higher compared to 5-BDBD (p < 0.05, n = 3).  
 
Figure 4.16 shows the inhibition concentration-response curve for STK864662 with 
its representative traces of responses on the lower panel. Structurally, STK864662 had 
its site 3 substituted with methoxy group. The first significant inhibition was observed 
from 3 µM of compound treatment (p < 0.05, n = 3). Based on the curve, the calculated 
IC50 value was 4.8 ± 0.82 µM which was significantly higher (p < 0.05, n = 3) than 5-
BDBD, indicating that chemical variation on this compound reduced its potency for 
inhibiting P2X4. The maximum inhibition observed was 53.8 ± 11.5 %, which was not 
significantly different (p > 0.05, n = 3) compared to 5-BDBD.  
 
Meanwhile, five of the tested compounds were found to cause no or minimal inhibition 
of calcium response. STK021512 and STK775918 did not significantly (both p > 0.05, 
n = 3) alter the peak calcium response regardless of the concentrations used (Figure 
4.17 and 4.18, respectively). Structurally, STK021512 had a major difference 
compared to other analogues tested in this study where it lacked the benzodiazepinone 
while STK775918 had its site 2 substituted with bromine. 
 
STK027946 only caused the significant inhibition of calcium response when 10 µM 
(9.5 ± 2.5 % inhibition) and 30 µM (12.0 ± 3.6 % inhibition) of compound were applied 
(p < 0.01 and p < 0.05, respectively, n = 3). This compound had methyl group at its 
site 2 (Figure 4.19). Meanwhile, STK079751 (Figure 4.20) and STK747973 (Figure 
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4.21) only caused significant inhibition after treatment with 30 µM of compound (19.1 
± 4.0 % and 25.2 ± 5.6 % inhibition, respectively; both p < 0.01, n = 3). Both 
STK079751 and STK747973 had their site 2 substituted with chlorine and fluorine, 
respectively.  
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Figure 4.15 Inhibition concentration-response for STK045532 at human P2X4 
receptor. 
Panel A shows the inhibition concentration-response curve for STK045532 (0.3 – 30 
µM) when the human P2X4 overexpressing cells were stimulated with 0.6 µM of ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of STK045532. (n = 3)  
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Figure 4.16 Inhibition concentration-response for STK864662 at human P2X4 
receptor. 
Panel A shows the inhibition concentration-response curve for STK864662 (0.3 – 30 
µM) when the human P2X4 overexpressing cells were stimulated with 0.6 µM ATP. 
Panel B shows its representative traces in the absence and presence of 30 µM of IA1 
dissolved in 1 % DMSO. All responses were normalised to mean peak response of 
vehicle control. The inset shows the chemical structure of STK864662. (n = 3) 
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Figure 4.17 Effect of STK021512 treatment on ATP-evoked response of the 
human P2X4 overexpressing cells. 
The bar chart illustrates the effects of different concentrations of STK021512 (0.3 – 
30 µM) on ATP-evoked response of the human P2X4 overexpressing cells. The 
concentration of ATP used was 0.6 µM. All responses were normalised to mean peak 
response of vehicle control. The top panel shows the chemical structure of 
STK021512. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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Figure 4.18 Effect of STK775918 treatment on ATP-evoked response of the 
human P2X4 overexpressing cells. 
The bar chart illustrates the effects of different concentrations of STK775918 (0.3 – 
30 µM) treatment on ATP-evoked response of the human P2X4 overexpressing cells. 
The concentration of ATP used was 0.6 µM. All responses were normalised to mean 
peak response of vehicle control. The top panel shows the chemical structure of 
STK775918. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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Figure 4.19 Effect of STK027946 treatment on ATP-evoked response of the 
human P2X4 overexpressing cells. 
The bar chart illustrates the effects of different concentrations of STK027946 (0.3 – 
30 µM) treatment on ATP-evoked response of the human P2X4 overexpressing cells. 
The concentration of ATP used was 0.6 µM. All responses were normalised to mean 
peak response of vehicle control. The top panel shows the chemical structure of 
STK027946. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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Figure 4.20 Effect of STK079751 treatment on ATP-evoked response of the 
human P2X4 overexpressing cells. 
The bar chart illustrates the effects of different concentrations of STK079751 (0.3 – 
30 µM) treatment on ATP-evoked response of the human P2X4 overexpressing cells. 
The concentration of ATP used was 0.6 µM. All responses were normalised to mean 
peak response of vehicle control. The top panel shows the chemical structure of 
STK079751. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
 
 
 
 
 
 
  
217 
 
 
 
 
 
 
 
Figure 4.21 Effect of STK747973 treatment on ATP-evoked response of the 
human P2X4 overexpressing cells. 
The bar chart illustrates the effects of different concentrations of STK747973 (0.3 – 
30 µM) treatment on ATP-evoked response of the human P2X4 overexpressing cells. 
The concentration of ATP used was 0.6 µM. All responses were normalised to mean 
peak response of vehicle control. The top panel shows the chemical structure of 
STK747973. Asterisk denotes p-value: * = <0.05, ** = < 0.01, *** = < 0.001. (n = 3) 
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4.3.3 Determining the mode of inhibition of inhibiting compounds 
Next, to further study the relationship between 5-BDBD and P2X4 receptor, an 
experiment was designed to determine the mode of inhibition. The mode of inhibition 
was determined by looking at the ATP concentration-response curves in the absence 
and presence of IC50 concentrations of each compound. Generally, there are two 
indications to determine a competitive inhibition. Firstly, the response in the presence 
of compound should reach the same peak response as the vehicle control when the 
concentration of agonist is increased and secondly, the curve of response for treated 
cells should shift to the right of curve for untreated cells which results in higher EC50 
value for treated cells than untreated cells. If the curves fulfil those two requirements, 
it could be deduced that a compound is a competitive inhibitor (Balazs et al., 2013). 
Whereas, if a compound is not competitive, the maximum peak response of treated 
cells could not reach the same magnitude as the untreated cells, even though high 
concentration of agonist was used. 
 
Since the inhibiting analogues were not vastly different from 5-BDBD, i.e., only 
variations at site 1 and 3, it was hypothesised that they would show competitive 
inhibition like 5-BDBD and this was later confirmed with the experiments. The 
characteristics shown by STK045532, STK731427, STK864662, IA1, IA6, IA7, IA8, 
IA9, and IA11 indicated that they inhibited P2X4 receptor competitively. The response 
curves for all compounds shifted to the right that subsequently yielded higher values 
of ATP EC50 compared to the untreated cells. All compounds produced the same 
maximum magnitude of calcium response between treated and untreated cells. An 
example for the plots is shown in Figure 4.22 which represents STK045532 while the 
rests can be found in Appendix V – XII. The summary of all results for this chapter is 
shown in Table 4.1. 
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Figure 4.22 ATP concentration-response in the absence and presence of 
STK045532. 
The plots show the ATP concentration-response in the presence (open square) and 
absence (close square) of 1.9 µM of STK045532. The EC50 value in the presence of 
STK045532 was significantly higher than that with the compound (p < 0.001). The 
difference between each data point was statistically calculated and marked with 
asterisk to indicate the level of difference. The right shift of treated cells curve 
compared to the vehicle control together with significant increase in EC50 value 
indicated the competitive mode of antagonism. The top panel shows the chemical 
structure of STK045532. Asterisk denotes p-value: * = < 0.05, ** = < 0.01, *** = < 
0.001. (n = 3) 
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Table 4.1 Summary of active compounds. 
Compound Structure IC50 
(µM)/ 
(p value)* 
 
Average 
maximum 
inhibition 
(%)/ 
(p-value)* 
Type of 
inhibition 
(p-value)** 
5-BDBD 
 
1.6 ± 0.63 56.8 Competitive 
(p < 0.05) 
STK045532 
 
1.9 ± 0.31 
(n.s.) 
74.5 
(p < 0.05) 
Competitive
(p < 0.001) 
STK731427 
 
1.0 ± 0.43 
(n.s.) 
 
47.9 
(p < 0.05) 
Competitive
(p < 0.05) 
STK864662 
 
4.8 ± 0.82 
(p < 0.05) 
53.8 
(n.s.) 
Competitive 
(p < 0.05) 
IA1 
 
2.3 ± 0.28 
(n.s.) 
55.4 
(n.s.) 
Competitive 
(p < 0.01) 
IA3 
 
9.6 ± 1.55 
(p < 0.05) 
32.0 
(p < 0.01) 
n.d. 
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Table 4.1 cont.: Summary of active compounds. 
IA6 
 
1.2 ± 0.18 
(n.s.) 
58.6 
(n.s.) 
Competitive 
(p < 0.05) 
IA7 
 
2.7 ± 0.96 
(n.s.) 
37.6 
(p < 0.05) 
Competitive 
(p < 0.05) 
IA8 
 
1.1 ± 0.28 
(n.s.) 
73.9 
(p < 0.05) 
Competitive 
(p < 0.05) 
IA9 
 
1.1 ± 0.65 
(n.s.) 
72.9 
(n.s.) 
Competitive 
(p < 0.01) 
IA11 
 
4.5 ± 0.63 
(p < 0.05) 
51.9 
(n.s.) 
Competitive 
(p < 0.05) 
*p-value is the statistical comparison between respected compound and 5-BDBD. 
** Statistical difference between EC50 values from treated and untreated cells. 
n.s. = no significant difference 
n.d. = not determined 
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4.3.4 Generating a hypothesis of the human P2X4-5-BDBD binding site using 
molecular docking approaches 
Docking simulations between 5-BDBD and its analogues were employed to predict 
the binding pose and orientation for understanding the observed pharmacological 
results. Generally, docking can be performed in two ways, which are blind and targeted 
docking. Blind docking refers to a docking simulation that does not define a fixed 
binding site which is commonly practised to identify a possible binding site for small 
molecules. Targeted docking is a docking simulation that has a predefined binding site 
and this type of docking is usual in lead optimisation and hit identification through 
virtual screening (Ghersi & Sanchez, 2009). 
 
In this study, targeted docking was employed since the data showed that 5-BDBD and 
its analogues competitively inhibited P2X4 likely by binding to the ATP binding site 
which was already identified through zfP2X4 crystal structure (Hattori & Gouaux, 
2012). Based on the human P2X4 model generated, it was observed that the 
conformation of three ATP binding sites at P2X4 receptors were slightly different, 
therefore the compounds were docked at each site to increase the sampling. Based on 
the docking results, the inhibiting compounds (i.e., 5-BDBD, STK045532, 
STK747973, STK864662, IA1, IA3, IA6, IA7, IA8, IA9, and IA11) shared a 
preferential pose, repeated across each binding site. The compounds took advantage 
of a deeper hydrophobic region of the binding pocket to accomodate protruding phenyl 
or halo-phenyl moieties, while ATP bound at a more superficial region than 5-BDBD 
and its analogues (Figure 4.23). 
 
Detailed analysis of the docking pose (Figure 4.24) revealed that the hydrophobic part 
of the binding site was the main region involved in the binding with 5-BDBD (and its 
active analogues). The residues that encapsulated the binding site were Phe294 and 
Arg295 at one subunit as well as Thr66, Lys67, Val86, Val90, and Ala93 at the 
neighbouring subunit. Interestingly, 5-BDBD and ATP shared two residues for 
binding, Arg295 and Lys67 (Hattori & Gouaux, 2012). Possibly, the residue that 
played a major role in 5-BDBD (and inhibiting analogues) binding was Arg295. The 
residue was important in the binding because it could establish one or two hydrogen 
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bonds with the carbonyl group of diazepinone on 5-BDBD (number of hydrogen bonds 
varied with different conformations). 
 
In the absence of inhibitor, binding of ATP induced a conformational change, and the 
side chain of Lys67 covered the hydrophobic pocket, which made the binding site 
inaccessible for 5-BDBD. However, in the absence of ATP, the binding site was open 
and thus 5-BDBD could access the pocket for binding.  
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Figure 4.23 Docking poses of 5-BDBD and ATP in P2X4 binding site. 
The figure shows the binding of both 5-BDBD and ATP. The docking poses of 5-
BDBD and ATP in the P2X4 pocket are represented by grey stick and green/orange 
stick, respectively. As seen in the figure, 5-BDBD went deeper into the pocket relative 
to ATP. The deeper pocket was benefited by the protruding bromophenyl. The pink 
ribbon is P2X4 receptor in its open, ATP-bound state while the blue ribbon is P2X4 
receptor in its closed state, which were overlaid on top of each other. Heteroatoms 
were coloured red for oxygen, orange for phosphate, blue for nitrogen, and dark red 
for bromine. 
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Figure 4.24 Docking poses between 5-BDBD and human P2X4 homology model. 
Left panel: 5-BDBD is represented with white stick, in the middle of the figure. Pink ribbon represents one subunit of P2X4 receptor (coded as A) 
and yellow ribbon represents the neighbouring subunit (coded as B). The figure displays four important residues for binding at chain A and three 
residues at chain B. The translucent mesh represents the space that 5-BDBD filled in the binding pocket. Right panel: Different viewing angle of 
docking pose. In the figure, Ala93B was close to para-position (substitution site 2) of phenyl. Thus, any para substitution would cause the 
compounds to lose its inhibitory properties as substituted atom would clash with Ala93B and prevent the fitting of compound in the binding pocket. 
Heteroatoms were coloured red for oxygen, blue for nitrogen, and dark red for bromine. 
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4.4 Discussion 
4.4.1 Structure activity relationship study of 5-BDBD and P2X4 
5-BDBD has been widely used in studies involving P2X4 receptor over the past decade 
despite the limited information until it was recently characterised pharmacologically 
(Balazs et al., 2013). This situation drives the curiosity to unveil more information 
about this compound to better enhance the understanding of its application in P2X4 
research field. Thus, this part of study focused on the structure activity relationship 
between 5-BDBD and P2X4 receptor. Firstly, several analogues of 5-BDBD were 
synthesised, purchased, and tested for their potency and secondly, the mode of action 
of each inhibiting analogue was determined. The interaction of the analogues with 
P2X4 receptor was subsequently simulated in virtual docking to further understand the 
experimental data. The 5-BDBD analogues differed in terms of three substitution sites 
which has been shown in Figure 4.1. This will be used to effectively explain the 
relationship between 5-BDBD and P2X4. 
4.4.1.1 Substitution at position 1 
Based on pharmacological data, all compounds that were substituted with either 
chlorine (IA1), trifluoromethane (IA3), and fluorine (IA11) at position 1 showed the 
inhibitory properties. IA1 yielded similar IC50 value as 5-BDBD but IA3 and IA11 
showed significantly higher IC50 values than 5-BDBD. In terms of the magnitude of 
maximum inhibition, both IA1 and IA11 produced similar magnitude with 5-BDBD 
whereas the IA3’s maximum inhibition was lower. The virtual docking showed that 
the docking poses of all three compounds were consistent with the docking poses of 
5-BDBD. 
 
However, the reduced potency of IA3 and IA11 might be explained with the effect of 
fluorine substitution. Whilst fluorine substitution in drug development has been 
extensively claimed for better biological activity, chemical or metabolic stabilities, and 
bioavailability in various classes of drugs including anti-cancer (Böhm et al., 2004; 
Hagmann, 2008; Isanbor & O’Hagan, 2006; Shah & Westwell, 2007), this was not the 
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case in this study. The fluorine substitution has significantly reduced the potency 
relative to 5-BDBD, which may be due to the increased lipophilicity and adjustments 
of pharmacokinetic properties that result in changes of primary pharmacology (Gillis 
et al., 2015). Overall, the substitution at position 1 was tolerated but fluorine-
containing analogues were observed to have reduced potency. 
4.4.1.2 Substitution at position 3 
Experimental data indicated that the compounds with their position 3 substituted with 
halogens, i.e., fluorine (IA6), chlorine (IA9), bromine (STK731427), and 
trifluoromethane (IA7), still showed inhibitory properties comparable to 5-BDBD 
potency. They did not markedly change the potency of compounds relative to 5-BDBD 
since their IC50 values were not significantly different. In agreement with 
pharmacological data, the in silico experiment showed that the substituent at site 3 
pointed away from the binding site and no evidence showed that those substituents 
took part in the binding. 
 
Substitution with methoxy (STK864662) however, significantly decreased its potency 
relative to 5-BDBD. The relatively long chain of methoxy compared to the other four 
analogues might create a steric clash with other residues that subsequently make the 
binding less favourable. Hence, site 3 substitution with halogens and trifluoromethane 
was tolerated but not with a longer chain substituent such as methoxy. 
4.4.1.3 Substitution at position 1 and 3 
Among the analogues, four of them had both of their position 1 and 3 substituted with 
halogens; IA2 (both substituted with bromine), IA4 (trifluoromethane), IA8 (chlorine), 
and IA10 (fluorine). IA2, IA4, and IA10 lost their inhibitory properties while IA8 still 
blocked P2X4 activity with a significantly higher maximum inhibition compared to 5-
BDBD. From a modelling perspective, the presence of two substituents bulkier than 
chlorine appeared to be excessive compared to the available space within the binding 
pocket, thus only IA8 was tolerated but not others. However, IA10 had two smaller 
substituents (fluorine) than chlorine but it was not active at antagonising P2X4 receptor 
activity. This data, nevertheless, was parallel with the data for IA11 (site 1 substituted 
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with fluorine) which also lost its inhibitory properties. This meant that fluorine 
substitution at site 1 caused the loss of inhibition. 
4.4.1.4 Commercially available analogues 
4.4.1.4.1 Substitution at position 2 
Pharmacological data demonstrated that any substitution at position 2 greatly 
compromised the efficacy of molecules to inhibit P2X4 activity. STK747973, 
STK079751, STK027946, and STK775918 were substituted with fluorine, chlorine, 
methyl, and bromine, respectively (in order of increasing substituent size). 
STK775918 which had the biggest substituent did not exhibit inhibition on the calcium 
response while the other three showed minimal inhibition relative to 5-BDBD when 
maximum concentration of compound was used (30 µM). The maximum inhibition 
recorded was 25.2 ± 5.6 %, 19.1 ± 4.0 % and 9.5 ± 2.5 % for compound STK747973, 
STK079751, and STK027946, respectively. 
 
As observed in the docking of 5-BDBD (Figure 4.24), substitution site 2 was in close 
contact with Ala93 of the receptor. The substitution of hydrogen with a bulkier 
substituent than hydrogen would produce a steric clash, thus impeding efficient 
binding. Combining the results from pharmacological and computational simulation 
data, a likely explanation was that when the substituent became bigger, the molecule 
was offset from its ideal position within the binding site. In short, it was concluded 
that any substitution at position 2 was non-tolerable.  
4.4.1.4.2 No substitution at any site 
Apart from those three substitution sites discussed above, there was one compound 
that did not have any substitutions at any of the three positions (only hydrogens), which 
was STK045532. Surprisingly, this compound exhibited a good inhibition, like that of 
5-BDBD and moreover significantly increased the maximum inhibition. Docking data 
showed this compound could bind at the orthosteric site of P2X4, in a similar 
conformation to those described previously. It is worth noting that there was a 
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hydrophobic interaction between the phenylic region of 5-BDBD and deeper pocket 
of orthosteric binding site. 
 
Taking the results from pharmacological and computational approaches, it can be 
deduced that the hydrophobic phenyl group was already sufficient for binding and that 
by substituting site 1 with halogen which made it more hydrophobic (e.g. as a 
comparison, XLogP3 value of 5-BDBD is 3.8 while 3.1 for STK045532, source: 
PubChem database) did not significantly enhance the potency (considering 
hydrophobic interaction would be stronger). It is likely that this interaction was not the 
most important interaction involved in binding or hydrophobicity difference has no 
significant impact on the binding potency. Meanwhile, the site 3 substitution was 
shown earlier to not involve in the binding interaction. Together, this showed that any 
substitution at either position 1 or 3 was not crucial for inhibitory action and potency. 
4.4.1.4.3 Compound that lacked diazepinone 
Compound STK021512 had a quite different backbone compared to 5-BDBD. It 
lacked the diazepinone ring that held the carbonyl group which was shown to form 
hydrogen bonds with Arg295 in virtual docking between the active compounds and 
human P2X4 receptor model. Based on the pharmacological data, this compound did 
not inhibit the response which suggested that there was no binding between the 
compound and P2X4 receptor. This data underlined that the diazepinone ring was 
essential for binding since the carbonyl group can form a hydrogen bond with Arg295. 
4.4.2 Mode of action 
The experimental data showed that all inhibiting compounds blocked the P2X4 
receptor competitively, just like 5-BDBD. The inhibition of all compounds was 
surmounted by high concentration of ATP, around 3 – 10 µM. In addition, the 
concentration-response curves of all compounds were shifted to the right of untreated 
cells, indicating that more ATP was required to overcome the inhibition; a classical 
indication of competitive antagonism. The unchanged mode of action across all 
compounds was also reflected in virtual docking where all active compounds docked 
into P2X4 binding pocket in the same way as 5-BDBD. Ample space around 
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substitution site 1 (refer to Figure 4.24) allowed substitution with halogens and 
trifluoromethane (although fluorine and trifluoromethane substitution relatively 
reduced the potency, likely because of pharmacokinetic changes). Meanwhile, 
substitution at position 3 was robust because the substituent faced outside of the 
binding pocket. 
 
In contrast with this finding, Abdelrahman et al. (2017) documented a different mode 
of action for 5-BDBD. Instead of competitive inhibition, their data indicated that 5-
BDBD was an allosteric antagonist. This contradicting finding might be due to 
different experiment settings used. In this study, the experiment setting was that the 
cells that were pre-incubated with 5-BDBD for 30 minutes and then stimulated with 
different ATP concentrations to displace 5-BDBD. However, the study by 
Abdelrahman et al. (2017) was performed in the other way around. Radiolabelled 
[35S]ATPγS was firstly pre-incubated for a period and then different concentrations of 
5-BDBD were applied to displace [35S]ATPγS. Based on the docking data from this 
study, the binding of ATP induced conformational change that caused the side chain 
of Lys67 to cover the hydrophobic pocket, which denied the entrance of 5-BDBD into 
the deeper pocket of orthosteric site. Therefore, that might explain the inability of 5-
BDBD to displace [35S]ATPγS even at high concentration because the entrance for 5-
BDBD was totally blocked as [35S]ATPγS remained at the binding pocket. 
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CHAPTER 5  
CONCLUSIONS 
 
5.1 Identification of thaspine as a P2X4, inhibitor through high throughput 
screening 
5.1.1 Conclusion 
In summary, the human P2X4 and P2X7, and mouse P2X4 DNAs were successfully 
inserted into pLVX-IRES-mCherry vector and transformed into E. coli, and DNA 
sequencing confirmed that there was no mutation occurred. The recombinant DNAs 
were then successfully transfected into human astrocytoma cells which then 
overexpressed the respective P2X receptors, as confirmed by calcium response and 
fluorescence microscopy. All overexpressing cells were characterised as the 
preparation for them to be used in the next phase of this study; the high throughput 
screening. 
 
Throughout the screening, eight positive modulator and six inhibitor hits were 
identified to show the potential modulations on calcium response of the human P2X4 
overexpressing cells. Further investigation led to the identification of thaspine as the 
most potent inhibitor among the hits. Thaspine was further characterised using the 
human P2X4 and other P2 overexpressing cells. It was found that thaspine blocks the 
human P2X4 receptor noncompetitively with an IC50 value of 3.81 ± 0.2 µM and it is 
also equipotent at the mouse P2X4 receptor (3.53 ± 0.26 µM). It is an irreversible and 
slow-acting compound with maximum inhibition observed after 30 – 40 minutes of 
pre-incubation. It also actively inhibits CTP-evoked response of the human P2X4 
receptor in a different host cells (HEK293) with a similar IC50 value of 3.99 ± 1.0 µM, 
which indicated that the inhibitory activity of thaspine is independent of the type of 
host cells or nucleotides used. 
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Other than that, it is not active at human P2X2, P2X2/3, P2X7, and P2Y6 at ~3-fold IC50 
concentration while at P2Y2, it is not active below 10 µM. The testing on BV2 cells 
showed that its inhibitory effect is prominent on IVM-potentiated response in both 
quiescent and LPS-activated cells, as also observed for PSB12062-treated cells. 
However, it slightly potentiates the response in quiescent cells when activated by ATP 
but has no effect in the LPS-activated cells. In terms of mechanism of action, the 
current data suggested that it does not act by internalising the P2X4 receptors but might 
diffuse through the plasma membrane and acts internally. However, the data are yet to 
be conclusive to support this theory. 
 
Compared to previously reported P2X4 antagonists — paroxetine (IC50 = 1.87 µM), 
N,N-diisopropyl-5H-dibenz[b,f]azepine-5-carboxamide (IC50 = 3.44 µM), PSB12054 
(IC50 = 0.19 µM), PSB12062 (IC50 = 0.9 µM), TNP-ATP (IC50 = 15.0 µM), 5-BDBD 
(IC50 = 0.5 µM), BX430 (IC50 = 0.54 µM), NP-1815-PX (IC50 = 0.26 µM), and 
duloxetine (IC50 = 1.59 µM) (Ase et al., 2015; Fischer et al., 2004; Gum et al., 2012; 
Hernandez-Olmos et al., 2012; Matsumura et al., 2016; Nagata et al., 2009; Tian et al., 
2014; Yamashita et al., 2016) — thaspine was less potent except the TNP-ATP. 
However, it has been demonstrated that it was equipotent at both human and mouse 
P2X4, unlike the PSB12054 and BX430 which were respectively less active and 
unresponsive at mouse P2X4. It also selectively inhibited the P2X4 compared to P2X2, 
P2X2/3, and P2X7 and was selective at P2Y2 and P2Y6 at concentrations of lower than 
10 and 30 µM, respectively. 
5.1.2 Future direction 
Thaspine is a novel potential compound that can be developed as an inhibitor for P2X4 
receptor or as a template to design a more potent compound. Yet, there are more 
experiments needed to be done to further characterise the compound. One of them is 
that thaspine should be tested in electrophysiology experiments to directly measure the 
P2X4 cation current in the cells. It is hoped that the electrophysiology experiment can 
give direct evidence of the inhibitory properties of thaspine at P2X4 receptor. 
 
Besides, as the data suggested that thaspine does not act by internalising P2X4 
receptors, this can be further tested by biotinylation of surface receptors, and analysed 
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by SDS-PAGE and immunoblotting to quantitate the membrane-bound P2X4 receptors 
in the presence and absence of thaspine pre-incubation. Whereas, for the second theory 
on the mechanism of action is thaspine acts on an internal epitope of P2X4, it can be 
verified using the electrophysiology experiment in an inside-out configuration or 
adding thaspine into internal solution in a whole-cell configuration. If thaspine acts 
from the cytosolic environment, the application of thaspine directly into the cytosol 
may exhibit a relatively faster inhibition (than observed in calcium assay) on cation 
current. 
 
In addition, this present investigation was not carried out on primary cells. It would be 
better if it is tested on primary cells such as microglial cells or macrophage that are 
reported to abundantly contain P2X4 receptors. Data acquired from such experiments 
would reflect a more accurate prediction for the in vivo data.  
5.2 Structure activity relationship study of 5-BDBD and P2X4 receptor 
5.2.1 Conclusion 
So far, this is the first study that explored the structure activity relationship of 5-BDBD 
and P2X4 receptor. In this part of study, a few novel findings were discovered. The 
first one was the substitution at either site 1 or 3 was tolerated. This was supported by 
molecular modelling, which identified a cavity able to accommodate a range of 
substituents. On the other hand, substitution at position 2 seriously impaired the ability 
of a compound inhibition because of clashing with Ala93 on the receptor that 
prevented the effective binding. On top of that, a compound without any substitutions 
at the considered positions was equipotent with 5-BDBD, indicating that the 
substitutions were not necessary for the inhibitory property. The carbonyl group at 
benzodiazepinone of 5-BDBD and Arg295 of receptor were the crucial elements of 
compound and receptor, respectively, for binding to occur. Apart from that, both 
pharmacological and virtual docking data led to a conclusion that 5-BDBD was a 
competitive inhibitor and the contradicting discoveries with previous report were a 
consequence of different experiment settings. 
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5.2.2 Future direction 
There are many experiments and analyses that can be done to explore 5-BDBD further 
but only experiments that are most related to this present study will be discussed. The 
mode of action of 5-BDBD can be further verified using two methods. One of them is 
Schild analysis which is a technique of measuring response in the presence of few 
concentrations of 5-BDBD, stimulated by extensive concentrations of ATP to 
surmount the inhibition. If responses for all 5-BDBD concentrations can reach the 
same maximum magnitude and there is a clear right-shift of sigmoidal curves 
compared to untreated cells, as well as significant change in EC50 value, it can be 
deduced that it is a competitive blocker. However, due to time constraint, this analysis 
was not performed. 
 
Another method to verify the finding is the mutagenesis of P2X4 receptor. Based on 
the docking data, Arg295 is critical for the binding of 5-BDBD and P2X4. Thus, by 
mutating Arg295, it is hypothesised that 5-BDBD cannot bind to the binding site and 
hence, lose its inhibitory property. However, there is also a chance that by mutating 
the residue, it will also impair the binding of ATP as Arg295 is one of six key residues 
that form hydrogen bond with ATP to form the binding. In that case, it is impossible 
to measure the ATP-evoked response because ATP unable to bind with P2X4. Having 
said that, there are also five other residues that might salvage the loss of Arg295 and 
establish the ATP binding conformation. 
 
Zemkova et al. (2007) did a mutation study on P2X4 and reported that the mutation of 
Arg295 into alanine or lysine severely impaired the sensitivity of mutants towards 
ATP. Nevertheless, they found that the loss of sensitivity could be rescued by IVM 
pre-treatment and ATP-evoked response was restored, with EC50 values of 267 ± 41 
µM for R295A and 57 ± 12 µM for R295K. Therefore, mutagenesis study of 5-BDBD 
could involve the mutation of Arg295 with lysine and pre-treating cells with IVM and 
5-BDBD as well as proper controls, to observe the effect of 5-BDBD on the mutants. 
If there is no inhibition observed on the IVM-potentiated response, it may indicate that 
Arg295 is the key player for binding and that 5-BDBD is a true competitive inhibitor. 
That is because 5-BDBD is hypothesised to bind at orthosteric site and if it loses its 
ability to bind when the key residue is mutated, it means that Arg295 is important for 
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binding to occur. Another way to determine the binding is by employing the saturation 
transfer difference nuclear magnetic resonance (STD-NMR). The tool can give 
information on the binding occurs between a ligand and protein by looking at the 
spectrum difference between the unbound and protein-bound ligand (Viegas et al., 
2011). Hence, the possibility of 5-BDBD binding with P2X4 mutants can be 
determined without the need to measure the ATP-evoked response. 
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APPENDICES 
Appendix I 
 
Chemical structures of potential positive modulators. 
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Appendix II 
 
 
Chemical structures of potential antagonists. 
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Appendix III 
 
 
Chemical structures of NSC17055 analogues. 
The upper part are the compounds that reduced ATP-evoked response and the lower 
part did not have effect on the response. 
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Appendix IV 
 
 
 
Chemical structures of 5-BDBD and commercial analogues. 
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Appendix V 
 
 
Chemical structures of synthesised 5-BDBD analogues. 
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Appendix VI 
 
 
 
ATP concentration-response in the absence and presence of STK864662. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 4.8 µM of STK864662. EC50 value in the presence of STK864662 
was significantly higher than that with the compound (p<0.05). The difference 
between each data point was statistically calculated and marked with asterisk to 
indicate level of difference. The right shift of treated cells curve compared to vehicle 
together with significant increase in EC50 value indicated competitive mode of 
antagonism. The top panel shows the chemical structure of STK864662. Asterisk 
denotes p value; * - <0.05, ** - <0.01, *** - <0.001. (n=4) 
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Appendix VII 
 
 
 
ATP concentration-response in the absence and presence of STK731427. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 1.0 µM of STK731427. EC50 value in the presence of STK731427 
was significantly higher than that with the compound (p<0.05). The difference 
between each data point was statistically calculated and marked with asterisk to 
indicate level of difference. The right shift of treated cells curve compared to vehicle 
together with significant increase in EC50 value indicated competitive mode of 
antagonism. The top panel shows the chemical structure of STK731427. Asterisk 
denotes p value; * - <0.05, ** - <0.01, *** - <0.001. (n=3) 
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Appendix VIII 
 
 
 
ATP concentration-response in the absence and presence of IA1. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 2.3 µM of IA1. EC50 value in the presence of IA1 was significantly 
higher than that with the compound (p<0.01). The difference between each data point 
was statistically calculated and marked with asterisk to indicate level of difference. 
The right shift of treated cells curve compared to vehicle together with significant 
increase in EC50 value indicated competitive mode of antagonism. The top panel shows 
the chemical structure of IA1. Asterisk denotes p value; * - <0.05, ** - <0.01, *** - 
<0.001. (n=3) 
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Appendix IX 
 
 
 
ATP concentration-response in the absence and presence of IA6. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 1.2 µM of IA6. EC50 value in the presence of IA6 was significantly 
higher than that with the compound (p<0.05). The difference between each data point 
was statistically calculated and marked with asterisk to indicate level of difference. 
The right shift of treated cells curve compared to vehicle together with significant 
increase in EC50 value indicated competitive mode of antagonism. The top panel shows 
the chemical structure of IA6. Asterisk denotes p value; * - <0.05, ** - <0.01, *** - 
<0.001. (n=4) 
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Appendix X 
 
 
 
ATP concentration-response in the absence and presence of IA7. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 2.7 µM of IA7. EC50 value in the presence of IA7 was significantly 
higher than that with the compound (p<0.05). The difference between each data point 
was statistically calculated and marked with asterisk to indicate level of difference. 
The right shift of treated cells curve compared to vehicle together with significant 
increase in EC50 value indicated competitive mode of antagonism. The top panel shows 
the chemical structure of IA7. Asterisk denotes p value; * - <0.05, ** - <0.01, *** - 
<0.001. (n=4) 
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Appendix XI 
 
 
 
ATP concentration-response in the absence and presence of IA8. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 1.1 µM of IA8. EC50 value in the presence of IA8 was significantly 
higher than that with the compound (p<0.05). The difference between each data point 
was statistically calculated and marked with asterisk to indicate level of difference. 
The right shift of treated cells curve compared to vehicle together with significant 
increase in EC50 value indicated competitive mode of antagonism. The top panel shows 
the chemical structure of IA8. Asterisk denotes p value; * - <0.05, ** - <0.01, *** - 
<0.001. (n=4) 
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Appendix XII 
 
 
 
ATP concentration-response in the absence and presence of IA9. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 1.1 µM of IA9. EC50 value in the presence of IA9 was significantly 
higher than that with the compound (p<0.01). The difference between each data point 
was statistically calculated and marked with asterisk to indicate level of difference. 
The right shift of treated cells curve compared to vehicle together with significant 
increase in EC50 value indicated competitive mode of antagonism. The top panel shows 
the chemical structure of IA9. Asterisk denotes p value; * - <0.05, ** - <0.01, *** - 
<0.001. (n=4) 
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Appendix XIII 
 
 
 
ATP concentration-response in the absence and presence of IA11. 
The plots show ATP concentration-response in the presence (open square) and absence 
(close square) of 4.5 µM of IA11. EC50 value in the presence of IA11 was significantly 
higher than that with the compound (p<0.05). The difference between each data point 
was statistically calculated and marked with asterisk to indicate level of difference. 
The right shift of treated cells curve compared to vehicle together with significant 
increase in EC50 value indicated competitive mode of antagonism. The top panel shows 
the chemical structure of IA11. Asterisk denotes p value; * - <0.05, ** - <0.01, *** - 
<0.001. (n=4) 
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